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Abstract
In horses, a painful and often debilitating disease known as laminitis can result in
impaired function and, in severe cases, euthanasia. Equine Metabolic Syndrome (EMS) is a
syndrome in horses that results in development of laminitis and is characterized by the
presence of general and/or regional adiposity (“cresty neck”), aberrations in blood lipid
concentrations, insulin resistance (IR) and/ or hyperinsulinemia.
Therapies have focused on improving the state of obesity and insulin resistance with
the goal of diminishing the likelihood of laminitis development. A definitive cause for
laminitis has not been established, but hyperinsulinemia and IR are likely candidates as
experimental states of hyperinsulinemia have been shown to induce laminitis and
improvements in insulin sensitivity and obesity have been associated with a decreased risk
of laminitis development.
This dissertation discusses associations between obesity and IR, as well as potential
therapies for alleviating insulin resistance with the ultimate goal of decreasing the risk of
developing laminitis.

Therapies evaluated included chromium and magnesium,

levothyroxine sodium, and metformin hydrochloride.

Horses were treated with each

supplement for 10 to 36 weeks, depending on the supplement tested, and physical
measurements such as body weight, neck circumference, and body condition score were
obtained. Throughout each study, blood concentrations of glucose, insulin, and plasma
lipids were analyzed. Chromium and magnesium currently do not appear to have any effect
on insulin sensitivity, whereas results of levothyroxine administration indicate therapeutic
responses, as does metformin, though results indicate further work are required.
Research contained in this dissertation focuses on the potential of identifying animals
at risk of developing IR and laminitis through measurement of blood biomarkers such as
adiponectin and glucagon-like peptide 1. Assays to measure markers included enzymelinked immunosorbent assays, western blots, and radioimmunoassays.

Glucagon-like

peptide 1 currently does not appear to differ between healthy and IR animals, but protein
band density of high-molecular weight adiponectin does appear to be lower in horses with
IR when compared to healthy animals.

v

There is still much to learn about IR in horses, and therapy appears to be dependent
on a case by case basis.

Key words: horse, obesity, insulin resistance, laminitis, equine metabolic syndrome
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Chapter 1
Literature Review
Laminitis is a common medical condition of equids that does not have a clear
pathogenesis.

This disease affects domesticated horses and ponies (Equus caballus)

throughout the world and has financial and welfare implications.1-3

It is a potentially

crippling disease of adult horses that can result in early retirement due to permanent lameness
or euthanasia.1 Laminitis is generally associated with, or diagnosed in conjunction with,
other medical conditions, including insulin resistance (IR), obesity, and pituitary pars
intermedia dysfunction (PPID), which is also known as equine Cushing’s disease.4 This
literature review will focus upon obesity and IR as risk factors for laminitis, and examine
potential treatments for these conditions.

1. Obesity and insulin resistance in horses and ponies
1.1 Body condition and fat mass assessment
A scoring system was devised by Henneke, et al.5 to assign a body condition score
(BCS) to horses. This scoring system has a scale ranging from 1 to 9, with 1 representing an
emaciated animal and 9 representing a morbidly obese animal. This scale allows a score to
be assigned after visual appraisal and palpation of fat at 6 strategic locations: over the ribs,
the area caudal to the shoulder, along the withers, in the tail head region, along the back, and
along the neck.5,6

This scoring system has been adapted and utilized by veterinarians,

nutritionists, and horse owners as a means to evaluate the horse’s condition compared to an
ideal score of 5. According to this system, a score ≥ 7 represents obesity.2,6 This is a
subjective method of assessment, however, and is prone to variability among scorers.
Alternative methods of assessing obesity are cadaver dissection,6,7 rump-fat thicknes,6,8,9 and
body mass index (BMI).6,10 Of these procedures, BCS and rump-fat thickness are the easiest
to perform.6 Rump fat thickness is measured using B-mode ultrasonography at a site 5 cm
lateral to midline at the center of the pelvic bone.6,8 Percentage body fat is calculated from
ultrasound measurements using the formula:8
% fat = 2.47 + 5.47 (rump fat in cm)

1.2 Adipose distribution
In obese horses that concurrently suffer from IR, there is often enlargement of adipose
tissues within the neck region, which is referred to as a “cresty neck”, or regional
adiposity.6,11 In humans, regional adiposity refers to an increased waist circumference and
this is a risk factor for metabolic syndrome (MetS).12 One can evaluate the deposition of
adipose tissue in the neck region of horses by obtaining mean neck circumference
measurements using the following procedure:6 with the horse carrying its head in a normal,
upright position, measure the distance (×) along the neck from the poll to the cranial aspect of
the withers (Figure 1). Perpendicular to the line of the neck, measure circumference at
0.25×, 0.50×, and 0.75×. As obesity increases or decreases, neck measurements change
accordingly. Mean neck circumference measurements were positively correlated with IR in
one study of obese insulin-resistant horses.6 A cresty neck scoring system, along with BCS
has also been found to have a strong association with blood variables such as insulin and
glucose concentrations.13 Both crest height and neck circumference are associated with
higher insulin, glucose, leptin, and triglyceride concentrations.13

Figure 1.1: Neck circumference measurements in the horse. From Frank N et al. Physical
characteristics, blood hormone concentrations, and plasma lipid concentrations in obese
horses with insulin resistance J Am Vet Med Assoc 2006;228:1,383-1,390.

2

2. Insulin resistance
2.1 Insulin secretion and function
Insulin is a hormone synthesized and secreted by the β cells of the pancreatic Islets of
Langerhans in response to hyperglycemia, and has the main function of regulating glucose
utilization and production.1,14 This hormone also affects lipid metabolism by enhancing
cellular glucose uptake and lipogenesis15,16, and blood circulation because of its vasodilatory
properties.17 Hypertension and vascular disease can result from hyperinsulinemia (high blood
insulin concentrations).18

Insulin is extracted by the liver after its secretion, with

approximately 50% lost on first pass.19-21
Insulin synthesis starts with a pro-insulin form consisting of an A-chain, B-chain, and
C-peptide (connecting peptide).22

During the synthesis of insulin, C-peptide serves an

integral role by linking the A and B chains and thereby ensuring correct folding and
interchain disulfide bond formation.22 Before functional insulin (A and B chains joined
together) is secreted, C-peptide is cleaved from the pro-insulin molecule, and remains stored
in secretory granules. After C-peptide is removed, the carboxyl end of the B-chain of insulin
has the appropriate conformation for binding to the insulin receptor.22 Insulin and C-peptide
are secreted in equimolar amounts so any difference in their ratio implies impaired insulin
clearance by the liver.22-23 The half lives of insulin and C-peptide are 4 minutes and >30
minutes, respectively.20,21,23,24
Insulin secretion is highly dependent on insulin sensitivity (SI). In a study of British
children, SI was dependent upon body mass index (BMI).25-27 This study revealed that insulin
sensitive people released less endogenous insulin in response to glucagon stimulation when
compared to individuals with type 2 diabetes mellitus and IR.25

2.2 Insulin receptor and signaling
Insulin is released by the pancreas in response to feeding and acts through an insulin
receptor mechanism to stimulate glucose uptake and regulation by adipose tissue, skeletal
muscle, and the liver.1,14,28 The insulin receptor is located within the cell membrane and is
composed of two α and two β sub-units which are linked by disulfide bonds.29,30 The α
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subunits are located extracellularly and are the site of insulin binding, while the β sub-units
consist of transmembrane and intracellular domains.30 The transmembrane domain conveys a
signal to the intracellular domain that insulin has bound to the receptor, and this signal
involves tyrosine kinase.29,30 When insulin binds to its receptor, tyrosine kinase is activated
and this leads to autophosphorylation of the β sub-unit at tyrosyl residues, which begins an
intracellular signaling pathway that causes phosphorylation of cytosolic protein substrates
such as insulin receptor substrate-1 (IRS-1).30

Upon activation of the receptor and its

intracellular signaling cascade, the insulin-responsive glucose transporter GLUT 4
translocates from intracellular vesicles within the cytosol to the cell membrane and this
allows passage of glucose into cells.29
The ability of insulin to enhance the total net disappearance of glucose from
extracellular fluid (plasma), by either inhibiting endogenous glucose production and/or
enhancing the use of glucose by the body represents SI.31 Insulin normally maintains plasma
glucose concentrations within a range and therefore protects the tissues from glucotoxicity.1
In horses, fasting blood glucose concentrations range from 60 to 90 mg/dL16, compared with
70 to 105 mg/dL in humans, but ranges do differ according to the assays utilized by
respective laboratories.32 Insulin is also responsible for stimulating lipogenesis and inhibiting
hepatic gluconeogenesis.28 Insulin resistance is defined and recognized by a subnormal
physiologic response to normal circulating concentrations of insulin.13,14

Fasting

hyperinsulinemia serves as an indicator of IR in horses and humans.33-35 Normal, healthy
state levels of insulin in humans is recognized at values of <25 µIU/mL32, while normal,
healthy state fasted insulin concentrations in horses are <20 µIU/mL.16 In humans, chronic
hyperinsulinemia is associated with consequences such as disorders of carbohydrate
metabolism, lipid metabolism, and vascular disease such as atherosclerosis.36,37

The

occurrence of laminitis in obese horses may be a result of IR and vascular disorders such as
atherogenesis, however, it has yet to be confirmed.36

2.3 Mechanisms of insulin resistance
Insulin resistance can be found in both physiologic (e.g. starvation, pregnancy) and
pathologic (e.g. obesity, hyperadrenocorticism) conditions.14,38 Proposed mechanisms of IR
include breakdown of insulin-signaling mediators, down-regulation of insulin receptors, or a
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decrease in number of insulin receptors.15,36,39,40 The most common mechanisms however,
involve alterations in post-receptor binding signaling pathways, associated with a decrease in
autophosphorylation of β sub-units, and therefore decreased tyrosine kinase activity.15,41,42
This causes a domino effect in which phosphorylation of IRS-1 decreases, leading to reduced
activation of phosphatidylinositol 3-kinase (PI3K).15,41,42 Impaired regulation of enzymes
such as hexokinase and glycogen synthase can also result in disruption of intracellular
glucose metabolism, which leads to reduction in insulin-mediated uptake of glucose and
subsequent storage by the liver as glycogen or by adipose tissue as fat.15,41-43
In horses, a syndrome that includes abnormal distribution of adipose tissue,
hyperinsulinemia, glucose intolerance, elevated plasma lipid concentrations, and a
predisposition to laminitis, is referred to as Equine Metabolic Syndrome (EMS).36 Horses
affected by this syndrome are usually between 8 and 18 years of age, are usually obese,
possess a “cresty neck”, and have excess adipose accumulation in the rump area and
prepuce/mammary region, as well as histories of laminitis and being an “easy keeper”.6,36
Plasma lipid concentrations increase with obesity and a lack of exercise in humans,
and this is explained by the fact that adipose tissues have a finite capacity to store fat, so
excess fat is found in the circulation and other tissues (i.e. skeletal muscle).6,44 Insulin, which
is often circulating at higher concentrations in obese humans than in non-obese humans, also
elicits lipogenic effects and inhibits lipase activity leading to improper accumulation of fatty
acids as diacylglycerols within tissues.6,44 This phenomenon can be referred to as lipotoxicity
and this process is capable of disrupting insulin receptor signaling in muscle cells or β cell
function within the pancreas.6,44 In one study looking at the physical characteristics and
plasma lipid profiles of a group of horses, it was found that plasma non-esterified fatty acid
(NEFA) concentrations were elevated in obese horses compared with non-obese
counterparts.6 A link has also been established between free fatty acids and the development
of obesity and IR (and Type 2 diabetes) in humans.36,45 Elevated NEFA concentrations
induce IR in both skeletal muscle and the liver.36,46 The fact that IR is associated with weight
gain, and loss, strongly suggests a cause and effect relationship.36
Horses with obesity-associated laminitis usually suffer from glucose intolerance.36
Glucose intolerance is diagnosed when hyperglycemia is prolonged due to delayed resolution
after a glucose load either intravenously, orally, or post-prandially (reflecting following a
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meal).36 In healthy individuals, the ingestion of a meal or glucose challenge, leads to an
increase in blood glucose concentrations at which time insulin is released by the β cells of the
pancreas.

The increase in serum insulin concentrations signals a halt to liver glucose

production via glycogenolysis and gluconeogenesis, and stimulates the uptake of glucose by
skeletal muscle and adipose tissue.36,40 The state of glucose intolerance implies insensitivity
of peripheral tissues (skeletal muscle and adipose tissue) or the liver to the actions of insulin,
that amounts of insulin produced by the β cells of the pancreas are decreased, or both.36,39
With respect to equids, it has been shown in earlier studies that pony breeds appear to be
glucose intolerant (relatively) when compared to horses.34,36,47

3. Lipid metabolism
3.1 Lipotoxicity
The development of an overweight or obese state is, by definition, due to a positive
energy balance.48 It has been shown, that when there is an imbalance between energy intake
and expenditure, fat is deposited due to a positive fat balance.48-50 Of the macro-nutrients
utilized by the body for energy (protein, carbohydrates, fat), dietary fat is the most energy
dense, providing approximately 37 kJ/g versus approximately 17 kJ/g by proteins and
carbohydrates.48 When dietary fat intake is increased, fat oxidation increases slowly leading
to an overall accumulation of fat in adipose stores due to a positive energy balance.48,51,52
In humans suffering from type 2 diabetes (T2D) and horses with IR, plasma NEFA
and cholesterol concentrations are increased, and an overall state of dyslipidemia exists.6,53,54
Blood NEFA concentrations increase with obesity and lack of physical activity in humans
because hormone sensitive lipase (HSL) increases, leading to enhanced mobilization of
NEFAs from adipocytes.6,44 This state of dyslipidemia causes fatty acids to be stored in nonadipose tissues such as muscle, liver, and pancreas, in patients suffering from T2D.48 One of
the main contributing factors to the development of IR is the overabundance of NEFAs
within the blood.55 Hydrolysis of stored triglyceride (TG) into fatty acids and glycerol is
regulated by insulin, as well as catecholamines and natriuretic peptides.55,56 Insulin normally
inhibits the hydrolysis of TG and increases fat storage by stimulating re-esterification of fatty
acids.55,57
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3.2 Ectopic lipid accumulation
High circulating NEFA concentrations can lead to ectopic accumulation of lipids in
skeletal muscle and liver, and a negative correlation exists between the degree of IR and the
TG content of skeletal muscle.53,58-61 Elevated plasma NEFA concentrations accompany
obesity, IR, and T2D in humans, and have also been noted in obese insulin-resistant horses
and ponies.6,58,62 These elevations drive the accumulation of intramyocellular lipids (IMCL)
and increase the severity IR by disrupting insulin receptor signaling and creating cell damage,
which is referred to as lipotoxicity.6,44,53,58,63,64
Intramyocellular lipids are small lipid droplets located in the sarcoplasm of muscle
cells and are predominantly found in the vicinity of the mitochondria.48 Lipotoxicity is
thought to occur by one or more of the following cellular/molecular mechanisms: 1)
inflammation, 2) diacylglycerol (DAG)/protein kinase C (PKC) pathway, or 3)
hyperinsulinemia.65

It is still unclear whether IMCL accumulation is the cause or

consequence of IR.53,65 Higher IMCL concentrations have been detected under physiological
conditions, such as muscles of endurance athletes and individuals undergoing short-term (4
week) exercise training.58,66,67 This discrepancy implies that higher IMCL concentrations are
a marker for other lipid metabolites that may be inducing IR, rather than a direct effect. 58
The mechanism by which IMCL plays a role in IR involves the insulin signaling
pathway.62

Diacylglycerols accumulate within muscle tissue and stimulate PKC, which

inhibits tyrosine kinase activity of the insulin receptor and tyrosine phosphorylation of IRS-1,
which decreases myocyte glucose uptake.62,68-70

In vivo studies and ex vivo biochemical

analyses of muscle tissue biopsies from humans indicate that obesity and IR are associated
with decreased mitochondrial fatty acid (FA) oxidative capacity.58,71-76 This may be the
result of decreased myocyte mitochondrial numbers, abnormal mitochondrial morphology, or
decreased levels of the mitochondria-associated enzymes required for FA oxidation.58,71-76 It
is therefore possible that the increased IMCL concentrations associated with IR in humans
result from a decreased capability to oxidize FA.58

Kelley et al.72 demonstrated that

mitochondria in patients with T2D are smaller and have morphological aberrations compared
with controls. It was also shown that the mitochondrial area was positively correlated with
insulin sensitivity.

Mitochondrial function might also be influenced by diet, with high
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saturated fatty acid diets having a stronger negative effect on hepatic and peripheral insulin
sensitivity than mono-unsaturated fatty acids and polyunsaturated fatty acids.68,77-79

3.3 The role of β-oxidation
The mechanism behind lipid-induced IR was proposed more than 30 years ago when
Randle and colleagues introduced the concept of a glucose-fatty acid cycle.68 In this cycle,
fatty acids and glucose are thought to compete for their respective substrate oxidation .80
Perdomo et al.58 found in work performed with L6 muscle cells that there was a distinct
influence of β-oxidation rate on the severity of IR in skeletal muscle. The equilibrium, or
lack thereof, between FA oxidation and re-esterification into TG is important in the
determination of lipid storage in muscle.62 Healthy skeletal muscle is characterized by
having the capacity to utilize either lipid or carbohydrate fuels for energy and to effectively
interchange between these two sources, depending on the stimulus and energy demands of the
tissue.62 For example, in a state of early starvation when glucose availability is minimal, the
body shifts from utilizing glucose as its energy source to using FAs produced by TG
oxidation.81
The inability of skeletal muscle to adequately oxidize TGs is an important aspect of
skeletal muscle insulin insensitivity in the obese or T2D state.62 Beta oxidation requires that
FAs leave the circulation, move into the sarcoplasm, and then enter the mitochondria by first
passing through the outer mitochondrial membrane and then the inner mitochondrial
membrane. In states of obesity and T2D, fatty acid synthesis is promoted, rather than
oxidation, which leads to lipid accumulation within skeletal muscle.62

3.4 Mechanisms of β-oxidation
3.4.1 Carnitine Palmitoyl Transferase
Entry of FAs into mitochondria is regulated by carnitine palmitoyltransferase-1
(CPT-1). Fatty acids that enter the cytosol of a muscle cell must first be converted to a fatty
acyl-CoA via acyl-CoA synthetase within the outer mitochondrial membrane.82 In order to
cross the inner-mitochondrial membrane, fatty acyl-CoA must join with carnitine and form
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acyl-carnitine, which is catalyzed by CPT-1 on the outer face of the inner mitochondrial
membrane.82 The acyl group is then transferred back to a CoA-SH to re-form fatty acyl-CoA
and a free carnitine.82 There is an even exchange between the matrix and the inter-membrane
space of carnitine for acyl-carnitine via carnitine acylcarnitine translocase.83,84
Carnitine palmitoyltransferase-1 is inhibited by malonyl-CoA, which is the first
intermediate in the synthesis of long chain fatty acids. When carbohydrate substrates are
ample, the concentration of malonyl-CoA increases, creating a negative feedback on CPT-1
activity and therefore inhibition of β-oxidation. Malonyl-CoA is formed from the conversion
of pyruvate, produced by glycolysis, into acetyl-CoA.

3.4.2 Adenosine monophosphate kinase
Adenosine monophosphate kinase (AMPK) is a fuel sensing enzyme that monitors
cellular energy status, increases glucose uptake, and activates catabolic pathways (βoxidation and glycolysis) leading to ATP production.85-88 This enzyme also inhibits anabolic
pathways (gluconeogenesis) that utilize ATP and has a regulatory role in two critical liver
functions, gluconeogenesis and lipogenesis.

A decrease in intracellular energy levels

activates AMPK and this is also the route of action for anti-diabetic drugs such as metformin
and the hormone adiponectin.64
The AMPK enzyme is a multi-substrate heterotrimer that contains a catalytic αsubunit and two regulatory, β and γ, subunits.86,89 Increases in the intracellular AMP:ATP or
creatine:phosphocreatine ratios lead to its activation.64,86 Phosphorylation on the threonine172 (Thr-172) residue can also lead to its activation.86

In its active form, AMPK

phosphorylates and consequently inactivates acetyl CoA carboxylase (ACC), which is its
direct substrate.85 When ACC is inactivated, malonyl-CoA concentrations decrease and this
leads to activation of CPT-1 and increased oxidation of long chain fatty acids.85,90
Interactions between AMPK and glycogen stores in muscle have been reported in
some studies, with this enzyme phosphorylating, and therefore inactivating, glycogen
synthase.86,91 It has also been shown that the β-subunit of AMPK contains a motif capable of
binding glycogen, which implies that it plays a role in depleting glycogen stores.86,92-94 One
study85 found that increased AMPK activation by the insulin sensitizing drug troglitazone
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caused an increase in long chain fatty acid oxidation, which reduced IMCL accumulation.
However, the resulting increase in glucose uptake stimulated lactate production, rather than
glycogen synthesis, as expected.85 A similar finding occurred in a study looking at the
influence of adiponectin on glucose uptake, in that glycogen synthesis decreased, whereas
lactate production increased.86

Increased β-oxidation lowers IMCL concentrations and

thereby protects cells from the harmful effects of FA accumulation on insulin signaling.
Work performed by Perdomo et al.58 suggests that β-oxidation also increases insulin
sensitivity independently of its impact on lipid accumulation. With its role in regulating and
influencing β-oxidation, AMPK is viewed as a “metabolic switch”.

4. Hepatic insulin resistance
4.1 Non-alcoholic fatty liver disease
The hepatic manifestation of IR in humans is referred to as non-alcoholic fatty liver
disease (NAFLD).95 This condition is one of the most common causes of liver dysfunction in
humans and arises from abnormal lipid droplet accumulation in hepatocytes, caused by
increased calorie intake and enhanced lipogenesis, particularly in states of IR.96 Messenger
RNA expression of key lipogenic enzymes is increased with obesity, IR, and dyslipidemia in
humans and this stimulates lipid synthesis.95,97 Fatty acids are taken out of the circulation by
the liver and undergo β-oxidation, storage as TG, or export within very low-density
lipoprotein (VLDL).98 In the fasted state, FAs are mobilized and energy is produced within
the liver through β-oxidation, whereas in the fed state insulin stimulates lipogenesis.98,99
The liver is one of the most important organs in the body and is involved in digestion,
detoxification, production, and storage.98 The liver has a central role in glucose and lipid
metabolism and it, along with skeletal muscle and adipose tissue, is a key site of insulin
action.99 It plays a major role in determining circulating insulin concentrations because 50 to
70% of insulin secreted by the pancreas is removed from the portal circulation by the liver on
first pass.100-103

Intrahepatic fat content can range from 0 to 100%, with the amount

increasing in parallel with obesity.101,104 In obese humans, patients with elevated intrahepatic
fat are affected by IR and hyperinsulinemia.101 Hepatic IR is defined by the ability of insulin
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to suppress hepatic glucose production, while not affecting lipid synthesis and VLDL
production.99,101,105,106 Hyperinsulinemia reflects both insulin clearance and insulin action.101
In one study examining the effect of liver fat on insulin clearance, Kotronen et al.

101

demonstrated that subjects with a high liver fat content (15%) were more obese, had higher
fasting glucose, insulin, and TG concentrations, higher liver enzyme activities, and lower
serum high density lipoprotein (HDL) concentrations than low liver fat (2%) patients. Those
individuals with higher liver fat content had more hepatic glucose production, indicating
hepatic IR.101 Hepatic IR and insulin clearance are independent determinants of fasting
serum insulin concentrations.101 Decreases in hepatic fat via drug therapy and weight loss
improves hepatic insulin sensitivity and increases insulin clearance.101 This reinforces the
theory that hepatic insulin sensitivity is a function of liver fat content.

4.2 Regulation of hepatic lipid content
Sterol regulatory element binding protein 1-c (SREBP1-c) is a key regulator of
hepatic FA metabolism that influences gene expression for enzymes such as fatty acid
synthase (FAS) that are involved in FA synthesis within the liver.99,107,108

Increased

expression of SREBP-1 has been shown to induce hepatic steatosis and hyperlipidemia.109-111
Peroxisome proliferator activated receptor alpha (PPARα), gamma (PPARγ), and
delta (PPARδ) also regulate hepatic FA metabolism.99

Insulin-sensitive liver, skeletal

muscle, and adipose tissues express PPARα and this leads to an up-regulation of genes
involved in FA uptake and β-oxidation.99 There are two isoforms of PPARγ; isoform-1 is
expressed in the liver and skeletal muscle and isoform-2 is only found in adipose tissue where
it is involved in the regulation of adipocyte differentiation and FA storage.99 Activation of
PPARγ increases FA uptake by adipose tissue and thereby decreases amounts delivered to the
liver via a mechanism referred to as “the fatty acid steal hypothesis”.99,112,113 In animal
models, PPARδ improves lipid profiles and increases energy expenditure, while also
increasing carbohydrate catabolism in the liver and suppressing hepatic glucose
production.63,99,114,115
The state of peripheral IR is thought to be a factor in the development of hepatic fat
accumulation since IR is characterized by hyperinsulinemia and insulin elicits lipogenic
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effects. Hyperinsulinemia also increases FA influx into the liver and stimulates hepatic TG
production.116 High serum insulin and glucose concentrations promote de novo lipogenesis
and NAFLD may ultimately lead to the development of hepatic IR.116

4.3 Visceral adiposity and the liver
The location of fat might also affect the development of obesity-associated metabolic
disorders. The visceral fat constituting truncal obesity is most closely associated with
metabolic syndrome (MetS) and adverse outcomes in humans.117-121

Human metabolic

syndrome is a syndrome comprised of a collection of risk factors for the development of type
2 diabetes and cardiovascular disease.122

Risk factors include dyslipidemia reflected in

elevated triglycerides and low high-density lipoproteins (HDL), elevations in blood pressure
and glucose, and abdominal obesity which has been associated with a pro-thrombotic and
pro-inflammatory state.122

The association between truncal obesity and MetS has been

explained by the “portal/fatty acid flux” theory. According to this theory, visceral fat has
enhanced lipolytic activity that increases the amounts of FAs that enter the portal circulation
and go directly to the liver, which leads to intrahepatic lipid accumulation and hepatic
IR.57,118,123

Subcutaneous fat on the other hand appears to be metabolically protective

because it is correlated with lower serum TG concentrations and higher HDL concentrations
as well as strong positive correlations with adipokines such as adiponectin and leptin
(discussed below).118 These adipokines improve insulin sensitivity in peripheral and hepatic
tissues.

5. Obesity and Inflammation
It has historically been the belief that fat tissue is nothing more than an energy
reserve; however, within recent years it has been established that adipose tissue is an
endocrine organ that secretes numerous hormones known as adipokines.1,124,125

These

adipokines are potential contributors to IR in humans and horses and are secreted by both
adipocytes and macrophages.124,126,127

Key underlying pathologic processes of obesity

therefore include chronic inflammation and dysregulation of adipokines.128 Macrophages are
the primary mediators of the immune response, and in adipose tissues they make up
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approximately 40% of the infiltrating cells of adipocytes in obese humans.124,129 Adipokines
are soluble compounds that are secreted by white adipose tissue (WAT) from adipocytes and
cells associated with WAT known as stroma vascular fraction cells.36,128,130,131 Multiple
adipose tissue-derived signaling molecules are currently being studied as correlates of IR.124
Endocrinologically active adipocytes are found in omental and retroperitoneal fat
tissues, which are associated with intra-abdominal adiposity in humans.4,125 Accumulation of
adipocytes in these locations is thought to be more significant that adipocytes in other
locations such as subcutaneous tissues and the lower extremities.36,62 In obese horses with
EMS, there can be accumulations of retroperitoneal fat subjacent to the body wall, sometimes
as thick as 3 to 5 cm.36
In horses, relationships exist among obesity, inflammatory cytokines, and insulin
sensitivity; inflammation increases with obesity and this is associated with a decrease in
insulin sensitivity.132 Adipocytes participate in the innate inflammatory response in horses.126
In IR humans, administration of anti-inflammatories such salicylates (aspirin) have been
shown to reverse IR, further supporting the role of inflammation.126,133 Since laminitis is
associated with both obesity and IR, it is postulated that adipose-derived inflammatory
cytokines are also associated with laminitis.126,132 Pro-inflammatory cytokines such as tumor
necrosis factor alpha (TNF-α) increase with obesity whereas anti-inflammatory cytokines
such as interleukin-10 (IL-10) decrease.132,134,135 However, the adipokines that are coming to
the forefront of investigations of IR and MetS in both horses and humans are leptin,
adiponectin, and resistin.

6. Adipokines and incretins
6.1 Leptin
The concept of a “thrifty gene” was first proposed for humans in 1962 by Neel,136 and
was proposed as an explanation for why some humans become obese and others do not. This
theory is based upon the belief that Paleolithic humans had to be thrifty in order to survive on
limited nutritional availability. The concept of the thrifty gene has also been proposed as a
mechanism for why some horses appear more metabolically efficient and are termed “easy
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keepers”.137 These animals gain weight on diets that would be considered nutritionally
sufficient for maintenance in most other horses.
Leptin is the product of the obese (ob) gene and is a 16 kDa hormone comprised of
167 amino acids.64,137-139 It is secreted by adipocytes and plays an important role in appetite
regulation and energy homeostasis.64,137-139 It was one of the first molecules to be classified
as an adipokine and is considered to be an anti-obesity hormone owing to its capacity to
regulate food intake.64 In horses and ponies, leptin concentrations are positively correlated
with BCS.137,140,141 Higher plasma leptin concentrations have also been positively correlated
with area under the curve (AUC) measures of insulin and glucose dynamics.6 Although the
measure of BCS reflects adiposity, it only measures subcutaneous depots of fat and therefore
there may be varying concentrations of leptin among horses of similar BCS.137,142
When considering leptin as a screening tool in horses for IR, one must also take
season into account. Fitzgerald and McManus143 found that serum leptin concentrations were
elevated in mature mares during late summer into early fall, and reached their lowest
concentrations during the winter. However, the same group subsequently determined that
leptin concentrations were higher in the winter than in the summer in young and mature
mares.144,145 Steelman et al.144 performed a study to examine the effects of grain meal size
and frequency on leptin concentrations. Horses receiving smaller, more frequent meals had
leptin secretion patterns similar to those seen on pasture, perhaps due to the similarity in feed
amounts. There was no diurnal variation in leptin secretion observed even though leptin
concentrations are higher in the evening versus the morning in mature horses.144,146,147

6.1.1Leptin secretion
Leptin and insulin share a similar pattern of secretion in that concentrations tend to
increase in fed states and decrease in fasted or feed restricted states, with leptin being
produced by adipose tissue in response to glucose uptake, and insulin by the pancreas in
response to elevations in circulating glucose concentrations.81,144 In studies evaluating effects
of feeding on leptin concentrations in mature mares and geldings, hyperleptinemia and
hyperinsulinemia were identified in 30% of a population of horses with high BCS.141,148,149
Leptin concentrations have been correlated with fasted insulin concentrations in other species
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such as the rat and rhesus monkey.146,148,150,151 Leptin stimulates glucose uptake and FA
oxidation within skeletal muscle and inhibits insulin secretion by acting through leptin
receptors on pancreatic β cells.138,152,153
Insulin and leptin have opposing actions.
lipolytic;

Insulin is lipogenic whereas leptin is

leptin also reduces adipose depot size through its ability to suppress insulin

secretion.154 There was a decrease in leptin concentration in healthy horses in response to
feed restriction;137 however, when food intake was no longer restricted, there was a slower
than expected increase in leptin concentrations when compared to other species. This delay
may represent an evolutionary adaptation to ensure increased feed consumption after the
body perceives a scarcity of forage.

6.1.2 Leptin function
It has been suggested that leptin functions as an “adipometer” that signals the brain
whether calorie reserves are sufficient or not.81

Leptin regulates fuel partitioning by

promoting β-oxidation and protein synthesis and inhibiting lipogenesis, which lowers TG
content in WAT without any resultant increase in circulating NEFA concentrations.154-156
When looking at the influence different fat reserves have on leptin concentrations, the
visceral/subcutaneous fat ratio has a moderately negative correlation with leptin.118 When
there is sufficient energy, the central nervous system directs the expenditure of excess
calories towards non-feeding activities such as reproduction and immunity.81
Leptin elicits an anorexic effect and in states of starvation this effect is lessened,
which stimulates feed intake.81 The hormone exerts its action by binding to the leptin
receptor (Ob-R) which is broadly expressed.99 There have been several variants of the
receptor described but the soluble leptin receptor is a major determinant of circulating leptin
concentrations. This receptor contributes to the pharmacokinetics and action of leptin by
stabilizing the molecule in the blood and preventing the bound form from interacting with
other leptin receptors without affecting the activity of the free hormone.99,157,158 Within the
hypothalamus, leptin exerts its effect by binding to its receptors at the arcuate nucleus and
thereby communicating the overall degree of adiposity, which in circumstances of obesity
leads to inhibition of food intake and a decrease in body fat mass due to increased calorie
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expenditure.81

In overfeeding, proopiomelanocortin (POMC) neurons are activated and

contribute to the decrease in food intake in response to a positive energy balance.159 The
decrease in body fat mass leads to a decrease in leptin concentrations, with this cycle
representing a classic negative feedback loop.81

6.1.3 Leptin resistance
Obesity is associated with leptin resistance instead of deficiency, with higher leptin
concentrations detected, implying impairment of negative feedback.81,137,159 The state of
leptin resistance is defined by high leptin concentrations with hyperphagia and obesity.159
Humoral mediator elevations in a negative feedback loop are the hallmark of a resistance
syndrome.81,160 Generally in a classic feedback loop, the cause of the resistance is either
receptor or post-receptor insensitivity, however with leptin there are two additional methods
in which resistance can be caused – impaired transport of leptin across the blood-brain barrier
or impairment of downstream neuronal signaling.81 In both human and animal models, the
majority of cases of leptin resistance occurs due to impairment at the blood-brain barrier or
receptor/post-receptor level.81 A state of peripheral leptin resistance is diagnosed when
exogenous doses of leptin are unable to elicit anorectic drive, indicating the inability of
circulating leptin to signal the brain.81 Central leptin resistance is defined by a lack of
response to leptin being administered directly to the brain and it appears from one rodent
model, that peripheral resistance is more severe or precedes central resistance.81,161
A transcription factor called STAT3 plays an important role in leptin resistance by
affecting the leptin-induced regulation of food intake and hepatic glucose production.154,159
The target gene for STAT3 is suppressor of cytokine signaling 3 (Socs3) which is produced
in response to cytokine signaling and provides negative feedback.159,162,163 It was shown in
animal experiments that Socs3 plays a role in leptin resistance, because mice with genetic
modifications that eliminated or inhibited its ability to bind the leptin receptor had decreased
food intake and body weight.159,164 Another mechanism in leptin resistance is phosphatase
PTP1B which is responsible for the dephosphorylation of Janus Kinase 2 (Jak2), the initial
tyrosine kinase involved in leptin receptor signaling.159,165,166 When the gene for this enzyme
is deleted, mice are lean and hypersensitive to leptin.159,165,166
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As leptin concentrations increase in the obese state, it appears to exert less influence
on centrally-mediated appetite and weight control81

Triglycerides have been shown to

decrease transport of leptin across the blood-brain barrier, and hypertriglyceridemia is
detected in obese humans and animals.81,167

6.2 Adiponectin
6.2.1 Structure and discovery
Adiponectin is a 30 kDa adipose-derived factor composed of 247 amino acids that
directly affects glucose homeostasis and regulates insulin sensitivity.86,168 The gene for
adiponectin was first isolated from adipose tissue in 1996 and has lower expression in obese
animals and humans.99,169

The protein itself, however, was discovered by multiple

laboratories throughout the 1990s and was given multiple names, including complementrelated protein 30, adipoQ, adipose most abundant gene transcript, gelatin-binding protein,
and adiponectin.169-172
Adiponectin has been studied in conjunction with MetS because its absence is noted
in states of IR and glucose intolerance, and it has been shown to induce weight loss, inhibit
hepatic glucose production, and increase FA oxidation.99,173,174 It is comprised of 4 regions;
an N-terminal region with no homology to any known proteins, a 27 variable amino acid
region, a collagen-like region, and a C-terminal globular domain that is homologous to
complement factor C1q and type VIII and X collagens.64,170,172 It is the most abundant
secretory protein of adipose tissue in humans and acts as an anti-inflammatory, insulin
sensitizing anti-diabetic hormone, and anti-atherogenic agent.124,171,175,176

Adiponectin

concentrations are inversely correlated with central adiposity, IR, and the homeostasis model
of IR (HOMA-IR), which is discussed below.124,171,175,176 It is the predominant adipokine
influencing SI and plays a role in FA oxidation, leading to lower plasma TG concentrations
and improved glucose homeostasis.175,177
Circulating adiponectin occurs as trimers, hexamers, and multimers with low
molecular weight (LMW; single trimer), mid-molecular weight (MMW; two trimers), and
high molecular weight (HMW; multiple hexamers) forms.64,86,177 Globular forms are also
isolated, which are comprised of the globular head (C-terminal end) portion of this adipokine.
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Plasma concentrations are approximately 5µg/mL in humans, with lower levels detected in
individuals suffering from T2D, IR, and hyperinsulinemia.108,168,177,178

Adiponectin

concentrations are higher in women compared to men and are generally reduced in obese
animals and in patients with T2D.168,175,177 In a study evaluating metabolic markers of IR in a
population of British children, there was no significant difference noted between boys and
girls;26 however, as children aged and BMI increased, there was a decrease in adiponectin
concentrations for both genders attributed to fat acquisition in the years before puberty. The
HMW form of adiponectin is proposed to have a stronger correlation with IR compared with
total circulating concentrations because this form is more biologically active.124,179
In horses, plasma total adiponectin concentrations reflect obesity and therefore fitness.
Gordon et al.180 showed that plasma adiponectin concentrations were higher in a research
population of physically fit Standardbred mares when compared to unfit counterparts. There
was no diurnal variation in adiponectin secretion detected in the same study. This lack of a
diurnal rhythm was also documented in humans, although one group detected a significant
decline in this adipokine at night.180-182

6.2.2 Adiponectin receptors
There are two known receptors for adiponectin, referred to as AdipoR1 and AdipoR2.
The first is predominantly expressed in skeletal muscle and WAT and shows a higher affinity
for the globular form of adiponectin, which increases FA oxidation and prevents diet-induced
obesity, when experimentally injected.86,128,183,184

In contrast, AdipoR2 is predominantly

expressed in the liver and only responds to the full length protein.86,184 Humans with IR and
T2D have lower expression of both receptors in skeletal muscle, and the expression of both
receptors is positively correlated with SI.177,185,186 Ceddia et al.86 demonstrated that, by
administering globular adiponectin to rat L6 myocytes, glucose uptake increased as a result of
increased GLUT4 translocation to the myocyte membrane. Adiponectin receptor knock-out
mice develop severe glucose intolerance and IR when both receptors are disrupted, proving
that these receptors play an important role in the regulation of insulin sensitivity.64,187 In the
same study it was shown that the two adiponectin receptors had functional differences, with
AdipoR1 being more tightly linked with AMPK activation and AdipoR2 being associated with
PPAR-α activation and the inhibition of inflammation and oxidative stress.64,187
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6.2.3 Role of adiponectin in insulin resistance
In humans, the prevalence of IR decreases with increasing plasma adiponectin
concentrations.124,168

Adiponectin is positively associated with SI, and states of

hypoadiponectinemia are associated with IR.124,176 The mechanisms by which adiponectin
exerts it effect on insulin action are not completely known, but are thought to involve PPARα, and AMPK activation, which increase FA oxidation in muscle and liver, and therefore
decrease tissue TG concentrations.64 Lowering TG concentrations within skeletal muscle
improves insulin signaling.
Several factors regulate the production of adiponectin by WAT, including
inflammatory cytokines such as TNFα and interleukin 6 (IL-6), as well as PPAR-γ.128,188,189
Activation of PPAR-γ increases levels of adiponectin and creates a shift in fat from visceral
to subcutaneous depots.118,190 van der Poorten et al.118 demonstrated that there is an inverse
correlation between adiponectin levels and visceral fat depots. The inflammatory effect of
TNFα is opposed by the anti-inflammatory effect of adiponectin.64,128,191

Adiponectin

inhibits TNFα release and attenuates the inflammation associated with obesity by inducing
production of other anti-inflammatory mediators such as interleukins 1 and 10 (IL-1, IL10).64,128,191 However, the expression of adiponectin is down regulated with obesity and
hypoadiponectinemia is observed in patients with visceral obesity and IR.98,108,174

This

observation is especially important in circumstances of excess visceral adipose tissue because
inflammation reduces adiponectin secretion.64,192

Increased inflammatory cytokine

production and the release of FA into the portal circulation leads to hepatic TG accumulation
and IR.64,192
The concept of a genetic influence on adiponectin concentrations has also been
proposed because offspring of hypertensive patients have lower plasma adiponectin
concentrations when compared to offspring of normotensive patients.175 Matsubara et al.193
showed that plasma adiponectin concentrations are negatively correlated with serum TG
concentrations and the atherogenic index, and are positively correlated with HDL-cholesterol
levels.168,193 It has also been shown that single nucleotide polymorphisms of genes encoding
adiponectin protein and receptors have associations with T2D phenotypes.177 Adiponectin is
not likely to be the main determinant of insulin sensitivity as many other factors have been
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associated with insulin sensitivity as well, but may be a marker of metabolic state which is
influenced by interactions among different organs (adipose, skeletal muscle, and liver).177

6.3 Resistin
6.3.1. Discovery and distribution
One of the newest adipokines to be discovered and studied for its role in IR and MetS
is resistin. Resistin was discovered by three research groups and has been associated with
IR.168,194-196 A link between resistin and IR has been found in animal models, but there have
been inconsistent results in humans.124,195,197 Resistin is a 12.5 kDa polypeptide hormone that
belongs to the family of small cysteine-rich secretory proteins.64,195

This adipokine is

expressed predominantly by adipose tissue, but is mainly produced by the infiltrating
macrophages of the adipose tissue, which are the primary mediators of the immune response
and represent up to 40% of adipose tissue.99,124,129,168,198,199
High plasma resistin concentrations are detected in humans with morbid obesity.168,200
This elevation in resistin may indicate a role in the pro-inflammatory state associated with
obesity.64,124 However, other investigators have failed to demonstrate a relationship between
obesity or IR and resistin expression.175 Resistin serves as a signaling molecule between the
energy storage organ of adipose tissue with the insulin-sensitive liver and skeletal muscle
tissues.46,201

6.3.2 Influence of resistin on insulin sensitivity
In rats, a sexual dimorphism has been found in the expression of the resistin gene,
with male rats having a greater expression compared to females.168,202

In animals and

humans, the administration of thyroid hormones increases basal and insulin-induced glucose
uptake by skeletal muscle, most likely due to an increase in GLUT4 function.168,203 In states
of drug-induced hypothyroidism, resistin mRNA expression increases in adipose tissue,
which suggests that decreased resistin concentrations are involved in the improvement in
insulin sensitivity seen with thyroid hormone supplementation.168,202

The treatment of
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patients with insulin-sensitizing drugs decreases resistin levels, further supporting the
suggestion that this adipokine is an important mediator of IR.36,195
Hivert et al.124 found that individuals with MetS had higher resistin concentrations
and lower levels of adiponectin. In this group, the prevalence of IR increased positively with
increasing concentrations of resistin.124 The expression of resistin is increased in response to
pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1, and resistin blood concentrations
are positively correlated with blood concentrations of these inflammatory markers.64,204
Resistin may also stimulate the same pro-inflammatory cytokines, implying a positive
feedback loop.128,132

6.3.3 Role of resistin in hepatic insulin resistance
Resistin is thought to be involved in the development of hepatic IR because infusion
of recombinant resistin impairs hepatic insulin sensitivity and increases hepatic glucose
production.99,198 Hepatic resistance mediated by resistin in states of diet-induced obesity has
been related to the inactivation and inhibition of AMPK and the opposing activation of ACC
and Socs3.109,205-207 It has been shown in rats that acute administration of resistin increases
blood glucose concentrations by both inhibiting insulin-stimulated glucose uptake and
enhancing hepatic glucose production.198,208,209
Singhal et al.

109

demonstrated that deleting the resistin gene (retn) in wild type and

ob/ob mice decreased hepatic TG content when compared to controls and lowered serum TG,
cholesterol, glucose and insulin concentrations. In the mice deficient for the resistin gene,
there was also a decrease in mRNA expression of SREBP-1, ACC, and FAS, as well as
protein levels of ACC. The receptor for resistin is currently unknown, but the induction of IR
via resistin has been attributed to reduced phosphorylation of AMPK and activation of
Socs3.109,206,207 In states of resistin deficiency, insulin sensitivity is improved, which leads to
decreased hepatic glucose production, improvement in hepatic IR, and increased glucose
uptake by peripheral tissues.109,205,206

In resistin deficient mice, key lipogenic genes,

including SREBP-1 and FAS, are suppressed in the liver whereas genes involved in lipolysis
remain unaffected.109
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Treating rat hepatocytes with resistin and insulin has been shown to significantly
decrease glycogen content, supporting the concept that resistin antagonizes the effects of
insulin on glucose uptake and storage201 via decreased glycogen synthesis or increased
glycogenolysis. Additionally, such treatment reduces the number of insulin receptors, and as
a consequence, there is a decrease in glycogen synthase activation and decrease in glycogen
phosphorylase, with an increase in hepatic glucose production.201 However, in the absence of
insulin, there was no effect of resistin on glycogen phosphorylase activity, which led to the
conclusion that resistin enhances glycogen phosphorylase activity by down-regulation of the
insulin receptor.201 This sequence of events may explain the association between resistin and
hepatic IR.

6.4 Glucagon-Like Peptide 1
6.4.1 Structure and discovery
Glucagon-like peptide 1 (GLP-1) was first discovered in 1968 when it was
established that a glucagon-like immunoreactive material secreted by L-cells of the intestine
in response to an oral glucose load was different from glucagon itself.210 It differed from
glucagon both physiochemically and biologically and was found to be a component of the
major proglucagon fragment that forms in parallel with glucagon during post-translational
processing.210,211 It is a 29-amino acid protein that is secreted in an active form, designated as
GLP-1 7-36 amide, and is inactivated to GLP-1 9-36 amide as a result of rapid removal of the
NH2 terminus by an enzyme known as dipeptidylpeptidase-4 (DPP-4).210,212 Glucagon-like
peptide 1 is an incretin hormone, which is defined as a hormone capable of amplifying the
glucose-induced secretion of insulin following oral glucose administration when compared to
intravenous glucose administration.213

6.4.2 Measurement of GLP-1
Since the active form of GLP-1 is degraded rapidly by DPP-4, it is necessary to
prevent its inactivation by treating blood samples with a DPP-4 inhibitor if active GLP-1 is
the hormone of interest.214 It has been determined that the majority of active GLP-1 secreted
is already inactivated by the time it reaches the portal vein, resulting in a short half-life of
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several minutes.214 Assays that measure total GLP-1 use antibodies directed towards the
carboxyl (COOH-) end of the protein, which is not cleaved by DPP-4.210 However, assays
designed to measure active GLP-1 utilize antibodies directed towards the intact NH2 terminus
as described above.

6.4.3 Association with insulin resistance and obesity
The main effect of GLP-1 is to enhance insulin secretion following an oral glucose
dose; however, it has recently been discovered that GLP-1 also affects gastric emptying rate
and satiety.215 By slowing the rate of gastric emptying, the glycemic response to a meal is
also diminished, aiding in glucose homestasis.215 Glucagon-like peptide 1 has also been
associated with inhibition of pancreatic glucagon secretion and hepatic glucose production.211
Studies have shown that there is abnormal secretion in conditions associated with
insulin resistance and/or obesity such as type 2 diabetes, polycystic ovary syndrome (PCOS),
and myotonic dystrophy.216-218 It has been determined that attenuated GLP-1 secretion is a
result of obesity, with lean subjects showing more pronounced responses to an oral sugar
challenge when compared to obese individuals.211,218 In a study of patients with MetS, it was
determined that fasting levels of serum GLP-1 were 28% higher in people with MetS,
compared to individuals with Pre-MetS.122 Elevations in fasting GLP-1 concentrations were
significantly related to the presence of dyslipidemia.122 This supports earlier findings that
higher fasting plasma concentrations of GLP-1 are associated with higher resting energy rates
and fat oxidation.219 Obesity is often associated with IR and diabetes as higher fat mass
inhibits insulin action.220,221
Polycystic ovary syndrome is one of the most common endocrine disorders in women
that negatively impacts fertility and increases the incidence of T2D.217 When compared to
normal women undergoing an oral glucose tolerance test, basal concentrations were found to
be similar during the early part of the test, but differed in the later part of the test, with lower
concentrations in PCOS patients.217 This is relevant to the finding that post-prandial GLP-1
concentrations and area under the curve values are significantly lower in type 2 diabetics
compared to people with normal glucose tolerance.218 However, in a study of 18 men with
myotonic dystrophy, which is characterized with pronounced IR and hyperinsulinemia, a
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significantly greater increase in GLP-1 concentrations was detected following an oral glucose
load compared to controls.216

Baseline GLP-1 concentrations were also lower in the

myotonic dystrophy patients compared to controls.

6.4.4 Potential role in therapy
Glucagon-like peptide 1 is associated with enhanced insulin secretion by the β-cells of
the pancreas and has been investigated as a therapy for impaired glucose control and
IR.212,222-225 In dogs that have undergone total pancreatectomy, administration of GLP-1 was
shown to potentiate insulin action during a hyperinsulinemic clamp, and this was attributed to
the effects of GLP-1 on insulin-stimulated glucose utilization.222 This study also showed
suppression of FA and glycerol concentrations because GLP-1 potentiates the anti-lipolytic
effects of insulin. In humans, administration of a GLP-1 analogue significantly reduced
glycosylated haemoglobin concentrations and improved fasting and post-prandial glucose
control when administered in conjunction with metformin.224 Hyperglycemia is a frequent
occurrence in critically ill patients on mechanical ventilation and total parenteral nutrition,
and this problem can adversely affect medical outcomes. The overall glycemic response to
enteral nutrient infusion was reduced in patients treated with GLP-1 over 270 minutes on 2
consecutive days compared with placebo and this was accompanied by increased insulin to
glucose ratio.223
Administration of DPP-4 inhibitors has also been evaluated as a potential therapy for
impaired glucose tolerance and IR.

Inhibitors have been evaluated on their own or in

conjunction with other anti-diabetic compounds.212

They enhance GLP-1 activity by

preventing its rapid inactivation following secretion by the small intestine.212 In dogs, the
DPP-4 inhibitor vildagliptin was found to increase hepatic glucose uptake during GLP-1
infusion.225 It was also determined that the oral administration of vildagliptin via stomach
gavage 20 minutes prior to glucose and GLP-1 infusions was capable of suppressing DPP-4
activity throughout the 4-hour test period.225
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6.4.5 Conclusions
Results of studies suggest that obesity, rather than IR, may play a more important role
in GLP-1 secretion as obese humans tend to show higher fasting concentrations but
diminished responses during oral glucose tests. This may allow GLP-1 to function as an
adequate marker for identifying humans and animals that are at greater risk for the
complications associated with obesity. Administration of GLP-1 or DPP-4 inhibitors appears
to improve insulin sensitivity and glucose tolerance.

At the time of writing, there are

currently three selective DPP-4 inhibitors, sitagliptin (Januvia), vildagliptin (Galvus), and
saxagliptin (Onglyza) available for use in the United States and Europe.212 Both GLP-1
analogues and DPP-4 inhibitors can therefore be used to treat impaired glucose tolerance and
insulin resistance.

7. Methods of assessing insulin sensitivity and resistance in the horse
7.1. Frequently-sampled intravenous glucose tolerance test
The frequently-sampled intravenous glucose tolerance test (FSIGTT) is used to
quantify insulin sensitivity via application of the minimal model.226-229

Minimal model

analysis is a mathematical construct that partitions glucose disposal into insulin-dependent
(insulin sensitivity – the capacity of insulin to promote glucose disposal) and insulinindependent (glucose effectiveness – the capacity of glucose to mediate is own disposal)
glucose utilization, while also estimating the sensitivity of pancreatic β-cells to glucose.226-229
The minimal model of glucose and insulin dynamics is a nonlinear regulatory model fitted to
data collected during the FSIGTT.31

7.1.1 Procedure in horses
An insulin-modified FSIGTT is performed in horses.228-231 The overall procedure of
this test is to administer a body weight (bwt) dependent bolus of dextrose intravenously,
collect samples at specific time points, and at 20 minutes post-dextrose, administer insulin
intravenously at a weight dependent dose, and then continue with collection of blood samples
for a test duration of 180 minutes.228,231 Hoffman et al.228was the first research group to
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utilize the FSIGTT for assessment of insulin sensitivity and glucose metabolism in the horse.
The procedure assessed by this group included baseline samples followed by administration
of a 50% dextrose solution bolus at 0.3 g/kg bwt via jugular catheter. Blood samples were
collected via catheter at time points 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, and19 minutes. At 20
minutes, an insulin bolus was administered through the catheter at a dose of 30 mU/kg bwt,
and sample collection resumed at 22 minutes and continued at times 23, 24, 25, 27, 30, 35,
40, 50, 60, 70, 80, 90, 100, 120, and 180 minutes. Glucose and insulin concentrations were
measured in each sample.228

7.1.2 Calculations
Minimal model analysis utilizes a computerized algorithm which supplies the
investigator with 3 variables: (1) the index of insulin sensitivity (SI), (2) glucose
effectiveness (Sg), and (3) the acute insulin response to glucose, (AIRg).31,227,228

The

disposition index (DI) is often calculated. The measure Sg represents the capacity of glucose
to mediate its own disposal, independent of changes in the circulating levels of insulin as well
as its ability to inhibit hepatic glucose production. The following formula is used:
G' (t) = -(X+ Sg) x G(t) + (Sg x Gb)
where G'(t) represents the rate of glucose clearance from plasma (min -1); X represents insulin
action; G(t) represents the plasma glucose concentration (mg/dL) at time t, G(0) is the
theoretical concentration of glucose at time 0; and Gb represents the basal glucose
concentration (mg/dL) which is maintained by hepatic glucose production.228,232
The SI value represents the capacity of insulin to promote glucose disposal (L mU-1
min-1) and can be defined as the fractional glucose disappearance per insulin concentration
unit and calculated using the following formulas:
X' (t) = -p2 x X(t) + (p3 x [I(t) – Ib])
SI = p3/p2
where X' (t) (min-2) represents the change in insulin action over time; p2 represents the rate
(min-1) of decline of insulin action; X(t) represents insulin action (min-1), p3 is the rate (min-1)
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of introduction of insulin into the interstitial space; I(t) is the insulin concentration (mU/L) at
time t; and Ib is the basal insulin concentration (mU/L).228,232
Pancreatic function is represented by AIRg (mU min L-1) which quantifies the
endogenous insulin secretion occurring in response to the glucose dose and is calculated
using the formula;
AIRg = ∫ [I(t) – Ib] x dt
where I(t) is the insulin concentration at time t and Ib is the basal insulin concentration.228
Finally, DI is an index that describes pancreatic β-cell responsiveness and accounts
for the influence of AIRg and Si and is calculated using the following formula;
DI = AIRg x SI.228

7.1.3 Use of the FSIGTT in horses
Hoffman et al.228 introduced the FSIGTT as a tool for examining glucose and insulin
dynamics in horses and responses to glucose were similar to other species.228,233,234 However,
Pratt et al.227 subsequently demonstrated that the standard FSIGTT without an insulin bolus
has a higher mean coefficient of variation when compared with the euglycemic
hyperinsulinemic clamp (EHC) technique, which is discussed below. It was noted that
insulin sensitivity can be more precisely estimated when there is a defined demarcation
between 1st and 2nd phase insulin responses, so the FSIGTT was modified to include an
insulin bolus.227 The insulin-modified FSIGTT has been used to detect IR in a group of
mature obese mares and provides important information regarding pancreatic insulin
output.29,228,235 Disadvantages of the EHC are that it is time consuming, requires trained
personnel, relies upon steady-state conditions, and demands constant adjustment, whereas the
FSIGTT is more straightforward, less invasive, and technically simpler to perform.31,227,228,232

27

7.2 Euglycemic hyperinsulinemic clamp
7.2.1 Introduction
The EHC technique involves inducing and maintaining a state of hyperinsulinemia via
continuous infusion of insulin, while at the same time maintaining euglycemia by
administering variable amounts of dextrose.227

Insulin infusion suppresses endogenous

glucose production by the liver and euglycemia provides physiologic inhibition of
endogenous insulin secretion.14

The clamp technique, like the FSIGTT, has been used

successfully in the horse.227,228,236,237
The EHC procedure was established by DeFronzo et al.237 in 1979 as a method of
quantifying insulin secretion and resistance in humans, using the principle that a patient with
normal insulin sensitivity would require more glucose to maintain euglycemia than an
individual with IR. This same situation was first demonstrated in a horse when a 29-year-old
mare suffering from persistent hyperglycemia and hypertriglyceridemia was evaluated.235
When simplified, the amount of glucose required to maintain basal concentrations is equal to
the amount of glucose taken up by the tissues, and therefore represents a measure of
peripheral tissue sensitivity to insulin. During the insulin infusion period, the amount of
glucose required to maintain euglycemia increases, so measurements taken during the plateau
period are utilized for calculations.14

7.2.2 Procedure in horses
Baseline blood samples are collected and then the horse is connected to a peristaltic
infusion pump which administers human recombinant regular insulin at a constant rate of 3
mU/min/kg bwt, or 5 to 20 mU.m-2.min-1 in humans, when the dose is based upon body
surface area.232

In an early study performed in horses, a priming dose of insulin was

administered at a dosage of 323 µmol/kg bwt dissolved in 50 mL saline over 10 minutes.14
Once the priming dose was administered, the constant infusion of insulin was started and
continued throughout the study at a rate of 43 µmol/kg.min-1.14 Dextrose was administered at
the same time as insulin to prevent hypoglycemia.
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The EHC procedure usually takes 180 minutes to perform and blood samples are
taken at 5 minute intervals so that glucose concentrations can be measured using a portable
glucometer.

Depending upon the measured glucose concentration, an infusion of 50%

dextrose solution is administered at variable rates by calibrated syringe pump so that blood
glucose concentrations are maintained within euglycemic range. In the procedure performed
by Pratt et al.,227 blood samples were also collected at 15 minute intervals for measurement of
insulin concentrations. The first 90 minutes of the clamp procedure can be considered an
equilibrium period, and the data collected from the samples obtained in the last 60 minutes
are utilized for the calculation of whole body glucose uptake and an index of insulin
sensitivity.227

7.2.3 Calculations
Whole-body glucose uptake (M) represents the amount of glucose taken up by
glucose utilizing tissues in response to insulin and it is assumed that hyperinsulinemia has
suppressed endogenous glucose production completely.227,237

Since euglycemia is not

maintained perfectly throughout the procedure, a correction factor referred to as the space
correction (SC) must be calculated to determine M. This correction is calculated to account
for the glucose that has been added to, or removed from, the glucose space outside of normal
metabolism. The following formula is used:
SC = (G2 – G1)(0.19 bwt)/(T x bwt)
where G1 and G2 represent the beginning and ending glucose concentrations of each time
interval, T is the time interval (5 minutes), bwt is calculated in kg, and (0.19 bwt) is equal to
the glucose space in liters. The result of this equation is required to calculate M:
M = GIR – SC
where GIR is the glucose infusion rate measured in mmol/kg/min.227,237
The index of insulin sensitivity measured from this technique is calculated from the
steady-state insulin concentration (I) which is the average of the serum insulin concentration
measured during the final 60 minutes of the EHC and is used to calculate the M/I ratio. This
ratio reflects the rate of glucose disposal per unit of insulin and serves as a reasonable index
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of insulin sensitivity.14,227,237 Another calculation for this index that can also be utilized and
is:
SIClamp = M/(G x ∆I)
where G is the blood glucose concentration during the steady-state, and ∆I is the difference
between the fasting and steady-state insulin concentrations.232
A study looking at the glucose disposal rate of both lean and obese mares found that
mares with a BCS of approximately 4.5 had glucose disposal rates ranging from 3.9 to 10.5
µmol/kg/min, while obese mares with a BCS of approximately 8.5 had glucose disposal rates
ranging from 0 to 14.5 µmol/kg/min.31,236

7.2.4 Conclusions
When tests were compared in horses, mean coefficient of variation was 14% for the
EHC compared to 24% for the FSIGT.227 Rijnen et al.14 also assessed the repeatability of
EHC results by performing the procedure in the same horses on 3 different occasions over a
3-week period. This study showed close agreement among the repeated tests in terms of M
values (0.013, 0.016, and 0.016 mmol/kg/min), but the M/I ratio had wider variability
(0.00037, 0.00057, and 0.00067 mmol/kg/min).14,227 A main advantage of the EHC is that it
provides a direct measure of whole body glucose disposal at a given level of insulinemia
under steady-state conditions.232 A limitation of this technique is that supraphysiological
levels of insulin are maintained during the procedure.232

7.3 Combined glucose-insulin test
7.3.1 Introduction
Many tests can aid in the diagnosis of diabetes mellitus, including fasting blood
glucose concentrations, intravenous glucose tolerance tests, and clamp techniques.238 A
glucose tolerance test measures the rate of clearance of glucose from the blood after oral or
IV administration, with the time for blood concentrations to return to baseline measured.235,239
Tests of insulin sensitivity measure the blood glucose response to an injection of exogenous
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insulin.235 Eiler et al.238 combined these two types of test and developed the combined
glucose-insulin test (CGIT) for use in horses. This test was designed for use in the clinical
setting and provides a more accurate measure of insulin sensitivity by combining information
from glucose tolerance and insulin challenge tests.

7.3.2 Procedure
When performing a CGIT, a single intravenous catheter is placed in the jugular vein
to serve as the route of dextrose and insulin infusion, as well as sample collection. Blood
glucose concentrations are measured using a hand-held glucometer. Once baseline values are
obtained, 50% dextrose solution is rapidly administered (<1 minute) at a dose of 150 mg/kg,
immediately followed by a bolus of human recombinant regular insulin at a dose of 0.1 U/kg
diluted in 3 mL of isotonic saline. Samples are collected by withdrawing 3 mL blood, which
is discarded, and then the blood sample is collected. Blood samples are collected at 0, 1, 15,
25, 35, 45, 60, 75, 90, 105, 120, 135, and 150 minutes.238
Healthy horses show a two phase blood glucose curve with a positive phase
(hyperglycemia) that goes above baseline and a negative phase (hypoglycemia) which falls
below baseline.

Each phase of the curve has an ascending and descending area, with

ascending occurring first followed by descending in the positive phase, and the reverse is
seen in the negative phase. In healthy animals, the positive phase should descend to baseline
concentration around 30 minutes post glucose and insulin administration, at which time the
negative phase begins and glucose concentrations fall below baseline. The nadir of glucose
concentration in the negative phase has occurred by 75 minutes after the start of the
procedure, at which time the ascending linear area begins around 105 minutes and is
completed by approximately 140 minutes. In horses with IR, the positive phase is prolonged,
causing a slower (≥ 45 minutes) return to baseline (Figure 1.2).6

7.3.3 Conclusions
The CGIT test is easily interpreted by examining graphed results or using the 45minute result as a cut-off value. The procedure is relatively simple to perform and well
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tolerated.238 Due to the simplicity and ease of this procedure, the CGIT is a recommended
test for diagnosing IR in horses.

7.4 Proxy measures of insulin sensitivity
7.4.1 Introduction
Proxies and surrogates are single sample predictors of insulin sensitivity that utilize
plasma glucose and insulin concentrations.33 They serve as inexpensive and easily applied
quantitative tools.232 Single samples often provide good representation of glucose and insulin
dynamics because they describe the chronic, non-agitated state of the individual.33 Treiber et
al.33 evaluated proxies for insulin sensitivity by comparing single plasma glucose and insulin
values to minimal model analysis results in horses.

7.4.2 Types of proxy measurement
There are currently five proxies used to screen insulin sensitivity and β-cell
responsiveness in humans, and two new proxies have been proposed for screening horses.33
The proxies currently utilized in human medicine are the homeostasis model assessment
(HOMA), the quantitative insulin sensitivity check index (QUICKI), the glucose-to-insulin
ratio, the percent HOMA-beta cell function (HOMA-BC%), and the insulin-to-glucose ratio.
The two new proxies established for use in horses are the reciprocal of the square root of
insulin (RISQI) and the modified insulin-to-glucose ratio (MIRG).

7.4.3 Equations for proxy measurements
For the following equations, all glucose and insulin values are basal measures and r is
the correlation coefficient used to compare predicted insulin sensitivity with SI from the
minimal model.
HOMA = (glucose-insulin)/22.5
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Figure 1.2: Glucose concentrations of non-obese (squares) and obese (diamonds) horses
during a CGIT. Glucose concentrations in obese horses remained above baseline for the
duration of the test, whereas concentrations in non-obese animals return to baseline by 15
minutes following a glucose infusion. From Frank N et al. Physical characteristics, blood
hormone concentrations, and plasma lipid concentrations in obese horses with insulin
resistance J Am Vet Med Assoc 2006;228:1,383-1,390.
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with 22.5 being a normalizing factor which is the product of fasting glucose (4.5 mmol/L)
and insulin (5 µU/mL) concentrations in healthy humans.232 An individual with normal
insulin sensitivity should, in theory, have a HOMA=1. This proxy has r values of 0.60 and
0.89 with SI.33,240,241
QUICKI = (log[glucose × insulin])-1
HOMA-BC% = (20 × insulin)/(glucose-63)
Correlations with SI are 0.89 for the QUICKI and 0.60 and 0.58 for the HOMABC.33,241,242 The insulin-to-glucose ratio is easily calculated and has correlation coefficients
of 0.79 and 0.86; this measure correlates with insulin secretion by the pancreas.31,33 In
contrast, the glucose-to-insulin ratio correlates with insulin sensitivity and has reported r
values of 0.73, 0.91, and 0.92 with SI.31,33,241
The RISQI proxy measure of insulin sensitivity was devised specifically for use in
horses by Treiber et al.33 and is calculated by the equation:
RISQI = 1/√insulin=insulin-0.5
The same group developed MIRG, which is a measure of pancreatic insulin output
and is calculated using the formula:
MIRG = (800-0.30 × [insulin-50]2)/(glucose-30)
Both RISQI (r = 0.77) and MIRG (r = 0.75) correlated well with SI and AIRg,
respectively in the population of horses studied.33 This group provided calculations for SI and
AIRg using proxy measurements:
SI = ((7.93)(RISQI)-1.03)
AIRg = ((70.1[MIRG])-13.8)

7.4.4 Use of proxy measures
The HOMA measurement was devised to take advantage of the reciprocal relationship
between basal insulin and basal glucose concentrations.33 In humans, the HOMA has good
correlation with EHC results, as well as the SI values obtained from the minimal model.33,240
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The QUICKI, similarly, was established for use in humans as a simple method of assessing
insulin sensitivity as it relies upon the same reciprocal relationship between insulin and
glucose.33,243 When compared, the QUICKI correlates better with insulin sensitivity.33,243
The glucose-to-insulin ratio is based upon the concept that the insulin-secreting
response of the β-cells is exaggerated with IR, despite normal glucose concentrations; a low
glucose-to-insulin ratio therefore indicates lower insulin sensitivity.33 In the case of diabetes
mellitus when hyperglycemia develops, the ratio increases, resulting in a conceptual flaw of
this particular proxy.232 This ratio has stronger correlation with insulin sensitivity than the
HOMA or QUICKI.33,35,244 The insulin-to-glucose ratio estimates the amount of insulin
secreted by β-cells in response to glucose; a high ratio indicates reduced insulin sensitivity
because there is compensatory secretion of insulin by the pancreas.33
The HOMA-BC% was first proposed in 1985 by Matthews et al.245 and correlates
well with clamp and IV glucose tolerance test results. This measure is a proxy for AIRg and
provides similar information to the insulin-to-glucose ratio.242 Studies in humans have shown
that estimates of β-cell function are adequate in groups of individuals with similar health, but
do not correlate well across different groups.244,246
In horses, RISQI correlates well with insulin sensitivity and MIRG with pancreatic
function , so these measures can be used to identify animals that are compensating for
decreased insulin sensitivity with increased pancreatic insulin secretion.33 Proxies for SI and
AIRg have specificity, sensitivity, and total predictive power of 85% and 88%, 45% and
50%, and 78% and 80%, respectively in horses.33,235

When combined, these measures can

aid in distinguishing healthy horses (normal SI and AIRg), from normoglycemic insulinresistant horses with compensatory insulin secretion (normal or low SI and high AIRg) and
hyperglycemic horses with β-cell failure (low SI and AIRg).33,235

Proxies also allow

investigators to make multiple determinations in a population or monitor clinical cases when
more accurate measures such as the FSIGTT or EHC are impractical.33

8. Treatment of insulin resistance
Drugs and supplements are used to treat IR in humans and horses, either directly or
indirectly via weight reduction, and these therapies will be reviewed in the following section.
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8.1 Levothyroxine
8.1.1 Introduction
Levothyroxine sodium (LT4) is a synthetic thyroid hormone used to treat
hypothyroidism, which is rare in adult horses.247 Studies performed by our research group
have established that LT4 can be administered to horses to promote weight loss.247-249 The
hypothalamic-pituitary-thyroid axis consists of the secretion of thyrotropin releasing hormone
(TRH) by the hypothalamus, which stimulates the release of thyrotropin stimulating hormone
(TSH) by the pituitary gland, which then stimulates the thyroid gland to release
triiodothyronine (T3) and thyroxine (T4). Thyroid hormones are measured as free T3, free
T4, total T3 or total T4. Free forms are physiologically active because they are readily
available for use by the cells, whereas total measures are the sum of free and bound forms. A
negative feedback loop occurs and LT4 significantly decreases TSH concentrations in
healthy, euthyroid horses.248,250

8.1.2 Levothyroxine use in horses
Sommardahl et al.248 administered LT4 to healthy adult horses over an 8-week period
and detected significant decreases in body weight compared to untreated controls. Total daily
doses of LT4 were 24, 48, 72, and 96 mg/d, with horses receiving LT4 at each dosage for 2
weeks at a time.

There were no significant changes in health parameters (heart rate,

respiratory rate, and rectal temperature) and only agitation was reported when horses received
96 mg LT4 per day.248 Loss of body weight may result from increased energy expenditure
and enhanced lipolysis.249,251 Humans receiving LT4 supplementation as a treatment for
hypothyroidism have lower BMI and lower serum concentrations of TG, total cholesterol
(TC), and VLDL.252,253 Rats receiving T4 supplementation have also shown increases in SI
resulting from increased rates of glucose disposal and glucose-stimulated insulin
secretion.252,253
Effects of LT4 supplementation on serum lipids and glucose dynamics were also
examined in the same study of healthy mares.249 After 8 weeks of supplementation, there
were significant decreases in plasma TG, TC, and VLDL concentrations in treated horses,
with weak correlations found between LT4 dose and TG and TC concentrations. These weak
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correlations may be explained by a cumulative effect of LT4 dosing since washout periods
were not inserted between treatment periods.249 No significant changes were noted for NEFA
concentrations, regardless of LT4 dose.

When effects of hypothyroidism on VLDL

concentrations have been examined, the opposite response was detected.254,255

Humans

suffering from hyperthyroidism show higher catabolic rates of VLDL-TG fractions, implying
that thyroid hormones stimulate the clearance of VLDL from the circulation.249,256
Associations also exist between hyperthyroidism and serum concentrations of other
lipoproteins and apolipoproteins.249,253 Thyroid hormones stimulate FA consumption by
increasing β-oxidation rate as well as uncoupled thermogenesis in hepatocytes.249,257,258 The
increase in β-oxidation in the liver is thought to lead to a reduction in the amount of TG
available for VLDL synthesis, and it has been found that the TG carried by VLDL in the
circulation is catabolized at a faster rate in humans suffering from hyperthyroidism.249,256
Use of LT4 in obese horses is important because obesity and IR are both risk factors
for laminitis and insulin sensitivity increases in response to LT4 treatment in horses.6,11,228
Horses receiving LT4 have shown a >2-fold increase in SI11 and significant increase in
insulin disposal rate.249 When LT4 was administered to healthy mares, insulin sensitivity
increased 1.8-, 2.4-, and 1.9-fold at 16, 32, and 48 weeks, respectively.11

A negative

correlation (r = -0.42) existed between SI and body weight, and glucose effectiveness
increased with treatment, while AIRg decreased. A maximum of 10% weight loss occurred
at 16 weeks and then body weight increased again. However, there was an overall decrease
in body weight of 5% compared with pre-treatment values.11 Weight loss may have been
even greater if feed intake had been restricted because horses were allowed out on pasture to
graze ad libitum. This is an important point because it has been shown that rats receiving
thyroid supplementation undergo weight loss associated with increased calorie expenditure,
decreased adipocyte size, and decreased fat pad weight, and also exhibit hyperphagia, which
can offset weight loss.11,251
In humans, cardiac abnormalities including tachycardia, arrhythmia, and hypertension
are associated with hyperthyroidism or overzealous use of LT4.249,259,260 Prolonged use of
LT4 in humans can result in left ventricular hypertrophy, but does not appear to affect heart
rate, blood pressure, or overall cardiac function.259,260 Since LT4 is commonly prescribed to
promote weight loss in obese horses, Frank et al.259 performed cardiac evaluations on the
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same mares described above that received 48 mg LT4/day for 48 weeks. No adverse effects
were noted when echocardiograms were performed and there were no changes in cardiac
troponin I concentrations or creatine kinase MB activities.

Serum tT4 concentrations

increased to levels 1.5- to 2-fold higher than reference range, but decreased again during the
withdrawal period.259
It should be noted that the duration of treatment in the aforementioned study was only
48 weeks, which is short in relation to the lifespan of horses. The duration of treatment may
therefore explain the lack of cardiac alterations seen in these horses.259-261

8.1.3 Levothyroxine and insulin sensitivity
One explanation for the increase in insulin sensitivity associated with thyroid
supplementation is that glucose transporter expression increases.

When mouse 3T3-L1

adipocytes are exposed toT3, GLUT1 and GLUT4 increase by 87% and 90% respectively,
causing a 3.6-fold increase in glucose uptake.249,262,263 Frank et al.11 detected higher mRNA
expression of GLUT4 in adipose tissue collected from LT4-treated horses, suggesting that
this transporter increases in abundance with treatment. However, the opposite effect was
observed in adipocytes harvested from rats that were treated with T4 for 7 days.263 There was
a decrease in the density of insulin receptors, a reduction in the amount of insulin-stimulated
glucose uptake, and a decrease in GLUT4 translocation to the plasma membranes upon
stimulation by insulin. It is possible that increased GLUT4 mRNA expression represents a
compensatory response to these alterations.
Weinstein et al.203 found that rats treated with T3 for 3 days showed increased (115%
and 136%) basal glucose uptake in both soleus and extensor digitorum longus muscles
respectively, as well as increased insulin-stimulated glucose uptake (55% and 42%,
respectively). These results indicate that thyroid hormone supplementation increases both
basal and insulin-stimulated glucose transport in mammalian skeletal muscle. This group
also demonstrated that GLUT4 protein expression increased in both muscle types. Results
also implied that T3 has a role in increasing the fractional partitioning of GLUT4 from its
intracellular stores to its location in the plasma membrane.203
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An increase in metabolic clearance rate of insulin has been detected in humans with
hyperthyroidism and rats that were treated with T4 for 5 days.264-266 Increases in insulin
binding and insulin receptor density have also been detected in adipocytes harvested from
rats receiving T4 therapy.266

The influence of LT4 on the glucose dynamics in horses has

been attributed to reductions in body weight, but direct effects must also be considered.249
Thyroid hormones also modulate proliferation and differentiation of adipocytes.267,268
In humans, hyperthyroidism enhances lipolysis while hypothyroidism has the opposite effect,
which can be attributed to increases cAMP and HSL activity.267 Viguerie et al.267 showed
that treatment of human adipose tissue cultures with T3 induced gene expression in
adipocytes, indicating that supplementation with thyroid hormone increases lipolysis.
Elevations in cAMP seen with thyroid supplementation result from down-regulation of
phosphodiesterase, the enzyme responsible for the hydrolysis of cAMP.267 When energy
supplies are low, via hypoglycemia, glucagon, or catecholamines, cAMP levels increase and
activate HSL which catalyzes breakdown of stored TG in adipose tissue into FA that can be
used for energy.82
Rats with hypothyroidism have an overall decrease in glucose turnover and glucose
utilization by skeletal muscle and adipose tissues.269,270 With thyroid supplementation, there
is an increase in AMPK activity, resulting in a subsequent decrease in ACC activity and
lower malonyl-CoA levels.269

This reduction in malonyl-CoA availability increases FA

oxidation and lowers the fat content of peripheral tissues such as skeletal muscle and adipose.
As previously noted, the decrease in fat accumulation in insulin-sensitive tissue often leads to
increased insulin sensitivity.269,271
Another mechanism by which LT4 might increase insulin sensitivity is through
modification of lipid metabolism. Hypothyroidism reduces activity of enzymes involved in
lipoprotein remodeling and lowers the number of LDL receptors, which are responsible for
internalization of cholesterol into cells.272 A recent study looking at the correlation between
thyroid function and MetS in humans found a negative relationship between FT4 and the
HOMA index, with low-normal FT4 concentrations associated with greater IR.273 This study
also found a significant negative correlation between levels of free T3 and free T4 and both
TC and LDL-cholesterol concentrations.

Hypercholesterolemia is associated with

hypothyroidism because LDL catabolism is inhibited by a lower number of LDL receptors.273
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Higher serum TG concentrations in hypothyroid patients are attributed to decreased activity
of hepatic TG lipase and slowed removal of circulating TG.273,274

8.1.4 Conclusions
Levothyroxine administration has been associated with weight loss and increased
insulin sensitivity in horses, but studies are now required to evaluate this treatment in obese
insulin-resistant horses with EMS.11,248,249,259

8.2 Metformin
8.2.1 Introduction
Metformin hydrochloride is an oral dimethylbiguanide anti-diabetic drug that is used
in human medicine to improve insulin sensitivity.64 This drug has been used in for the
treatment of T2D in humans since 1957 and is currently the most widely prescribed insulinsensitizing drug.275-278 A study in obese women with polycystic ovary syndrome (PCOS)
that received one of 2 doses of metformin for 8 months, showed hepatic fat content decreased
in response to treatment.275 Metformin is an attractive drug because it is cost-effective and
has beneficial modes of action.276

8.2.2 Metformin use in horses
Durham et al.276 examined the efficacy of metformin in insulin-resistant horses at a
15 mg/kg bwt twice daily dosage and showed that treatment significantly lowered serum
insulin and glucose concentrations, as well as proxy measures of insulin sensitivity and
pancreatic output. In human studies, there are consistent initial reductions in fasting insulin
and glucose concentrations along with improved insulin sensitivity.276,279,280

However,

efficacy waned over time in the study performed by Durham et al.276 and the same finding
was reported by Vick et al.281 These results suggest insulin sensitivity deteriorates over time
or the pharmacodynamics differ from other drugs. The optimum metformin dose in man is
approximately 2,000 mg/d, with a range of 500 to 3,000 mg/d.278 In horses, dosages have
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ranged from 5.6 to 16.8 mg/kg bwt.276,281 Furthermore, the oral bioavailability of metformin
is < 10% in the horse, compared with 40-60% in humans, with peak levels 1 to 3 hours postdosing, and a half-life of 4 to 9 hours.276,282,283

8.2.3Mechanisms of metformin action
Metformin has diverse modes of action that include both insulin-dependent and
insulin-independent actions to promote insulin-stimulated glucose uptake as well as glycogen
and TG synthesis, lipolysis, and inhibition of hepatic glucose production.276,279,284 Plasma
lipid concentrations also decrease with metformin treatment.276,285
Treatment of rats with metformin elicits dose- and time-dependent activation of
AMPK.277 Phosphorylation of AMPK is promoted by AMP in response to a decrease in the
ATP:AMP ratio, with the threonine 172 residue (Thr 172) becoming phosphorylated.277 It
has also been proposed that metformin may elicit its influence on AMPK activation by either
directly activating the AMPK-kinase, or by making AMPK a better substrate for this enzyme
by binding to it directly.277 By enhancing the activation of AMPK, the activity of ACC
decreases, which lowers malonyl-CoA levels.277 Beta oxidation and lipolysis are stimulated
as malonyl CoA concentrations decrease.
Lipogenesis is also decreased with metformin treatment, as the activation of AMPK
leads to a down-regulation of genes involved in FA synthesis, such as FAS.277 Insulin
stimulates lipogenesis via the lipogenic transcription factor SREBP-1c, which affects genes
such as FA synthase.277 Zhou et al.277 showed that incubation of rat hepatocytes with
metformin strongly suppressed SREBP-1c.

These effects

may explain the ability of

metformin to lower serum TG and VLDL concentrations in vivo.277 Metformin also inhibits
tyrosine phosphatase hPTP-1B and it should be noted that mice that do not express this
protein are very resistant to obesity.286-288 This may explain why individuals using metformin
often maintain or lose weight.

Inhibition of hPTP-1B also lowers blood lipid

concentrations.287
Gluconeogenesis by the liver is also inhibited by treatment with metformin and this is
attributed to activation of AMPK and the insulin receptor.277 Results of several studies
indicate that active AMPK is required for metformin to exert its inhibitory effects on hepatic
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glucose production.277,287

Studies have also implicated AMPK activation in stimulating

glucose uptake by skeletal muscle.277,289,290 Zhou et al.277 showed that there was an increase
in the activity of the catalytic sub-units of AMPK when rat skeletal muscle was incubated
with metformin, and also a significant increase in glucose uptake that was additive after the
addition of insulin.
Metformin might also regulate hepatic glucose production via activation of the insulin
receptor. This signals that energy supplies are sufficient, and by its activation, it inhibits
glucose production by the liver. Metformin increases tyrosine kinase activity, as well as
tyrosine phosphorylation of the insulin receptor, and therefore its activation.287 Both insulin
binding and metformin increase the phosphorylation of tyrosine residues in the β-subunit of
the insulin receptor in a comparable amount, however, it takes metformin longer to elicit its
effect (90 minutes) compared to insulin (20-30 minutes).287

8.2.4 Conclusions
Metformin acts by decreasing hepatic glucose production and increasing skeletal
muscle glucose uptake.87 It is believed that metformin accomplishes this by decreasing
lipogenesis, increasing lipolysis, activating AMPK, and activating the insulin receptor. This
drug is considered safe in humans, although side effects seen in humans include
gastrointestinal symptoms of diarrhea, abdominal comfort, nausea, and anorexia.279 Given
the sensitivity of horses to developing colic, close attention must be paid to animals receiving
metformin. However, no adverse reactions have been noted to date when metformin has been
administered to horses orally.276 Metformin might therefore serve as a safe and affordable
treatment for IR in horses.

8.3 Chromium
8.3.1 Introduction
Chromium (Cr) is an essential trace mineral required by mammals, and plays a role in
carbohydrate and lipid metabolism.291,292 In 2001, it was established by the US Food and
Nutrition Board that the daily adequate intake for men was 35 µg and 25 µg for women.292
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Chromium has two main oxidative forms, trivalent (Cr+3) and hexavalent (Cr+6); the trivalent
form is the most stable whereas the hexavalent form has been shown to cause clinical
cancer.291,293 The trivalent form is found in foods, such as egg yolks, whole grain products,
nuts, meat, and dietary supplementation.294 Chromium supplements are available in many
forms, including picolinate, chloride salt, and complex forms with nicotinic acid and amino
acids.294 Of these forms, the picolinate form appears to be the most stable and biologically
available.294 When compared to chromium chloride, which has a bioavailability of 0.4% at a
dose of 1,000 µg/d, chromium picolinate has a bioavailability of 2.8%.294,295
Studies in Eastern and Western world populations show positive metabolic effects of
both chromium picolinate and chromium chloride (CrCl) by resulting in decreases in fasting
plasma glucose concentrations, increased insulin sensitivity, and a reduction in the
requirement of oral anti-diabetic drugs.294,296

Absorption of chromium is enhanced by

administration of vitamin C and amino acids, but is diminished by the use of antacids, and
intake of simple sugars.294 The highest levels in the body are found in the liver (an important
site of glucose metabolism), spleen, and the kidneys, and the normal range in blood is 4.9 to
9.5 ng/mL in humans.294,295,297,298 In diabetics, there is a decrease in circulating levels of
chromium, and an increase in urinary excretion of this mineral.30,294,298,299

Chromium

supplementation has also been shown to reverse diabetes induced by glucocorticoid
administration, as patients treated with 600 µg Cr/d showed reductions in fasting plasma
glucose concentrations from 250 to 150 mg/dL, and the use of hypoglycemic drugs was
reduced in 50% of patients.294,300

This was attributed to chromium lowering cortisol

concentrations.301,302 It has also been shown that increased ingestion of simple sugars and
elevations in cortisol lead to an increase in chromium losses, and perhaps this plays a role in
the IR that occurs in horses with pituitary pars intermedia dysfunction or those that develop
pasture-associated laminitis.303,304 However, results have been inconsistent. This may be
explained by the lower doses that are tested (~200-250 µg/d), or the limited bioavailability of
certain formulations, such as chromium chloride (CrCl3).294,305,306
The importance of chromium in the diet was demonstrated by Schwarz and Mertz307
in 1959 when it was found that rats fed a diet containing yeast as their sole protein source,
had difficulty clearing glucose, but this function returned when chromium (Cr+3) was added
to the diet.295,307 The idea of chromium deficiency having a role in the development of IR
and diabetes in humans came about in 1977, when a patient on long term total parenteral
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nutrition developed clinical signs of diabetes, including glucose intolerance and peripheral
neuropathy that required insulin administration of 45 units/d for control.291,294,298 When
chromium supplementation was added at 200µg/d to the patient’s parenteral nutrition
formulation, diabetic signs resolved and insulin use was no longer required.291,294,298
Chromium is now routinely added to parenteral nutrition preparations.303

Chromium

deficiency has been observed in humans suffering from elevated blood concentrations of
glucose, insulin, TG, and cholesterol, and lower HDL concentrations; however, the hallmark
sign of chromium deficiency is still impaired glucose tolerance.294,301 Unfortunately there is
no reliable method for assessing deficiency other than observing the expected beneficial
changes to glucose, insulin, and lipid variables before and after supplementation.295,303
Deficiency can occur for the obvious reason of inadequate dietary intake, but also develops
with poor intestinal absorption. Chromium absorption is improved by the addition of a
chelator, and picolinic acid is most commonly used.308,309

8.3.2 Chromium and insulin sensitivity
Chromium increases insulin sensitivity in rats, with Kim et al.291 demonstrating that
fasting insulin concentrations decreased by approximately 50% and area under the insulin
curve decreased by almost 60% in response to treatment.291 Other studies have also shown
improvement in insulin sensitivity and fasting glucose and insulin concentrations,
independent of changes in body weight or body fat percentage.291,303,310 In contrast, Uusitupa
et al.311 detected significant reductions in the BMI of elderly patients suffering from impaired
glucose tolerance. In another study, Martin et al.312 concluded that chromium does not
induce weight loss, but may help to regulate weight gain so that there are smaller increases in
body weight, percentage body fat, and total abdominal fat compared to individuals receiving
placebos. Preventing an increase in body weight of 0.5 to 1.0 kg/yr becomes significant in
long-term clinical trials.301

8.3.3 Chromium and lipid metabolism
There have also been variable results related to changes in serum lipid profiles
following chromium supplementation.294,313

Elevations in serum cholesterol and the
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formation of aortic plaques have been attributed to feeding rats low-chromium diets because
these abnormalities were not detected in rats receiving supplemental CrCl.308,314 In a doubleblind, crossover study, Press et al.308 evaluated effects of chromium picolinate on TC, LDL,
HDL, TG, apolipoprotein A-I, and apolipoprotein B. Apolipoprotein B is the principal
protein of VLDL and LDL whereas apolipoprotein A-I is the principal protein of HDL.
Patients were administered 200 µg/d chromium picolinate and after 6 weeks of therapy there
was a significant decrease in TC (7%; 276 to 256 mg/dL), LDL (10.5%; 200 to 178 mg/dL),
and apolipoprotein B (16%; 155 to 130 mg/dL), whereas apolipoprotein A-I levels
significantly increased with supplementation.308 A significant decrease in TC after 4 months
of treatment with 1,000 µg chromium picolinate /d has also been detected

303

. Chromium

picolinate may therefore serve as a treatment for hyperlipidemia, which has been associated
with obesity and IR in horses. In the aforementioned studies, improvement in blood lipid
profiles was most pronounced in individuals with the highest lipid concentrations before
treatment.294,315

8.3.4 Chromium mechanisms of action
Chromium potentiates insulin action by inducing auto-amplification of the insulin
294

signal.

The concentration of insulin receptors varies depending on the tissue type, with an

approximate concentration of 40 receptors per cell in erythrocytes to >200,000 in adipocytes
and hepatocytes.294 In the early 1980s, Wada et al.316 were the first to have a breakthrough in
the mechanism of chromium function by the isolation and characterization of a chromiumbinding oligopeptide referred to as low-molecular weight chromium-binding substance
(LMWCr) or more commonly known as chromodulin.295,316 It has a molecular weight of only
1.5 kDa (approximately) and is comprised of only 4 amino acid residues, i.e., glycine,
cysteine, glutamate, and aspartate.295,317 This oligopeptide binds four equivalents of chromic
ions, and this binding plays a role in its potentiating effect of insulin action.295 The site of
activation of chromodulin appears to be at or near the tyrosine kinase active site of the βsubunit of the insulin receptor, and the binding of four chromium ions is required for optimal
activity.295
As blood glucose concentrations increase, insulin secretion by the pancreas is
stimulated leading to binding and activation of the insulin receptor. As circulating levels of
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insulin increase, there is an influx of chromium from the circulation to within insulinsensitive cells.295 The form of chromodulin that is not bound to chromium (apochromodulin)
is stored within the cytosol and nuclei of insulin-sensitive cells.295 The transfer of chromium
into the insulin-sensitive cells from the circulation is likely to be mediated by transferrin, and
as chromium enters the cells, it binds to apochromodulin to form holochromodulin (Cr4chromodulin).295,318

The newly formed holochromodulin binds to the activated insulin

receptor and as a result, maintains the receptor’s active conformation and amplifies its
signal.295 The bound holochromodulin amplifies the insulin receptor signal by stimulating
concentration dependent tyrosine kinase activity of the insulin receptor in the presence of
insulin, but not in its absence.294 Not only is there increased activation of tyrosine kinase,
which stimulates intracellular signaling, but there is also inhibition of tyrosine phosphatase
activity, and this prolongs activation of the insulin receptor.294 All of these actions increase
insulin sensitivity. Chromium supplementation also increases insulin binding by increasing
the number of insulin receptors.291

8.3.5 Chromium toxicity
Chromium picolinate is the most popular form of chromium supplement, and it should
be noted that this form of Cr is absorbed in a different fashion from that of dietary Cr.295 It is
a remarkably stable complex that remains intact for several hours in synthetic gastric juice
and is capable of passing through the jejunum intact.295,319 The reference dose of safety for
Cr, as established by the U.S. Environmental Protection Agency (EPA) is 350 times the upper
limit of the daily intake dose of 200 µg/d.303 When humans that have taken the supplement
over prolonged periods have been examined, significant DNA cleavage has been detected and
this is attributed to the production of hydroxyl radicals.295,320 This occurs as picolinate causes
the redox potential to shift to the chromic center, making it susceptible to reduction and
therefore reactive oxygen species production.292

There has also been increased lipid

peroxidation in rats with DNA damage, but doses used in these studies have been 20 times
higher than those used in humans.292,321 There have been no reports of chromium picolinate
consistently affecting the health of humans at recommended doses, but isolated cases include
weight loss, anemia, thrombocytopenia, dermatitis, hypoglycemia, and liver dysfunction and
kidney failure.292,303
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8.3.6 Conclusions
Results of studies evaluating chromium supplementation have been mixed, so there
are questions about whether individuals suffer from different degrees of chromium
deficiency. Chromium shows promise as a supplement for the improvement of insulin and
glucose dynamics, but the questions about safety of the picolinate form warrant further
investigation. It must still be determined whether chromium supplementation improves
insulin sensitivity in insulin-resistant horses.

8.4 Magnesium
8.4.1 Introduction
Magnesium (Mg2+) is the second most abundant intracellular cation after
potassium.322

It has been established as a cofactor for over 300 metabolic reactions,

including protein synthesis, cellular energy production and storage, and glucose and insulin
metabolism.322,323 There are at least three different pools within the body: Extracellular (1%),
intracellular (34%), and skeletal (65%).323,324 In humans, low blood Mg2+ concentrations
have been associated with increased risk of MetS and T2D.322,325,326 Several foods that are
good sources of dietary Mg2+, include almonds, halibut, bananas, milk chocolate, and peanut
butter.322 Magnesium is an intracellular cation, so circulating levels may not provide an
accurate measure of overall body Mg2+ status. Low plasma Mg2+ concentrations are a
specific, but not sensitive indication of deficiency.322 Plasma Mg2+ concentrations remains
fairly constant in healthy humans and range from 0.75 to 0.96 mmol/L, with a recommended
daily intake of 310 to 420 mg/d for adult humans.322,327

8.4.2 Magnesium deficiency
The primary sites of intestinal Mg2+ absorption are the distal jejunum and ileum, and
intestinal absorption is inversely proportional to the amount ingested from dietary or
supplement sources.324 It was found that an intake of 36 mg/d resulted in 65% absorption,
while intake of 973 mg/d only resulted in an absorption of 11%.324 Magnesium deficiency is
likely to contribute to the development of diseases such as MetS and T2D, but it is also
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possible that these diseases lower magnesium stores.128 The balance of Mg2+ within the body
is controlled by the kidneys, and diets low in Mg2+ have reduced urinary excretion. In
humans with T2D, there is an increase in urinary magnesium due to glucosuria.324 The
normal range of urinary Mg2+ output is 120 to 140 mg/d.324
In both rodents and humans, Mg2+ deficiency has been associated with both IR and
MetS.322 Guerrero-Romero and Rodríguez-Morán328 found that serum Mg2+ concentrations
were significantly lower in people with MetS compared with those who were healthy (1.8 ±
0.3 mg/dL vs. 2.2 ± 0.2 mg/dL). A close association with dyslipidemia was also detected.
Magnesium deficiency may also play a role in T2D. Lima et al.329 found that 75% of people
with poorly controlled T2D had low Mg2+ concentrations and approximately 31% had low
intracellular Mg2+ concentrations. Hyperinsulinemia is a hallmark of IR, and in a study of
obese children without T2D, Mg2+ concentrations were inversely correlated with fasting
insulin concentrations and positively associated with QUICKI values (178.8 ± 19.8 vs. 63.2 ±
6.6 pmol/L and 0.31 ± 0.04 vs. 0.35 ± 0.01, respectively).322,330
States of Mg2+ deficiency can result from decreased nutritional intake and increased
renal losses. It is uncertain if supplementation elicits the same effect as increasing dietary
Mg2+ intake.128,327

Major manifestations of Mg2+ deficiency in man can include

neuromuscular abnormalities as well as biochemical (hypokalemia and hypocalcemia) and
cardiovascular abnormalities.324 Guerrero-Romero et al.331 worked to establish whether Mg2+
supplementation improves insulin sensitivity in a study of humans that did not suffer from
T2D. Affected patients suffered from IR and hypomagnesemia (serum concentration ≤ 0.74
mmol/L). When supplementation was administered at 2.5g/d, serum Mg2+ concentrations
significantly increased (0.61 ± 0.08 to 0.81 ± 0.08) and HOMA-IR decreased (4.6±2.8 to
2.6±1.1).322,331 This result indicates that Mg2+ supplementation may address risk factors for
T2D and lower the probability of disease.

8.4.3 Effects of magnesium on insulin sensitivity
Magnesium exerts its positive effects by affecting insulin action.

Deficiency of

intracellular Mg2+ suppresses tyrosine kinase activity of the insulin receptor causing a
decrease in insulin sensitivity.332 Another potential mechanism is the role of Mg2+ as a
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calcium (Ca2+) channel blocker because in states of Mg2+ depletion there is a rise in
intracellular Ca2+.322,333,334
Insulin is a key hormone in the regulation of Mg2+ metabolism and is capable of
stimulating its intracellular accumulation.323,327 However, activation of the insulin receptor is
required for this action, which is diminished in states of hyperinsulinemia due to
desensitization of the receptor.323,327 It has been suggested ATPase pumps are stimulated
when insulin binds its receptor and this increases Mg2+ entry into the cell.323,335 Elevations in
intracellular Ca2+ accompany Mg2+ deficiency because of increased uptake of extracellular
Ca2+ as well as release from intracellular stores.324

Increased

intracellular Ca2+ may

negatively impact insulin sensitivity in adipocytes and skeletal muscle, and the antagonistic
role of Mg2+ may be the mechanism by which it improves insulin sensitivity; Mg2+ can
function as a weak Ca2+ channel blocker.322,323
With a reduced function of the insulin receptor in states of hyperinsulinemia, there is
a decrease in Mg2+ influx which reduces its capacity to regulate Ca2+ influx.323,324
2+

deficiency in Mg

A

lowers intracellular potassium concentrations and results in a partial

depolarization that favors Ca2+ influx.323,324 Draznin et al.336 showed that gluteal adipocytes
incubated with insulin showed a significant increase in cytosolic Ca2+ concentrations, and as
a result, had no cellular uptake of glucose, even in the presence of insulin. Elevations in
blood glucose also result in higher intracellular Ca2+ concentrations and this may lower Mg2+
concentrations and inhibit insulin receptor activity and insulin-stimulated glucose uptake.337

8.4.4 Effect of magnesium on tyrosine kinase activity
Effect of Mg2+ on insulin sensitivity are multi-factorial and involve reduction in
tyrosine kinase activity of the insulin receptor as well as modulation of intracellular Ca2+
concentrations.128 In order for the insulin receptor to elicit its effect, it must first bind insulin
which causes a conformational change and begins the intracellular signaling cascade, starting
with autophosphorylation of β-subunits on tyrosine residues. Suárez et al.333 showed a
reduction in glucose clearance rate of 40% during an IVGTT in rats fed a diet designed to
lead to hypomagnesemia. This same group of rats also showed a decreased insulin response,
implying an impairment of the pancreatic β-cell response, as well as reduced insulin
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sensitivity. The concentration of Mg2+ is critical in the phosphorylation of tyrosine kinase of
the insulin receptor, and a deficiency of this mineral impairs phosphorylation.322,327,338
Hyperglycemia occurs with Mg deficiency and this is associated with a decrease in
insulin-stimulated glucose uptake.333

Pancreatic insulin output is also decreased and

diminished β-cell function is related to the Mg2+ to Ca2+ ratio.333 It has been established that
Mg2+ deficiency impairs the body’s ability to handle blood glucose, at both the basal and
post-prandial (or induced if during a tolerance test) levels.322,327,338 Whether this results from
decreased insulin receptor signaling or impaired β-cell function has yet to be definitively
determined.

8.4.5 Magnesium excess
Magnesium toxicity is very rare and has not been extensively studied. Since Mg2+ is
lost in the urine and absorption is inversely proportional to intake, it would be very difficult to
induce toxicity, except in cases of renal insufficiency.324 In 1998, a tolerable upper intake
level for Mg2+ was established as 350 mg/d for humans that are 9 years and over.324,339
In the rare situations in which toxicity occurs, the first symptoms are neuromuscular
in nature and begin with the absence of tendon reflexes at serum concentrations of 5 to 7
mg/dL, and progress to respiratory complications at 9 to 12 mg/dL, with muscle paralysis and
cardiac or respiratory failure developing at 1mg/dL and above.324

Less severe toxicity

symptoms include diarrhea, dehydration, nausea, flushing, double vision, slurred speech, and
weakness.324,339,340

8.4.6 Conclusions
No studies have been performed to date to examine the therapeutic effect of Mg2+
supplementation on insulin sensitivity in horses. Given its positive outcomes in humans and
rats and the wide margin of safety, Mg2+ supplementation should be considered as treatment
for IR in horses.
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8.5 Cinnamon
8.5.1 Introduction
Cinnamon (Cinnamomon cassia), which is also known as sweet wood, has long been
used in Eastern medicine.301,341,342

This nutraceutical contains methylhydroxychalcone

polymer (MHCP) that increases insulin sensitivity by mimicking the action of insulin.341-343
Aqueous extracts of cinnamon potentiate insulin activity as much as 20-fold.301 Not only has
cinnamon been implicated in the improvement of insulin action, but it may also inhibit HMGCoA reductase activity, resulting in lower blood lipid concentrations in humans and
animals.341,344

8.5.2 Cinnamon and glycemic control
Qin et al.342 performed one of the first in vivo studies to examine the effects of
cinnamon administration on insulin action in non-anesthetized rats. Rats received either
saline or 2 doses (30 m/kg bwt or300 mg/kg bwt) of cinnamon daily for 3 weeks and then
underwent EHC and skeletal muscle biopsy procedures. Rats receiving cinnamon extract had
significantly higher glucose infusion rates compared to controls (30 mg/kg: 118%; 300
mg/kg: 146%), suggesting increased whole body glucose utilization, compared with controls.
When muscle tissue was evaluated, rats receiving cinnamon had significantly higher tyrosine
phosphorylation of the insulin receptor β-subunit, when compared to control animals (118%
greater than control).

Phosphorylation of IRS-1 (133% greater than control) was also

significantly increased (41% above control).342 This study showed that orally administered
cinnamon enhanced in vivo glucose utilization in a dose dependent manner.342
Mang et al.341 examined effects of an aqueous cinnamon extract on fasting blood
glucose, lipid, and glycated hemoglobin (HbA1c) concentrations in diabetic humans. The
supplement was administered across a 4-month period three times daily with meals, and was
compared with a placebo.

After 4 months of supplementation, there was a significant

reduction in plasma glucose from baseline, and the mean absolute percentage difference was
significantly lower compared to the placebo group (10.3 ± 13.2% versus 3.37 ± 14.2%,
respectively).341 There were no significant differences in HbA1c or lipid concentrations
between groups. Kahn et al.344 also found that cinnamon supplementation significantly
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lowered blood glucose concentrations, with decreases ranging from 18 to 29%, which are
higher than previously reported.341

It has been suggested that the beneficial effects of

cinnamon are more pronounced in patients with poorer glycemic control before therapy.341 It
has also been noted that cinnamon has greater effects in patients taking anti-diabetic drugs
because these individuals have higher insulin sensitivity and cinnamon has the same action as
insulin.301

8.5.2 Cinnamon and insulin sensitivity
In states of IR, decreased phosphorylation of the insulin receptor can most likely be
attributed to the action of tyrosine phosphatases, which have been detected at elevated
cytosolic levels in aged IR rats.343,345 In vitro studies have shown that cinnamon enhances the
uptake of glucose by activating the insulin receptor.341,343 This occurs through stimulation of
the kinase activity required for autophosphorylation of the insulin receptor and enhanced
glycogen synthase activity. Cinnamon is also capable of improving the anti-oxidant status of
diabetic individuals, as metabolites of lipid peroxidation (malondialdehyde) decrease with
cinnamon supplementation, implying protection of cells against oxidation.301
One of the compounds that increases dephosphorylation of the insulin receptor is
PTP-1B and cinnamon potentiates the effect of insulin by inhibiting PTPase activity.343
When rat adipocytes were incubated with wortmannin, an agent that inhibits PI3K, the insulin
response from cinnamon or insulin was diminished, suggesting that cinnamon, like insulin,
acts through a signaling pathway upstream of PI3K.343 Cinnamon acts specifically on protein
tyrosine phosphatases above the level of PI3K.

8.5.4 Conclusions
Cinnamon elicits strong positive response on insulin activity, whether by directly
enhancing phosphorylation of the insulin receptor and its downstream components, or
inhibiting the dephosphorylation of those same sites.

Humans and rodents have not

experienced any adverse health effects as a result of cinnamon supplementation, so this
nutraceutical should be evaluated as a treatment for IR in horses.
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9. Pituitary pars intermedia dysfunction
9.1 Introduction
Pituitary pars intermedia dysfunction (PPID), which is also called equine Cushing’s
Disease, is the most common endocrinopathy affecting horses. This endocrine disorder is
diagnosed in horses ranging from 7 to 42 years, with approximately 85% being >15 years at
the time of diagnosis.346,347 The incidence of PPID has increased over time as a result of
greater awareness, an increase in the geriatric horse population, and availability of diagnostic
tests.347
Clinical signs of PPID develop when the pars intermedia enlarges and eventually
forms one or more functional adenomas. There is clonal expansion of POMC-secreting cells
secondary to loss of hypothalamic dopaminergic innervations.4,346,348,349

The release of

dopamine from the hypothalamus inhibits the synthesis of POMC peptides, and this lack of
dopaminergic inhibition is responsible for the higher ACTH concentrations detected in horses
with PPID.346

9.2 Influence of PPID on insulin sensitivity
Horses with PPID have histories of obesity-induced laminitis in their younger years.36
Excess

glucocorticoids

can

also

induce

abnormal

adipose

tissue

distribution,

hyperinsulinemia, increased plasma lipid concentrations, and glucose intolerance.4,36 It has
also been speculated that EMS predisposes horses to PPID by playing a role in the loss of the
dopaminergic inhibition.
Insulin and cortisol antagonize one another, so glucocorticoids might have a direct
impact on insulin function.4,36 Proposed mechanisms of glucocorticoid-induced IR include
reduction in the number of insulin receptors, decreased receptor affinity for insulin, and
defects in the intracellular insulin signaling pathway.4 The pars intermedia of the pituitary
gland also secretes corticotrophin-like intermediate peptide, and this is a secretagogue of
insulin in genetically obese mice.348,350 Mouse 3T3-L1 adipocytes treated with ACTH also
show a transient decrease in insulin-induced glucose uptake by 45%, implying that ACTH,
rather than cortisol plays a role in the IR associated with PPID.351
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Excessive exposure to glucocorticoids in PPID could also result in IR through the
over accumulation of intra-abdominal adipose tissue. Accumulation of omental adipocytes
has been associated with increased expression of 11β-hydroxysteroid dehydrogenase 1 (11βHSD1), which converts biologically inactive cortisone to active cortisol.36,352,353 This may
play a role in the development of IR if cortisol impairs insulin-induced inhibition of hepatic
glucose production and thereby induces hyperglycemia. Glucocorticoids raise blood glucose
concentrations and induce transient IR to preserve glucose delivery to essential tissues such
as the central nervous system and heart.4,352 It is important to note, however, that measured
cortisol concentrations are not always elevated in horses with PPID.36,354
Higher blood lipid concentrations are detected in horses with PPID and this reflects
stimulation of catabolic pathways and increased lipolysis.352 This enhanced catabolic effect
is also related to the characteristic rounded abdomen and loss of muscle mass observed with
PPID as protein breakdown causes decreases in muscle mass and tone.346,348,352 In states of
IR, dietary carbohydrates are diverted to the liver for the production of triglyceride and
ultimately stored in peripheral tissues.34,36 This accumulation of lipids in tissues can also
perpetuate IR, as previously discussed.

9.3 Effects of season on glucose testing in horses with PPID
Work performed by McFarlane et al.355 revealed seasonal variability in pars
intermedia activity. Seasonal alterations in plasma α-MSH concentrations indicate that pars
intermedia melanotrophs become hyperplastic in the fall compared to other times of the
year.354,355 This finding has been reinforced by other studies in which higher plasma ACTH
and α-MSH concentrations have been detected in September, and it is now accepted that false
positive results will be obtained when PPID testing is performed in the fall.10,354-356

The

dexamethasone suppression test for PPID is also affected by season.354 Since glucocorticoids
antagonize insulin, seasonal variation would also be expected to alter blood glucose and
insulin concentrations, but this question has not been addressed in horses. 347,348
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10. Equine laminitis
10.1 Introduction
Laminitis is a painful condition of equids that can result in permanent lameness.1,347
In a survey performed by the USDA in 1998, it was found that 13% of farms had at least one
horse develop laminitis within the previous year and 4.7% either died or were euthanized.357
The cause of laminitis is not always identified, but contributing factors include
gastrointestinal tract disease, endocrine disorders (e.g. PPID), and IR.4,347 The time course of
laminitis can be described as 5 stages; (1) Predisposition stage – animals suffer from a
predisposing factor such as genetics, nutritional/metabolic, inflammatory (sepsis), and/or
mechanical/trauma, (2) Development stage (prodromal) – this stage generally takes hours to
days after a triggering event such as the rapid fermentation of soluble carbohydrates, (3)
Acute stage – clinical signs are evident and there are demonstrable structural and metabolic
lesions, along with the loosening of the connective tissue between the hoof wall and pedal
bone, (4) Sub-acute stage – this stage can go on for weeks to months and is usually
characterized by less obvious clinical signs, and (5) Chronic or persistent Stage – repair of
damage can never be complete and there is generally some degree of persistent
lameness.2,3,358

10.2 Laminar damage
The hoof-lamellar junction is formed by the attachment of the epidermal aspect of the
hoof wall to the underlying dermal connective tissue, and ultimately the pedal bone.352
Laminitis is a degradative inflammatory condition of the foot in which the lamellar interface
becomes damaged, resulting in separation of the sensitive and insensitive lamellae
(dermoepidermal separation) at the level of the basal keratinocytes and their attachment to the
underlying lamellar basement membrane (LBM).1,352,359 The feet of equids suffering from
laminitis have typical physical characteristics that include solar prolapse, divergent growth
lines (or laminitic rings) that typically are close at the toe and diverge at the heel, a widening
of the white line zone, and an elongated narrow foot.36,360
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10.3 Pathophysiology of laminitis
Laminitis has been associated with impaired endothelial function with increased
enodthelin-1 (ET-1, a vasoconstrictor) and decreased nitric oxide (NO, a vasodilator).2,36,361
These alterations in NO and ET-1 levels are compatible with findings in patients with
diabetes.4,36,362 Insulin has been associated with vasodilation and capillary recruitment in
skeletal muscle, and increased digital pulses observed with laminitis may be due to this
effect.363,364

Increased digital pulses have been palpated when laminitis has been

experimentally induced in ponies by infusing exogenous insulin intravenously at
supraphysiological concentrations.363

In human diabetics, the common occurrence of

neuropathy of the feet is attributed to an increase in venous pressure resulting in foot
ulceration.363,365 Arteriovenous anastamoses develop as a consequence of hyperinsulinemia
in these patients and may also play a role in the development of laminitis in insulin-resistant
horses, with shunting of the blood depriving laminae of nutrients.363

10.4 Risk factors for pasture-associated laminitis
Laminitis is a common condition in equids, but it is important to note that not all
animals under the same managerial practices develop the condition. This suggests that some
horses and ponies are predisposed to pasture-associated laminitis. It is therefore important to
identify animals with greater predisposition so that disease can be prevented.
Treiber et al.366 were able to identify ponies from an inbred herd that showed greater
risk of developing pasture-associated laminitis and referred to this as pre-laminitic metabolic
syndrome (PLMS). In a herd of 170 Dartmoor and Welsh ponies, 54 animals had histories of
pasture-associated laminitis (pre-laminitic; PL) and the remaining 116 ponies did not (never
laminitic; NL).

A dominant mode of inheritance was detected for PLMS and affected

ponies had higher body condition scores and elevated blood concentrations of insulin and TG
concentrations.366

Proxies for insulin sensitivity and β-cell function were calculated

(discussed earlier) and PL ponies had insulin sensitivity scores in the lowest reference
quintiles and β-cell function scores in the highest reference quintile, indicating IR with
pancreatic compensation. When animals were assessed using PLMS, thirteen PL ponies
developed pasture-associated laminitis in May whereas NL ponies remained unaffected.366
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10.5 Insulin resistance and laminitis susceptibility
Horses and ponies with EMS and PPID are susceptible to pasture-associated laminitis.
Insulin status is a strong predictor of laminitis in horses with PPID.363,367 Horses were more
likely to develop laminitis and survive less than 2 years after diagnosis if basal insulin
concentrations were >188 µU/mL. Hyperinsulinemia is associated with IR and it has been
shown that extended exposure to exogenous insulin lowers production of vasodilators such as
NO and increases production of vasoconstrictors such as ET-1.2,361,368

This finding is

inconsistent with the known vasodilatory properties of insulin, but can be explained by the
presence of IR.15 Platelet activation has also been implicated in the pathophysiology of
laminitis and increases thromboxane activity.2,369,370
Insulin resistance may also play a role in the pathogenesis of laminitis by reducing
glucose availability to laminae, which results in separation of the sensitive and insensitive
laminar tissues.363 In a study by Asplin et al.363, it was hypothesized that insulin toxicity has
a role in the development of laminitis. Prolonged hyperinsulinemia was induced in ponies by
infusing exogenous insulin and the mean insulin concentration was 1,036 µU/mL during
infusion. All treated ponies developed laminitis in all four feet. Lamellar explants were
obtained and damage was consistent with laminitis. Results of this study indicate a role for
insulin toxicity in the development of laminitis and this may have important repercussions in
animals that experience carbohydrate overload.363 Epidermal basal cells of lamellar tissues
lack insulin receptors, but they are present on endothelial cells which supports the theory that
vascular impairment resulting from hyperinsulinemia and IR contributes to laminitis.363,371

10.6 Conclusions
Laminitis has no definitive cause, but is associated with obesity, IR, and
hyperinsulinemia, which are components of EMS. Several studies to date have shown that
impairment of the vasculature plays a role in laminitis and recent evidence suggests that IR
and hyperinsulinemia affect blood flow.

Laminitis has distressing outcomes that are

financial, physical, and emotional. Further studies are required to diagnose and manage IR
and hyperinsulinemia in horses, in order to prevent laminitis.
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11. Synopsis
As has been discussed throughout this literature review, there are many factors that
affect the development of laminitis, and also the predisposing conditions for this disease such
as IR and hyperinsulinemia. New treatments and management practices must be developed
for EMS to control IR and hyperinsulinemia, and thereby lower the risk of laminitis.
Additional diagnostic tests must be developed to identify at-risk horses by assessing insulin
sensitivity and metabolic disturbances.

This dissertation will therefore focus upon the

management and diagnosis of EMS in horses with the goal of evaluating therapies for IR and
the identification of animals most likely to be at risk of developing IR and therefore laminitis.
It is hypothesized that chromium and magnesium, L-T4, and metformin will be capable of
improving SI and decreasing body measurements, while active GLP-1 and adiponectin may
be associated with different levels of severity of IR and obesity and consequently serve as
biomarkers of horses at increased risk of developing laminitis in the future.
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Chapter 2

Effects of a supplement containing chromium and magnesium on
morphometric measurements, resting glucose and insulin
concentrations, and insulin sensitivity in laminitic obese horses
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This chapter is a revision of a paper that has been accepted for publication in Equine
Veterinary Journal.
My primary contribution to this paper included I) execution of the study discussed
herein and II) primary author of this paper. Co-authors include Dr. Nicholas Frank who I)
served as mentor, II) co-designer, and III) editor of the study, Sarah B. Elliott who served as
laboratory technical support, and Dr. Raymond Boston who served as data analyst (minimal
model analysis).

Abstract
Insulin resistance (IR) has been associated with an increased risk of pastureassociated laminitis in ponies and is associated with obesity and reduced insulin sensitivity in
horses and ponies. Current therapies focus on alleviating insulin resistance and obesity due
to their connection to laminitis. Chromium and magnesium have been touted as capable of
improving insulin sensitivity in humans, and as a result, supplements containing chromium
and magnesium are commercially available for use in horses. However, to date there is no
scientific evidence of their efficacy in equids. The purpose of this study was to determine if a
supplement containing chromium, magnesium, and various herbs was capable of affecting
physical measurements, blood variables, and insulin sensitivity in previously laminitic horses.
Fourteen obese horses with histories of laminitis were randomly allocated to receive 2 oz. of
supplement once daily (n = 8), or serve as controls (n = 6), for a total of 16 weeks. Two
horses with active laminitis were included in the treatment group. Hyperinsulinemia was
detected in 12/14 horses prior to treatment. Glucose and insulin data from one mare was
excluded due to persistent laminitis. Mean ± SD (n = 13) insulin sensitivity was 0.64 ± 0.62
× 10-4 L·min-1·mU-1 prior to treatment for the remaining 13 horses. Time and treatment ×
time effects were not significant for any of the variables examined, with the exception of
resting insulin concentrations which significantly increased over time (P = 0.018). Results of
this study do not support the administration of chromium and magnesium to manage obesity,
regional adiposity, hyperinsulinemia, or insulin resistance in horses.
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2.1 Introduction
Strategies for treating insulin resistance (IR) must be evaluated in horses because this
condition has been associated with increased risk of pasture-associated laminitis in equids.
372,373

Chromium and magnesium supplements are readily available to horse owners and are

often administered to horses with IR and laminitis. Chromium supplements have been used
in human medicine since the 1970s when it was discovered that patients developed diabetes
mellitus while receiving total parenteral nutrition and affected individuals benefited from
chromium supplementation.291,293,294 Chromium is thought to elicit its effects by enhancing
intracellular post-insulin receptor signaling pathways.294 This may occur through enhanced
tyrosine kinase activity or reduced tyrosine phosphatase activity, which prolongs the effects
of insulin binding to its receptor and thereby increases insulin sensitivity.294,295 Chromium
supplements are taken by people with IR or type 2 diabetes mellitus and both chromium
picolinate and chromium chloride lower fasting plasma glucose concentrations, increase
insulin sensitivity, and reduce requirements for oral anti-diabetic drugs in humans.331,374
Dietary chromium tripicolinate also improves glucose tolerance in healthy non-obese cats
when supplemented at 300 or 600 parts per billion in the diet.375
Magnesium deficiency has been associated with IR and metabolic syndrome in
rodents and humans.374 In one study, serum magnesium concentrations were significantly
lower in 192 human subjects with metabolic syndrome when compared with 384 healthy
individuals, and an association exists between magnesium deficiency and dyslipidemia.328,374
In addition, magnesium supplementation has been associated with improved HOMA-IR
scores in humans, indicating improved insulin sensitivity.331,374 This mineral is thought to
elicit its positive effects on insulin sensitivity by enhancing intracellular signaling and
increasing tyrosine kinase activity via calcium channel blockade.323,332
Chromium supplementation has previously been evaluated in horses, but results have
varied markedly among studies.376-378

In contrast, there is little information available

regarding magnesium supplementation in horses and studies have not been performed to
determine the effects of magnesium supplementation on insulin sensitivity. This study was
therefore undertaken to test the hypothesis that a dietary supplement containing chromium
and magnesium would lower resting glucose and insulin concentrations and increase insulin
sensitivity in horses. We specifically selected laminitic obese horses for this study because
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obesity, IR, and laminitis are associated.372,373 and can be collectively referred to as Equine
Metabolic Syndrome (EMS).36,379

2.2 Materials and Methods
Horses – Fourteen adult horses donated to the University of Tennessee because of
recurrent laminitis episodes were included in the study. Inclusion criteria for the study
included histories of laminitis, obesity, and impaired insulin sensitivity (SI). Twelve horses
had a history of laminitis according to the owner and referring veterinarian (n = 12) and 2
horses suffered from clinical laminitis at the time of the study.

Clinical laminitis was

defined by bilateral forelimb lameness and radiographic evidence of third phalanx rotation.
All horses were obese, which was defined as a body condition score ≥ 7 using the 1 to 9
scoring system developed by Henneke et al.9 The study was performed between January and
May 2008. Nine geldings and 5 mares were included in the study and horses ranged in age
from 8 to 20 years (median, 14 years), with initial body weights ranging from 422 to 595 kg
(median, 454 kg).
Diet – All horses were fed to provide 1.25 × digestible energy for maintenance
according to National Research Council guidelines,380 with 670 kcal/day supplied by 0.25 kg
oats/d (fed in the morning) and the remainder with Orchard/Timothy grass hay.

Feed

analysis was performed by a commercial forage testing laboratory.a Hay fed to study horses
contained 6.2 % water-soluble carbohydrate, 5.2 % ethanol-soluble carbohydrate, and 0.7 %
starch on a dry matter basis. Water was available ad libitum. Horses were fed between 0700
and 0800 and again between 1500 and 1630.
Experimental design – A randomized study design with repeated measures was
applied across a 16-week study period. Twelve previously laminitic obese horses were
randomly allocated to treatment (n = 6) and control (n = 6) groups and two obese horses with
clinical laminitis were included in the treatment group.

Horses in the treatment group

received 56g (2 oz) of a powdered dietary supplement containing chromium (5 mg/d as
yeast), magnesium (8.8 g/d as oxide/proteinate), as well as Gymnema sylvestri, Banaba leaf
extract, American ginseng, ginger root, cinnamon, biotin, L-carnitine, Bittermellon extract,
a

Dairy One Forage Testing Laboratory, Ithaca, NY
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and Fenugreek seed. Dosages of chromium and magnesium supplied by the supplement were
determined by the manufacturer. Supplement was top-dressed on oats in the morning for 16
weeks and horses were monitored to ensure that all of the feed and supplement were
consumed. Horses in the control group received the same feed without added supplement.
Custom farrier care was provided and housing assignments were determined by foot
stability. Previously laminitic horses were housed in pairs (one horse allocated to each
group) within three dirt paddocks measuring 15-m × 55-m (n = 6) or kept in individual stalls
(2.75-m × 3.5-m) and attached outdoor dry-lots (3.7-m × 10-m; n = 6). Clinically laminitic
horses (n = 2) were housed in individual stalls (3.7-m ×3.7-m) within the University of
Tennessee Large Animal Hospital. Frequently-sampled intravenous glucose tolerance test
(FSIGTT) procedures were performed at 0, 8, and 16 weeks, and blood was collected for
complete blood count (CBC) and plasma biochemical analyses at the same time points.
Horses that were housed in paddocks or barn stalls were transported to the hospital 2 days
beforehand for acclimatization to their environment. Testing procedures and treatment
periods were staggered across a 2-week period with animals tested in pairs (one horse from
each group). The study protocol was approved by the University of Tennessee Institutional
Animal Care and Use Committee.
Physical examination measurements – Physical examination variables, including
rectal temperature, heart rate, and respiratory rate were recorded along with morphometric
measurements at 0, 8, and 16 weeks. Morphometric measurements included body weight,
body condition, girth circumference, and neck circumference.

Neck circumference was

measured perpendicular to the neck crest at 0.25, 0.50 (mid neck), and 0.75 of the distance
from the withers to the poll with a measuring tape, as previously described.6
FSIGTT procedure − A 14-gauge polypropylene catheter was inserted into the
jugular vein the day before each FSIGTT was performed. Horses were fed grass hay and
provided with water while testing was performed. The insulin-modified FSIGTT procedure
first described by Hoffman228 and modified by Tóth et al.381 was used. Plasma and serum
were harvested via low-speed (1,000 × g) centrifugation and then stored at –20 oC until
further analysis. Pre-injection (time = 0) glucose and insulin concentrations are referred to as
resting concentrations.
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Blood glucose and insulin concentrations – Plasma glucose concentrations were
measured by use of a colorimetric assayb on an automated discrete analyzer.c Serum insulin
concentrations were determined by use of a radioimmunoassayd validated for use with equine
sera in our laboratory. Each sample was assayed in duplicate and intra-assay coefficients of
variation < 5% or < 10% were required for acceptance of glucose and insulin assay results,
respectively.
Plasma lipid concentrations – Triglyceride and cholesterol were measured with
enzymatic colorimetric reagentse,f on the same automated discrete analyzer. Nonesterified
fatty acid (NEFA) concentrations were measured by use of an in vitro enzymatic colorimetric
test kitg on a microtiter plate reader.h Each sample was assayed in duplicate and intra-assay
coefficients of variation < 5% were required for acceptance of results.
Interpretation of FSIGTT data by use of the minimal model – Values for insulin
sensitivity (SI), glucose effectiveness (Sg), acute insulin response to glucose (AIRg), and
disposition index (DI) were calculated for each FSIGTT in accordance with the minimal
model382 by use of commercially available softwarei,j and previously described methods.228,383
Disposition index was calculated via multiplication of AIRg by SI.
Statistical analysis – Insulin concentrations did not fit a normal distribution, so data
were log-transformed prior to analysis. Groups were compared prior to treatment (time = 0
months) using t-tests and then treatment, time, and treatment × time effects were evaluated by
repeated-measures ANOVA, using statistical software.k When a main effect was significant,
the protected least significant difference mean separation method was used to compare
different groups and time points. Significance was defined at a value of P < 0.05.

b
c
d
e
f
g
h
i
j
k

Glucose, Roche Diagnostic Systems Inc, Somerville, NJ
Cobas Mira, Roche Diagnostic Systems Inc, Somerville, NJ
Coat-A-Count Insulin, Siemens Medical Solutions Diagnostics, Los Angeles, CA
Triglyceride, Wako Chemicals USA, Richmond, Va
Cholesterol, Wako Chemicals USA, Richmond, Va
NEFA C, Wako Chemicals USA, Richmond, Va
UV-160, Shimadzu, Kyoto, Japan
MinMod Millennium, version 6.10, Raymond Boston, University of Pennsylvania, Kennet Square, PA
Stata 9.2, Stata Corporation, College Station, TX
PROC MIXED, SAS, version 9.2, SAS Institute Inc., Cary, NC
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2.3 Results
Physical examination variables remained within normal limits for all horses, with the
exception of one mare with clinical laminitis that suffered from persistent lameness and
tachycardia. Morphometric measurements did not change significantly throughout the study
period in control or treated animals (Table 2.1).

Complete blood counts and plasma

biochemical analysis results remained unaffected by treatment or time. Gamma-glutamyl
transferase and aspartate aminotransferase activities exceeded laboratory reference ranges on
at least one occasion in 9/14 (64.3%) and 6/14 (42.9%) horses, respectively (Table 2.2).
However, GGT activity was found to be significantly lower in treated animals versus control
animals overall.
Pre-treatment insulin concentrations ranged from 11.4 to 621.9 µU/mL (median; 57.1
µU/mL) and hyperinsulinemia (> 30 μU/mL) was detected in 12 of 14 horses at the start of
the study. Pre-treatment SI values (n = 14) ranged from 0.05 to 2.11 (median: 0.48) × 10-4
L.min-1.mU-1, and 8 horses had values ≤ 0.50 × 10-4 L.min-1.mU-1. Glucose and insulin data
from the mare with persistent lameness were excluded from statistical analyses because this
animal remained painful and received phenylbutazone treatment. Marked hyperinsulinemia
was detected in this mare at all time points, with serum insulin concentrations ranging from
417 to 1,098 µU/mL. This mare had a pre-treatment SI value of 0.20 × 10-4 L.min-1.mU-1.
Pre-treatment resting glucose and insulin concentrations did not differ between
treatment (n = 7) and control (n = 6) groups, and hyperglycemia was not detected at any time
during the study.

There were no effects of time or treatment on resting plasma glucose

concentrations, but insulin concentrations significantly increased (P = 0.018) over time
(Figure 2.1). Plasma total cholesterol and non-esterified fatty acid concentrations were not
affected by treatment or time, but mean triglyceride concentrations were higher (P = 0.024) in
the control group. Treatment × time effects were not significant for any of the lipid variables
examined. Minimal model variables were not affected by time or treatment in this study
(Table 2.3).
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Table 2.1: Mean ± s.d. physical measurements for 14 laminitic obese horses that received a
dietary supplement in their feed once daily or remained untreated for 16 weeks.
Group

Time (wk)

T × time

Variable
0

8

16

BodyWeight
(kg)

Control (n = 6)

492.5 ±57.5

497.6 ± 56.5

494.8 ± 51.7

Supplement (n = 8)

460.6 ± 63.8

468.0 ± 57.0

469.7 ± 46.0

BCS

Control (n = 6)

7.5 ± 0.5

7.6 ± 0.7

7.7 ± 0.8

Supplement (n = 8)

7.7 ± 0.8

7.7 ± 0.7

8.1 ± 0.7

Control (n = 6)

84.8 ± 3.3

84.1 ± 5.7

81.3 ± 3.8

Supplement (n = 8)

83.5 ± 4.1

82.9 ± 3.3

81.9 ± 2.9

Control (n = 6)

100.3 ± 6.6

99.8 ± 9.2

96.6 ± 8.9

Supplement (n = 8)

99.8 ± 5.2

100.3 ± 6.1

97.8 ± 5.0

Control (n = 6)

111.5 ± 7.6

111.5 ± 8.7

110.3 ± 7.8

Supplement (n = 8)

113.4 ± 5.7

114.1 ± 5.4

113.7 ± 4.1

Control (n = 6)

98.9 ± 12.6

98.4 ± 13.8

96.1 ± 13.9

Supplement (n = 8)

98.9± 13.4

99.1 ± 13.9

97.8 ± 13.8

P

0.814

0.626

0.25x neck (cm)

0.50x neck (cm)

0.75x neck (cm)

Mean neck
circumference
(cm)

0.667

0.921

0.530

0.686

BCS = Body condition score; x = Distance from the poll to the withers; T = Treatment
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Table 2.2: Mean ± s.d. resting blood measures for 14 laminitic obese horses that received a
dietary supplement in their feed once daily or remained untreated for 16 weeks. Glucose and
insulin data from one clinically laminitic horse that suffered from persistent lameness were
excluded.

Variable

Group

T × time

Time (wk)
0

8

16

Glucose

Control (n = 6)

5.28 ± 0.30

5.47 ± 0.67

5.26 ± 0.37

(mmol/L)

Supplement (n = 7)

5.14 ± 0.30

5.39 ± 0.48

5.28 ± 0.51

Insulin

Control (n = 6)

73.7 ± 38.7

123.9 ± 104.2

144.9 ± 136.1

(µU/mL)

Supplement (n = 7)

60.3 ± 55.7

88.7 ± 81.2

93.6 ± 106.7

GGT

Control (n = 6)

35.0 ± 17.3a

70.7 ± 84.8a

44.7 ± 21.5a

(IU/L)

Supplement (n = 8)

23.6 ± 12.4b

26.1 ± 13.0b

26.9 ± 10.0b

AST

Control (n = 6)

317.5 ± 53.6

364.5 ± 111.7

335.7 ± 62.3

(IU/L)

Supplement (n = 8)

284.1 ± 70.8

304.1 ± 62.1

330.3 ± 65.1

TG

Control (n = 6)

0.53 ± 0.18a

0.55 ± 0.25a

0.50 ± 0.17a

(mmol/L)

Supplement (n = 8)

0.31 ± 0.07b

0.32 ± 0.07b

0.35 ± 0.08b

Cholesterol

Control (n = 6)

1.92 ± 0.30

1.95 ± 0.26

1.98 ± 0.28

(mmol/L)

Supplement (n = 8)

1.91 ± 0.27

1.91 ± 0.16

1.95 ± 0.18

NEFA

Control (n = 6)

101.8 ± 61.3

117.6 ± 129.2

59.0 ± 18.3

(µmol/L)

Supplement (n = 8)

150.1 ± 63.8

109.4 ± 74.2

69.8 ± 50.0

P

0.911

0.597

0.546

0.565

0.259

0.935

0.949

GGT = Gamma glutamyl transferase; AST = Aspartate aminotransferase; TG = Triglyceride;
TC = Total cholesterol; NEFA = Non-esterified fatty acids; T = Treatment
Means with different superscripts within the same row differ significantly when P < 0.05
67

Table 2.3: Mean ± s.d. minimal model analysis values obtained from frequently-sampled
intravenous glucose tolerance test data for 13 laminitic obese horses that received a
supplement containing chromium and magnesium (n = 7) or remained untreated (control
group; n = 6) for 16 weeks. Data from one clinically laminitic horse that suffered from
persistent lameness were excluded.

Variable

SI × 10-4
(L.min-1.mU-1)

Sg × 10-2
(min-1)

AIRg
(mU.min. L-1)

DI × 10-2

Group

Time (wk)

T × time

0

8

16

Control (n = 6)

0.66 ± 0.71

0.77 ± 0.94

1.30 ± 2.20

Supplement (n = 7)

0.87 ± 0.73

0.92 ± 0.74

1.00 ± 1.05

Control (n = 6)

2.19 ± 1.88

1.67 ± 1.16

2.50 ± 1.53

Supplement (n = 7)

1.67 ± 0.78

1.40 ± 1.15

2.49 ± 1.58

Control (n = 6)

1,474 ± 593

1,457 ± 826

1,367 ± 777

Supplement (n = 7)

995 ± 511

896 ± 838

922 ± 752

Control (n = 6)

653 ± 591

658 ± 777

680 ± 854

Supplement (n = 7)

634 ± 427

631 ± 531

607 ± 514

P

0.678

0.822

0.949

0.985

SI = Sensitivity to insulin; Sg = Glucose effectiveness; AIRg = Acute insulin response to
glucose; DI = Disposition index; T = Treatment
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Control (n = 6)

Treated (n = 7)

Figure 2.1: Mean ± s.d. resting serum insulin concentrations at 0 (light gray bars), 8 weeks
(dark gray bars), and 16 weeks (white bars) in 13 laminitic obese horses that received a
supplement containing chromium and magnesium (n = 7) or remained untreated (control
group; n = 6) for 16 weeks. Data from one clinically laminitic horse that suffered from
persistent lameness were excluded. Insulin concentrations significantly increased (P = 0.018)
over time.
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2.4 Discussion
Administration of a supplement containing chromium and magnesium once daily for
16 weeks did not alter morphometric measurements, blood variables, or insulin sensitivity in
this study of laminitic obese horses. Serum insulin concentrations significantly increased
over 16 weeks, which suggests an effect of season or diet on resting insulin concentrations.
Chromium did not alter SI, Sg, AIRg, or DI in this study, and this finding is consistent
with results of previous studies in which chromium has failed to alter glucose or insulin
dynamics in horses.376,378,384 Vervuert et al.376 failed to detect any effects of yeast-chromium
supplementation (4.15 or 8.3 mg/day) on glucose and insulin concentrations in horses, and
Cartmill et al.315 reported that glucose dynamics and insulin sensitivity remained unaffected
by chromium propionate administration (4 mg/day for 30 days) in high body condition score
horses. Frequently-sampled intravenous glucose tolerance tests and minimal model analyses
were performed in the latter study and these variables remained unaffected by treatment.

In

a recent study, Uyanik et al. administered 0, 200, or 400 µg/day chromium picolinate orally
to horses for 45 days and measured glucose and lipid concentrations.378

Glucose

concentrations remained unaffected by treatment, but plasma triglyceride concentrations
decreased with chromium treatment at the 400 µg/day dosage. Administration of 200 µg or
400 µg chromium picolinate once or twice daily for 3 months did not affect resting glucose or
insulin concentrations, or responses to exogenous insulin in insulin-treated diabetic dogs.385
Other studies have shown that chromium significantly alters glucose and insulin
concentrations in horses.377,386,387

Ott and Kivipelto377 evaluated a basal diet alone and the

same diet with 175, 350, or 700 µg chromium added per kilogram concentrate in
Thoroughbred and Quarter Horse yearlings. Yearlings that received chromium at the highest
dosage had faster glucose clearance rates than animals in the control group. Pagan et al.387
also reported a positive effect of chromium supplementation on glucose dynamics in adult
horses. Significantly lower plasma glucose concentrations were detected during exercise and
3 hours following a meal containing 5g yeast-chromium.

Lower plasma glucose

concentrations were also detected 1 hour post-feeding in the same horses. In a study of aged
(> 20 years) mares, Ralston et al.386 administered 0.01 mg/kg or 0.02 mg/kg chromium-Lmethionine for 4 weeks and detected lower peak insulin responses to a concentrate meal in
the 0.02 mg/kg group.
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Based upon the results reported here, the combination supplement evaluated in this
study did not have its intended effects. This may be explained by the subjects selected for
study or the specific formulation tested. Only horses with chronic health problems were
evaluated in this study, so further studies are required to evaluate chromium and magnesium
supplements in less severely affected animals. Other formulations should also be evaluated
in the future.

Several forms of chromium are available for use, including chromium

picolinate, chloride, and complexes with nicotinic acid and amino acids, in addition to the
yeast form evaluated here.294 Of the different formulations of chromium available for use in
humans, chromium picolinate has the highest stability and bioavailability.294

Oral

bioavailability of chromium chloride is 0.4% after administration of 1,000µg/d in humans
whereas chromium picolinate has 2.8% bioavailability at the same dosage. Further studies
are required to determine the oral bioavailability of chromium in horses because results of
this study may reflect inadequate absorption. It is important to note that the dosage of
chromium included in this supplement and the duration of administration may have had some
influence on the lack of effect seen here. As noted earlier, there are discrepancies in the
literature in reference to dosages of chromium, duration of treatment studied, and effects of
respective treatments.376-378,384-387
To the authors’ knowledge, this is the first study to evaluate the effect of magnesium
supplementation on insulin and glucose dynamics in horses. According to National Research
Council recommendations, adult horses should receive 15 mg magnesium/kg/d, which is
equivalent to 7.5 g per day for a 500kg mature horse.388 The amount of magnesium provided
in this study (8.8 g/day) therefore exceeded maintenance requirements. Studies involving
magnesium supplementation have yielded mixed results in humans. Rodríguez-Morán and
Guerro-Romero389 reported that magnesium supplementation increased insulin sensitivity in
type 2 diabetic patients with low serum magnesium concentrations (≤ 0.74 mmol/L) prior to
treatment.

In contrast, there was no improvement in insulin sensitivity detected when

overweight nondiabetic adults received a magnesium oxide supplement for 12 weeks.390
These differences suggest that supplements have a greater effect on insulin sensitivity when
subjects suffer from magnesium deficiency. Magnesium status was not determined in this
study, so further research is required to examine this question in obese insulin-resistant
horses.
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Our results may also reflect inadequate magnesium absorption or improper dosing.
Hintz and Schryve391 reported mean absorption of 49.5 ± 10.9% when diets containing 25 to
90 mg magnesium per kg body weight were fed to weanlings and ponies, and results of a
second study by the same authors revealed 40.2 to 54.0 % absorption, depending upon the
amount of magnesium provided in the diet.392 Absorption was not measured in the study
reported here, so it is possible that the oral bioavailability of magnesium was lower when
combined with other nutraceuticals.
Body weight was monitored in this study, but administration of the supplement was
not associated with weight loss. Effects of chromium supplementation on body weight have
been inconsistent in human studies, with some subjects showing a decrease in body mass
index and others remaining unaffected.303,308,311

It has therefore been concluded that

chromium supplementation prevents weight gain, but does not induce weight loss
humans.

312

in

Anecdotal reports suggest that neck circumference decreases in horses with

regional adiposity in response to magnesium supplementation. Mean neck circumference
positively correlates with area under the insulin curve values from combined glucose-insulin
tests in obese insulin-resistant horses, indicating that this physical characteristic serves as a
phenotypic marker for IR in horses.6 Neck circumference-to-height ratio also positively
correlates with blood insulin, glucose, triglyceride, and leptin concentrations in ponies.13
Both neck circumference and insulin sensitivity remained unaffected by chromium and
magnesium supplementation in the study reported here.
Blood lipid concentrations were not affected by treatment in this study. This finding
was unexpected considering results of previous studies.

Total cholesterol, low-density

lipoprotein, and apolipoprotein B concentrations significantly decreased in humans after
supplementation with 200 µg chromium picolinate per day for 6 weeks,303 and total
cholesterol concentrations decreased significantly in subjects receiving 1,000 µg chromium
picolinate per day for 4 months.308 Triglyceride concentrations were higher in the control
group in the study reported here, but this was attributed to group allocation rather than
treatment.
Plasma biochemical analysis results provide new information because γ-glutamyl
transferase and aspartate aminotransferase activities were elevated in laminitic obese horses.
A definitive diagnosis could not be reached for this problem and only limited testing was
72

performed, but these findings suggest the presence of hepatic lipidosis, which occurs in
humans and is described as non-alcoholic fatty liver disease.95 This condition is associated
with obesity and IR in humans, and results from abnormal lipid droplet accumulation within
hepatocytes.96 Triglyceride accumulates within hepatocytes because of increased caloric
intake, increased fatty acid concentrations, and increased lipid synthesis. Biopsy samples
must be collected in the future to determine whether hepatic lipidosis is present in laminitic
obese horses.
A significant increase in serum insulin concentrations was detected across the 16week period between January and May. Season affects plasma adrenocorticotropin hormone
concentrations in horses, with higher values detected in September, compared with January or
May, 356 but it has not been determined whether insulin concentrations are similarly affected.
This change in insulin concentrations over time may also represent an effect of diet on this
variable. Horses were fed to provide digestible energy at 1.25 × the daily maintenance
requirement with the goal of maintaining body weight. This strategy was successful because
mean body weight did not vary significantly over time. However, horses may have received
more calories during the study or certain components of the diet may have affected insulin
concentrations. Resting insulin concentrations were measured in serum collected from horses
with access to hay, rather than samples collected under short-term fasting conditions. It is
therefore conceivable that insulinemic responses to hay increased as the study progressed.
Blood samples should be collected under both fasted (feed removed 6 hours beforehand) and
fed conditions in future studies to further investigate seasonal alterations in insulin
concentrations.
In conclusion, the supplement containing chromium and magnesium evaluated in this
study did not alter morphometric measurements, blood variables, resting insulin
concentrations, or insulin sensitivity in previously laminitic obese horses, and did not support
our hypothesis. Additional research is required to determine the oral bioavailability and
appropriate

dosages

for

chromium

and

magnesium

supplements

in

horses.
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Chapter 3
Effects of levothyroxine sodium on body condition, blood
measures of metabolic status, and glucose dynamics in obese,
previously laminitic horses
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This chapter is a paper to be considered for submission to the American Journal of
Veterinary Research.
My primary contribution to this paper included I) execution of the study discussed
herein and II) primary author of this paper. Co-authors include Dr. Nicholas Frank who I)
served as mentor, II) co-designer, and III) editor of the study, Sarah B. Elliott who served as
laboratory technical support, and Dr. Raymond Boston who served as data analyst (minimal
model analysis).

Abstract
Obesity, regional adiposity, insulin resistance (IR), and laminitis are components of
Equine Metabolic Syndrome (EMS). Previous work has shown that levothyroxine sodium
induces weight loss and improves insulin sensitivity in healthy horses kept on a weight
reduction diet. The purpose of this study was to assess the efficacy of this treatment in horses
with EMS kept on a maintenance diet. It was hypothesized that levothyroxine sodium would
significantly alter physical characteristics, glucose dynamics, and markers of metabolic status
in horses with EMS. Ten horses with obesity, IR, and a history of laminitis were evaluated
over a 36-week period. Seven horses received levothyroxine sodium orally at a dosage of 48
mg/day (24 weeks) and then 72 mg/day (12 weeks) once daily in 0.25 kg oats, while 3 other
horses received oats alone. Body weights, morphometric measurements, and frequentlysampled intravenous glucose tolerance tests were performed at 0, 12, 24, and 36 weeks.
Analysis of variance analysis revealed significant time × treatment effects for withinhorse change in body weight (P = 0.049) and mean neck circumference (P = 0.027), but no
significant change in BCS (P = 0.350). Mean body weight decreased by 30.8 ± 14.0 kg over
36 weeks in treated horses and by 6.5 ± 24.6 kg in the three control animals. Treatment did
not affect area under the glucose curve values (time × treatment; P = 0.511), but area under
the insulin curve tended to decrease over time in treated animals (time × treatment; P =
0.061; Fig. 4). No significant treatment × time effects were detected for insulin sensitivity (P
= 0.210) or other minimal model values. Levothyroxine induces weight loss and reduces
neck circumference in horses with EMS when animals are kept on a weight maintenance diet,
but does not influence glucose dynamics or insulin sensitivity.
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3.1 Introduction
Obesity, regional adiposity, and insulin resistance (IR) are risk factors for laminitis in
horses and this collection of conditions is referred to as Equine Metabolic Syndrome
(EMS).372,373

Previous studies performed by our research group have shown that the

administration of levothyroxine sodium (L-T4) at varying doses (24 to 96 mg L-T4/d) induces
weight loss, and this is accompanied by increased insulin sensitivity in healthy adult
horses.11,248,249,259 In one study, eight healthy adult mares received L-T4 at dosages of 24, 48,
72, and 96 mg/d, with each dose administered for 2 weeks.249 Significant improvement in
insulin sensitivity (SI) was detected as horses lost weight. Improvements in circulating
triglycerides (TG) and total cholesterol (TC) were also noted.249 In a more recent study, L-T4
was administered at a dosage of 48 mg/d to 6 healthy adult mares for 48 weeks.11 A
significant decrease in body weight occurred in response to treatment and SI significantly
increased. The effects of L-T4 administration on body weight have also been evaluated in
obese Morgan horse mares. Four horses received 48 mg L-T4/d for 24 weeks and four other
horses remained untreated (unpublished data).

Body weight, BCS, and mean neck

circumference significantly decreased and SI increased in both groups indicating that L-T4
treatment and controlled calorie intake are both capable of eliciting significant improvements
in body condition and insulin sensitivity.
Results of our previous studies indicate that L-T4 treatment induces weight loss in
healthy and obese horses and this is accompanied by an increase in SI. However, diet was a
confounding factor in our study of obese Morgan horse mares, so it must be determined
whether L-T4 exerts independent effects on body weight in obese horses. We hypothesized
that the administration of L-T4 would significantly alter physical characteristics, glucose
dynamics, and markers of metabolic status in horses with histories of laminitis and chronic
obesity, when provided a maintenance diet.

3.2 Materials and Methods
Horses – Ten adult horses that were previously donated to the University of Tennessee were
included in the study. All horses had EMS and were obese with histories of laminitis.
Laminitis status was determined from statements given by the owner or referring
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veterinarian, as well as radiographic evidence of laminitis or divergent growth rings. Obesity
was defined by a body condition score (BCS) of ≥ 7/9 according to the 1 to 9 scoring system
developed by Henneke et al.9 The study was performed between July 2008 and May 2009.
Custom farrier care was provided as needed and animal housing assignments were
determined by foot stability.

Horses were housed in pairs within three dirt paddocks

measuring 15-m × 55-m (n = 6), or were housed alone in individual stalls (2.75-m × 3.5-m)
with attached outdoor dry-lots in a barn (3.7-m × 10-m; n = 4). Horses did not have access to
pasture throughout the duration of the study. Six geldings and four mares were included in
the study and ranged in age from 6 to 20 years at the initiation of the study (median, 15
years), with initial body weights ranging from 430 to 589 kg (median, 490 kg).
Diet – All horses were fed to provide 1.25 × digestible energy for maintenance according to
2007 National Research Council guidelines380 with 670 kcal/day supplied by 0.5 lb oats/d
(fed in the morning) and the remainder with an Orchard/Timothy grass hay, as determined by
the DE content of feeds, which was measured by a commercial forage testing laboratory.a
Hay fed to study horses came from 3 different batches and provided 5.2 to 11.9 % watersoluble carbohydrate, 3.9 to 6.0% ethanol-soluble carbohydrate, and 0.2 to 3.9% starch on a
dry matter basis. Water was available ad libitum and animals were fed between 0700 and
0800 and again between 1430 and 1530.
Experimental design – A completely randomized study design with repeated measures was
used across a 36-week period. Horses were allocated to treatment (n = 7) and control (n = 3)
groups after pre-treatment (time = 0) testing. Horses housed in pairs within paddocks were
randomly assigned to the two groups and horses housed in the barn were allocated to
treatment (n = 4) or control (n = 2) groups. Physical measurements and insulin-modified
frequently-sampled intravenous glucose tolerance test (FSIGTT) procedures were performed
at 0, 12, 24, and 36 weeks. Blood was collected for a complete blood cell counts (CBC) at
time 0 and for plasma biochemical analyses at times 0, 12, 24, and 36 weeks. Horses were
transported to the teaching hospital 2 days prior to testing procedures to allow acclimation to
their environment. Testing procedures and treatment periods were staggered across a 2-week
period with animals tested in pairs. Horses in the treatment group received levothyroxine
sodium at a total daily dosage of 48 mg/d (0 - 24 weeks) and at a dosage of 72 mg/d for the
remainder of the study (24 – 36 weeks). Levothyroxine powder was top-dressed on oats in
a

Dairy One Forage Testing Laboratory, Ithaca, NY
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the morning for 36 weeks and horses were monitored to ensure that all feed and supplement
was consumed. Control animals received the same feed without addition of supplement. At
the completion of the study period treated animals received weaning dosages of L-T4 of 24
mg L-T4/d for 1 week followed by 12 mg L-T4/d for 1 week. The study protocol was
approved by the University of Tennessee Institutional Animal Care and Use Committee.
CBC and plasma biochemical analysis – Complete blood cell counts were performed on
whole blood using an automated analyzer.b Plasma biochemical analyses were used to
measure blood urea nitrogen, calcium, creatinine, glucose, phosphorus, total bilirubin, total
protein, albumin and globulin, and activities of creatine kinase, aspartate transaminase, and γglutamyl transferase in samples of heparinized plasma by use of an automated discrete
analyzerc with reagents provided by the manufacturer.
Morphometric measurements – Physical examination variables including rectal
temperature, heart rate, and respiratory rate were recorded along with morphometric
measurements at 0, 12, 24, and 36 weeks. Morphometric measurements included body
weight, body condition, girth circumference, and neck circumference. Neck circumference
was measured perpendicular to the neck crest at 0.25, 0.50 (mid neck), and 0.75 of the
distance from the withers to the poll with a measuring tape, as previously described.6 Mean
neck circumference values were calculated.
FSGITT procedure – A 14-gauge polypropylene catheter was inserted into the jugular vein
the day before each FSIGTT was performed. Horses were allowed access to grass hay and
water while testing was performed. Patency of the IV catheter was maintained before the test
by injection of 5 mL of saline solution containing heparin (4 U/mL) into the catheter every
6h. For the FSIGTT procedure, an injection cap and infusion setd (length, 30 cm; internal
diameter, 0.014 cm) were attached to the catheter. The FSIGTT procedure first described by
Hoffman et al.228 and modified by Toth et al.381 was used; 100 mg glucose/kg bwt was
infused as a bolus within 1 min as 50% (wt/vol) dextrose solutione followed by 20 mL
heparinised saline. Blood samples were collected via the catheter 10, 5 and 1 min before and
1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, and 19 min after infusion of dextrose. At 20 min, regular

b
c
d
e

ADVIA 120 Haematology System, Bayer Healthcare LLC, Tarrytown, NY
Hitachi 911, Boehringer Manheim Corp., Indianapolis, IN
Butterfly, Abbott Laboratories, North Chicago, IL
Dextrose 50% injection, Abbott Laboratories, North Chicago, IL
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insulinf was administered (20 mU/kg body weight) followed by 20 mL heparinised saline.
Blood samples were subsequently collected at 22, 23, 24, 25, 27, 30, 35, 40, 50, 60, 70, 80,
90, 100, 120, 150, and 180 min relative to dextrose infusion. At each time point, 3 mL blood
was withdrawn from the infusion line and discarded.

Blood was collected into tubes

containing sodium heparin and tubes without anticoagulant and then 5 mL heparinised saline
was infused. Plasma and serum were harvested via low-speed (1,000 × g) centrifugation and
then stored at –20o C until further analysis. Pre-injection (time = 0) glucose and insulin
concentrations are referred to as resting concentrations.
Blood and glucose concentrations – Plasma glucose concentrations were measured by use
of a colorimetric assayg on an automated discrete analyzer.h Serum insulin concentrations
were determined by use of a radioimmunoassayi validated for use in horses.393 Each sample
was assayed in duplicate and intra-assay coefficients of variation < 5% or < 10% were
required for acceptance of glucose and insulin assay results, respectively. Samples with
insulin concentrations greater than the highest value of the standard curve were diluted with
serum from a healthy horse.
Plasma lipid concentrations – Triglyceride and total cholesterol concentrations were
measured with enzymatic colorimetric reagentsj on an automated discrete analyzerh Each
sample was assayed in duplicate and intra-assay coefficients of variation < 5% were required
for acceptance of results.
Interpretation of FSIGTT data – Values for insulin sensitivity (SI), glucose effectiveness
(Sg), acute insulin response to glucose (AIRg), and disposition index (DI) were calculated
for each FSIGTT in accordance with the minimal model382 by use of commercially available
softwarek,l and previously described methods.228,383 Disposition index was calculated via
multiplication of AIRg by SI. Area under the curve values for glucose (AUCg) and insulin
(AUCi) concentrations were also calculated using statistical software.m

f
g
h
i
j
k
l
m

Humulin R, Eli Lilly and Co., Indianapolis, IN
Glucose, Roche Diagnostic Systems Inc., Somerville, NJ
Cobas Mira, Roche Diagnostic Systems Inc., Somerville, NJ
Coat-A-Count insulin , Diagnostic Products Corp., Los Angeles, CA
Wako Chemicals USA, Richmond, VA
MinMod Millennium, version 6.10, Raymond Boston, University of Pennsylvania, Kennet Square, PA
Stata 9.2, Stata Corporation, College Station, TX
PROC MIXED, SAS, version 9.2, SAS Institute Inc., Cary, NC
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Statistical analysis – Insulin and γ-glutamyl transferase concentrations did not fit a normal
distribution, so data were log-transformed prior to analysis. Repeated-measures analysis of
variance (ANOVA) was performed using statistical software.m

Treatment, time, and

treatment × time effects were evaluated. When a main effect was significant, the protected
least significant difference mean separation method was used to compare different groups and
time points. Significance was defined at a value of

P < 0.05.

3.3 Results
One horse from each group failed to complete the study. A horse from the LT4 group was
found dead with fibrinohemorrhagic colitis and a control group horse was euthanized due to
persistent laminitis. Horses in the treatment group received LT4 in amounts equivalent to
dosages of 0.09 – 0.11 mg/kg bwt when receiving 48 mg LT4/d and 0.14 – 0.18 mg/kg bwt
when receiving 72 mg LT4/d. Physical examination variables remained within normal limits
throughout the study in all horses. Mean pre-treatment body weight did not differ between
control and treatment groups (Table 3.1). A significant time × treatment effect was detected
for within-horse change in body weight with decreases of 31 ± 14 kg and 7 ± 25 kg occurring
in treatment and control groups, respectively (P = 0.049; Figure 3.1). No difference in pretreatment BCS was detected between groups. Treatment and time × treatment effects (P =
0.125 and P = 0.350, respectively) were not statistically different. Statistical analysis to
assess the influence of housing did not reveal a significant effect (P = 0.195). Mean ± s.d.
neck circumference also showed a significant treatment × time effect (P = 0.027; Figure 3.2)
with changes of -3.0 ± 2.0 cm and 1.6 ± 1.0 cm in treatment and control groups, respectively.
A weak positive correlation was found between mean neck circumference and AUCi (r =
0.24), whereas a weak negative correlation was found between treatment period and mean
neck circumference (r = - 0.18). Mean ± SEM neck circumference-to-height ratio also
showed a significant treatment × time effect (P = 0.031; Figure 3.3).
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Table 3.1: Mean ± s.d. physical measurements for 10 previously laminitic obese horses that
received levothyroxine sodium at a dosage of 48 mg/d for 24 weeks and then 72 mg/d for 12
weeks (n = 7) or remained untreated throughout the study period (n = 3).
T × time

Time (months)
Variable

Group
0

3

6

9

P

Body Weight
(kg)

Control (n=3)
Treated (n=7)

524.8 ± 76.84
489.1 ± 46.61

521.1 ± 80.58
473.2 ± 50.81

511.1 ± 74.32
471.9 ± 48.29

518.3 ± 80.09
458.3 ± 49.40

0.049

BCS

Control (n=3)
Treated (n=7)

8.7 ± 0.29
7.9 ± 0.53

8.3 ± 0.58
7.9 ± 0.67

8.2 ± 1.04
7.8 ± 0.49

8.3 ± 0.76
7.4 ± 0.53

0.350

0.25x neck
(cm)

Control (n=3)
Treated (n=7)

81.7 ± 3.21
80.5 ± 3.62

83.7 ± 2.08
80.6 ± 3.78

83.7 ± 2.25
78.5 ± 3.89

83.0 ± 2.00
77.7 ± 2.80

0.334

0.50x neck
(cm)

Control (n=3)
Treated (n=7)

99.0 ± 3.61
95.1 ± 4.60

98.7 ± 2.89
96.1 ± 5.61

98.5 ± 3.28
93.1 ± 7.30

101.8 ± 2.75
92.7 ± 4.72

0.114

0.75x neck
(cm)

Control (n=3)
Treated (n=7)

115.3 ± 3.51
109.5 ± 5.19

113.3 ± 0.58
108.3 ± 5.25

112.7 ± 4.51
107.4 ± 6.22

115.8 ± 3.33
105.6 ± 6.49

0.046

Mean neck
circumference
(cm)

Control (n=3)
Treated (n=7)

98.7 ± 16.8
95.0 ± 14.5

98.6 ± 14.8
95.0 ± 13.9

98.3 ± 14.5
93.0 ± 14.5

100.2 ± 16.5
92.0 ± 14.0

0.027

Neck-to-height
(ratio)

Control (n=3)
Treated (n=7)

0.65 ± 0.04
0.60 ± 0.02

0.65 ± 0.05
0.63 ± 0.02

0.65 ± 0.03
0.62 ± 0.02

0.66 ± 0.03
0.61 ± 0.02

0.031
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Figure 3.1: Mean ± s.d. change in body weight (kg) at 12, 24, and 36 weeks for 10
previously laminitic obese horses that received levothyroxine sodium at a dosage of 48 mg/d
for 24 weeks and then 72 mg/d for 12 weeks (n = 7) or remained untreated (n = 3).
Treatment × time; P = 0.049. Measurements were obtained at 12 (white), 24 (gray), and 36
weeks (black). Asterisk indicates a significant difference between groups at a specific time
point.
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Figure 3.2: Mean ± SEM mean neck circumference (cm) at 0, 12, 24, and 36 weeks for 10
previously laminitic obese horses that received levothyroxine sodium at a dosage of 48 mg/d
for 24 weeks and then 72 mg/d for 12 weeks (n = 7; white) or remained untreated throughout
the study period (n = 3; black). Treatment × time; P = 0.027. Asterisk indicates a significant
difference between groups at a specific time point.

83

Complete blood cell counts were normal for all horses prior to treatment, and plasma
biochemical values did not change significantly over time. However, γ-glutamyl transferase
and aspartate aminotransferase activities exceeded laboratory reference ranges on at least one
occasion in 5/10 (50 %) and 4/10 (40 %) horses, respectively (Table 3.2). Plasma total
cholesterol concentrations significantly increased over time in the control group, but not the
L-T4 group (P < 0.001).

Plasma triglycerides did not differ between groups, but

hypertriglyceridemia (> 85 mg/dL) was detected in 2/10 (20 %) animals on at least one
occasion.
Resting hyperinsulinemia (> 30 µU/mL) was detected in 6/10 (60%) of horses prior to
treatment and concentrations ranged from 15.0 to 183.1 µU/mL (median; 51.53 µU/mL).
Pre-treatment SI values (n = 10) ranged from 0.02 to 3.01 (control; 0.09 to 3.01, treated; 0.02
to 2.35, median; 0.34) × 10-4 L·min-1·mU-1 (Table 3.3) and 5 horses had values ≤ 0.50 × 10-4
L·min-1·mU-1.

There were no significant treatment × time effects detected for insulin

sensitivity (P = 0.210), glucose effectiveness (P = 0.447), acute insulin response to glucose
(P = 0.773), or disposition index (P = 0.639).

3.4 Discussion
Results of this study indicate that the administration of L-T4 induces weight loss and
reduces neck circumference in previously laminitic obese horses even when animals are
consuming a weight maintenance diet. Weight loss was significantly greater when treated
horses received 72 mg L-T4/d, which suggests that this higher dose may be more appropriate
for horses with chronic obesity and IR. Our hypothesis that horses kept on a maintenance
diet would lose weight with L-T4 treatment was supported, so a more pronounced decrease in
body weight would be expected if L-T4 treatment were combined with a weight reduction
diet. Horses were fed to provide 1.25× DE because results of an earlier study demonstrated
that horses maintained body weight on this diet (Chapter 2). By providing a diet to maintain
body weight, weight loss can be attributed to L-T4 treatment.
Horses included in this study showed wide individual variation in weight loss and this
may be explained by the chronicity of obesity. Obese horses in this study showed only 4%
loss in body weight compared to 4 – 10% loss in healthy horses from our previous
84
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Figure 3.3: Mean ± SEM mean neck circumference-to-height ratio at 0, 12, 24, and 36 weeks
for 10 previously laminitic obese horses that received levothyroxine sodium at a dosage of 48
mg/d for 24 weeks and then 72 mg/d for 12 weeks (n = 7; white) or remained untreated
throughout the study period (n = 3; black). Treatment × time; P = 0.031. Asterisk indicates a
significant difference between groups at a specific time point.
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Table 3.2: Mean ± s.d. resting blood measures for 10 previously laminitic obese horses that
received levothyroxine sodium at a dosage of 48 mg/d for 6 months and then 72 mg/d for 3
months (n = 7) or remained untreated throughout the study period (n = 3).

T × time

Time (weeks)
Variable

Group
0

12

24

36

P

Glucose
(mg/dL)

Control (n=3)
Treated (n=7)

92.85 ± 2.72
90.07 ± 5.18

91.44 ± 9.17
89.13 ± 6.71

91.43 ± 5.52
96.12 ± 8.20

101.68 ± 12.69
96.50 ± 5.45

0.321

Insulin
(µIU/mL)

Control (n=3)
Treated (n=7)

72.92 ± 95.48b
83.72 ± 60.55ab

47.92 ± 69.05b
82.31 ± 57.00ab

68.11 ± 69.80b
82.36 ± 78.13ab

141.26 ± 147.23a
55.14 ± 42.16ab

0.009

GGT
(IU/L)

Control (n=3)
Treated (n=7)

38 ± 33
26 ± 8

79 ± 110
31 ± 17

22 ± 10
37 ± 27

21 ± 10
37 ± 22

0.295

AST
(IU/L)

Control (n=3)
Treated (n=7)

313 ± 103
296 ± 45

262 ± 119
295 ± 76

242 ± 7
291 ± 91

286 ± 61
316 ± 76

0.846

TG
(mg/dL)

Control (n=3)
Treated (n=7)

44.76 ± 9.06
48.77 ± 28.73

59.26 ± 7.36
43.71 ± 17.49

32.12 ± 4.71
48.01 ± 23.62

31.51 ± 6.96
40.88 ± 31.50

0.128

TC
(mg/dL)

Control (n=3)
Treated (n=7)

63.23 ± 7.77cde
68.94 ± 9.47bcde

63.35 ± 3.06cde
69.15 ± 10.32abc

73.38 ± 9.13a
67.76 ± 6.88abc

75.16 ± 4.80a
66.98 ± 6.03abc

< 0.001

GGT = Gamma glutamyl transferase; AST = Aspartate aminotransferase; TG = Triglyceride;
TC = Total cholesterol; T = Treatment

86

Table 3.3: Mean ± s.d. minimal model analysis values obtained from insulin-modified
frequently-sampled intravenous glucose tolerance test data for 10 previously laminitic obese
horses that received levothyroxine sodium at a dosage of 48 mg/d for 6 months and then 72
mg/d for 3 months (n = 7) or remained untreated throughout the study period (n = 3).

Time (weeks)
Variable

Time × T

Group
0

12

24

36

P

SI × 10-4 (L.min-1.mU-1)

Control (n=3)
Treated (n=7)

1.38 ± 1.49
0.55 ± 0.85

0.52 ± 0.42
0.74 ± 0.70

0.94 ± 0.65
0.85 ± 0.70

0.83 ± 0.70
0.88 ± 0.74

0.210

Sg × 10-2 (min-1)

Control (n=3)
Treated (n=7)

0.02 ± 0.01
0.54 ± 1.38

0.01 ± 0.00
0.03 ± 0.01

0.01 ± 0.01
0.02 ± 0.01

0.01 ± 0.01
0.02 ± 0.01

0.447

AIRg (mU.min. L-1)

Control (n=3)
Treated (n=7)

679 ± 264
1341 ± 500

797± 344
1403± 735

953 ± 389
1292 ± 603

1003 ± 944
1111± 457

0.773

DI × 10-2

Control (n=3)
Treated (n=7)

1164 ± 348
594 ± 766

503 ± 475
885 ± 1009

666 ± 440
958 ± 891

608± 425
786 ± 561

0.639

SI = Sensitivity to insulin; Sg = Glucose effectiveness; AIRg = Acute insulin response to
glucose; DI = Disposition index; T = Treatment
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studies.11,248 Variation might also have arisen from differences in dose because the dosage of
L-T4 ranged from 0.09 to 0.11 mg/kg for the first 24 weeks and then increased to 0.14 to 0.18
mg/kg bwt. Housing assignments could also have affected results because weight loss was
greater in some of the treated animals housed outdoors in dirt paddocks.
Levothyroxine sodium is a synthetic form of thyroxine that reduces body weight
through an increase in metabolic rate via increased mitochondrial respiration rate and
increased fatty acid cycling.394 Both lipolysis and lipogenesis increase creating a “futile
cycle” that results in the dissipation of energy, with the ultimate favoring of lipolysis.394
Thyroid hormone agonists have a favorable effect on cholesterol concentrations due to upregulation of hepatic enzymes responsible for degradation of cholesterol as well as reductions
in circulating triglyceride concentrations.273 Administration of 500 µg/kg/d of L-T4 to rats to
induce hyperthyroidism resulted in a 44% increase in insulin-stimulated glucose transport as
well as an increase in the number of GLUT4 glucose transporters, indicating an improvement
in insulin sensitivity.395
In humans with hyperthyroidism, enhanced lipolysis can be attributed to increased
production of cyclic adenosine monophosphate (cAMP) and enhanced hormone sensitive
lipase (HSL) activity.267 This enhances hydrolysis of stored triglycerides and increases
production of free fatty acids (FFA), which are used for energy by the body.82 Thyroid
supplementation has also been associated with an increase in adenosine monophosphate
kinase (AMPK) activity resulting in increased fatty acid oxidation and decreased fatty acid
accumulation within peripheral insulin-sensitive tissues such as skeletal muscle and adipose
tissue.269 This decrease in fat accumulation in insulin-sensitive tissues has been associated
with increased insulin sensitivity. Increased AMPK activity may impact insulin sensitivity
by enhancing insulin receptor substrate-1 (IRS-1), which is an important rate-limiting
component of the intracellular insulin signaling pathway.269,271
In dogs, the administration of levothyroxine at a dosage of 22 µg/kg bwt to
hypothyroid dogs resulted in an increase in energy expenditure which was significant when
compared to pre-treatment values.396 Mean energy expenditure increased from 32.2 ± 9.4
kcal/kg/d to 42.9 ± 10.6 kcal/kg/d. Pre-treatment values were lower than normal dogs, but
post-treatment values did not differ significantly.

A synergistic relationship between

triiodothyronine and insulin has been proposed and this relationship may explain the
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improvement in insulin sensitivity associated with L-T4 administration.397 Both insulin and
T3 are involved in the regulation of glucose transport proteins, including GLUT4, and are
also known to stimulate expression of hexokinase and glycogen synthase which have
important roles in glucose uptake and disposal.397 Triiodothyronine and insulin reciprocally
regulate glycolysis and glucose storage by influencing cyclic AMP activity.397 Conversion of
L-T4 into T3 would therefore be expected to elicit this response.
A significant reduction in mean neck circumference was identified in the horses
studied here and this is important because mean neck circumference has been positively
correlated with AUCi in a previous study of obese insulin-resistant horses.6

Positive

correlations have also been detected for mean neck circumference-to-height ratio and insulin,
glucose, triglyceride, and leptin concentrations in ponies.13

Hyperinsulinemia was also

detected in 40% of horses in a population of moderate, overweight, or obese horses when a
cresty neck score of ≥ 3/5 was detected.13 A significant decrease in mean neck circumference
was associated with a trend towards lower AUCi in the study reported here, but SI values did
change significantly.
Blood concentrations of triglycerides and total cholesterol remained unaffected by
treatment in this study. This was an unexpected finding because studies in humans and
horses have shown that plasma total cholesterol, triglyceride, and LDL concentrations
decrease following administration of L-T4.249,394 Horses studied here did not suffer from
hypercholesterolemia, but hypertriglyceridemia was detected in 2 of the 10 horses during the
study period.

Triglyceride concentrations have been used to differentiate between never-

laminitic and pre-laminitic ponies in a previous study and may be an indicator of laminitis
risk in equids.373 Since hypertriglyceridemia was only detected on one occasion in each of
the affected horses in this study, this finding may reflect alterations in diet or L-T4
administration.
Area under the insulin curve tended to decrease with treatment, suggesting an increase
in insulin sensitivity or decrease in pancreatic insulin secretion. However, SI did not increase
significantly over time and AIRg, which is a measure of pancreatic insulin output, remained
unaffected.

Individual horse variability within the control group may be attributed to

differences in responses to diet or season. Season affects SI in humans. In a study of healthy
elderly humans, SI decreased in the summer and increased during the winter months.398

A
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larger number of horses should be included in future studies to strengthen the study design.
Obese insulin-resistant horses may also show greater variability in SI and AIRg than healthy
animals. Individual horses also varied markedly over time with respect with minimal model
values, particularly within the control group. Resting hyperinsulinemia was detected in 6 of
10 horses in this study and improvements in AUCi and AIRg suggest that insulin secretion by
the pancreas was decreasing over time in treated animals. This may be important because it
has been shown that experimentally-induced hyperinsulinemia can induce laminitis in healthy
ponies.363 Unfortunately, only three animals in the control group completed the study and this
represents a weakness of the study design.
Plasma biochemical analysis results showed elevations in γ-glutamyl transferase and
aspartate aminotransferase activities in 50% and 40% of horses, respectively. This provides
new information regarding the effects of obesity and IR on general health. Although only
limited testing was performed, these findings suggest the presence of hepatic lipidosis.
Hepatic lipidosis can occur in humans and is described as non-alcoholic fatty liver disease.
This condition results from abnormal lipid droplet accumulation within hepatocytes, as a
consequence of obesity and IR.95,96 Lipid droplets are triglycerides that accumulate within
hepatocytes due to increased caloric intake, elevated FFA concentrations, and increased
intrahepatic lipid synthesis.96 Additional research is required to determine whether hepatic
lipidosis occurs in obese insulin-resistant horses.
In comparison with results of previous studies, L-T4 treatment did not significantly
increase SI, but only a significant decrease in body weight and mean neck circumference was
detected in the study reported here. Explanations for this finding include the small number of
horses evaluated, differences among individual horses, and additional variability introduced
when minimal model analyses were performed. Our results suggest that administration of LT4 at the 72 mg/d dosage would be expected to elicit greater changes in insulin and glucose
dynamics, so this should be considered for future studies. No obvious adverse health effects
were associated with L-T4 treatment. However, it should be noted that one mare died
unexpectedly following 2 weeks of L-T4 treatment at the 48 mg/d dosage. It was concluded
by necropsy and histopathology that this mare died from acute fibrinohemorrhagic colitis,
which was unlikely to be a result of L-T4 administration.
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It is also necessary to evaluate the pharmacokinetics and pharmacodynamics of L-T4
in horses. When the pharmacokinetics of levothyroxine were examined in dogs, an oral
solution showed bioavailability of only 22% at a dosage of 40 µg/kg bwt and administration
for 14 days did not result in drug accumulation.399 Food intake delayed both the rate and
extent of absorption by 45% in dogs. In humans, oral bioavailability of levothyroxine ranges
from 70 to 80% when administered in a fasted state.400 Pharmacokinetic studies are therefore
needed to determine whether oral bioavailability differs between normal and chronically
obese insulin-resistant horses or if feeding affects absorption.
We conclude that levothyroxine sodium induces weight loss and reduces mean neck
circumference in previously laminitic obese horses and these changes occurred when horses
were provided with a weight maintenance diet, supporting our hypothesis. Although no
significant improvement in insulin sensitivity was detected in this study, AUCi results
suggest that L-T4 alters insulin dynamics.
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Chapter 4
Effects of metformin hydrochloride on glucose and insulin
dynamics during transition to grass paddocks in obese insulinresistant horses
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This chapter is a paper to be considered for submission to the American Journal of
Veterinary Research.
My primary contribution to this paper included I) execution of the study discussed
herein and II) primary author of this paper. Co-authors include Dr. Nicholas Frank who I)
served as mentor, II) co-designer, and III) editor of the study, Sarah B. Elliott who served as
laboratory technical support, and Dr. Raymond Boston who served as data analyst (minimal
model analysis).

Abstract
Metformin hydrochloride is used as a treatment for insulin resistance (IR) in equids.
This drug may also be useful for controlling IR when insulin-resistant horses are reintroduced
to pasture. We tested the hypothesis that metformin alters glucose dynamics in insulinresistant horses undergoing reintroduction to grazing. Six adult horses with chronic IR were
transferred to grass paddocks after spending > 15 months confined in stalls with attached
gravel turnout areas.

Glucose and insulin dynamics were assessed using the combined

glucose-insulin test (CGIT) before and 1, 2, 4, 6, 8, and 10 wk after horses were transferred to
grass paddocks. After horses were housed in grass paddocks for 2 wk, they were treated with
metformin (15 mg/kg q12h) for 2 wk, taken off treatment for 2 wk, and then treated with
metformin at a high dosage (30 mg/kg q12h) for 2 wk. Horses were also reevaluated 2 wk
later.
Time effects were significant (P < 0.001) for resting plasma glucose concentrations
and area under the glucose curve (AUCg) values. Mean glucose concentrations increased
from 81.2 ± 3.4 to 99.4 ± 6.7 mg/dL over 1 wk and then decreased to 81.9 ± 4.0 mg/dL by 10
wk. No differences were detected between pre- and post-metformin mean values for resting
glucose concentrations or AUCg at either dosage level. However, mean AUCg significantly
decreased (18.6%) across the 10-week study period.

Metformin did not affect glucose

dynamics in this study, but AUCg decreased over time when insulin-resistant horses were
transferred to grass paddocks. Time effects were significant (P < 0.001) for fed and fasted
serum insulin concentrations. Area under the insulin curve (AUCi) values significantly (P =
0.003) decreased by 42% throughout the study period. All horses had insulin concentrations
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> 100 mU/L at 45 min of the CGIT at the beginning of the study and 3 of 6 horses at week =
10.
Horses did not develop laminitis when turned-out on pasture, and insulin sensitivity
appeared to improve over time according the AUC values. This suggests that metformin may
be able to prevent exacerbation of insulin resistance when at risk animals are turned-out on
pasture.

4.1 Introduction
Insulin resistance (IR) is a major health concern in horses because of its association
with

pasture-associated

laminitis.372,373

Metformin

hydrochloride

is

an

N,N-

dimethylbiguanide agent that has been available since the 1950s and is used for the treatment
of type 2 diabetes in humans.401-403 Metformin lowers blood glucose concentrations without
inducing hyperinsulinemia, hypoglycemia, or weight gain.287 Several mechanisms of action
have been proposed for metformin including inhibition of hepatic gluconeogenesis
glycogenolysis,401,403 increased glucose uptake by skeletal muscle and therefore increased
glycogenesis,279 enhanced fatty acid oxidation in muscle and liver, and inhibition of
lipogenesis and cholesterol and triglyceride synthesis.402

Metformin also enhances

intracellular activity of the insulin receptor by inhibiting tyrosine phosphatase and stimulating
tyrosine kinase,287 which increases insulin sensitivity.
Metformin is a potential treatment for IR in horses because generic forms are
relatively inexpensive. However, studies to date in horses have shown varying results.
Johnson et al. 404 were the first to report metformin use in a horse with type 2 diabetes. This
animal showed positive response to metformin when the drug was administered a single time
at a dosage of 500 mg, in combination with 5 mg glyburide.

Interstitial glucose

concentrations returned to reference range 4.5 hours after metformin administration. Vick et
al. subsequently assessed the effects of metformin on insulin sensitivity and reproductive
cyclicity in obese mares.281 This study showed inconsistent results, with an improvement in
insulin sensitivity detected with twice daily administration of 1.5 grams metformin, but not
with 3 or 4.5 grams. Finally, a clinical study performed by Durham et al. showed that proxy
measures of insulin sensitivity improved when horses with IR and recurrent laminitis
received metformin at a dosage of 15 mg/kg bwt q12h.276
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It has been assumed since Treiber et al.372 published their findings that insulin
sensitivity decreases when horses and ponies are grazing on pasture. In the aforementioned
study, insulin-resistant ponies exhibited further decreases in insulin sensitivity between
March and May when the starch content of pasture grass increased. Ponies also developed
laminitis during this period, which provided evidence of an association between IR and this
condition in equids. On the basis of these results, insulin sensitivity would be expected to
decrease when insulin-resistant horses are transferred from stalls to grass paddocks.
Metformin treatment can therefore be considered in this situation to address diet-induced IR.
We therefore hypothesized that insulin sensitivity would decrease when obese insulinresistant horses were permitted to graze on grass and then increase again in response to
metformin treatment. Treatment with metformin was delayed for 2 weeks to assess glucose
and insulin concentrations during the transition, and two dosages were evaluated.

4.2 Materials and Methods
Horses – Six adult horses with EMS that had previously been donated to the University of
Tennessee were included in the study. All horses were obese, as defined by a body condition
score (BCS) ≥7/9 according to the 1 to 9 scoring system developed by Henneke et al.9 Mean
BCS was 8 ± 1. Each horse had a history of IR and at least one episode of laminitis
according to the owner and/or referring veterinarian. The study was performed over 10
weeks beginning in August 2009 and ending in November 2009. Custom farrier care was
provided as needed. All horses had been housed individually in stalls (2.75-m × 3.5-m) with
attached outdoor drylots (3.7-m × 10-m) for ≥ 15 months. Following baseline measurements,
horses were transferred to individual orchard grass paddocks (15-m × 55-m) for the
remainder of the study. Three mares and 3 geldings were included in the study and horses
ranged in age from 7 to 21 years (median, 15 years), with initial body weights ranging from
432 to 558 kg (median, 465 kg).
Diet – All horses were fed a standard ration consisting of 0.25 kg of oats twice daily which
provided 1,340 kcal/day, and orchard/timothy grass mixture hay which provided 820 kcal/lb
fed. Horses received 8.5 to 10 lb hay twice daily to meet their digestible energy requirement
for maintenance in the each day, and also consumed pasture grass after they were transferred
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to paddocks. Water was available ad libitum via automatic waterers. Horses were fed
between 0700 and 0800 and again between 1900 and 2000.
Experimental design – A randomized block design, blocked on horse, was used across the
10-week study period, with all horses receiving the same treatments. Physical measurements
and combined glucose-insulin test (CGIT) procedures were performed at 0 (stall), 1, 2, 4, 6,
8, and 10 weeks. Initial testing was performed when horses were housed in stalls (Week 0),
and then repeated after the transition to grass paddocks. Horses were treated twice daily for
14 days during two treatment periods (Weeks 2-4 and 6-8) separated by a 2-week washout
period.

Resting glucose and insulin concentrations were measured under fed conditions 24h

before each CGIT and then again under fasting conditions at the beginning of each test. The
study protocol was approved by the University of Tennessee Institutional Animal Care and
Use Committee.
Treatments – Metformin tabletsa (1,000 mg) were ground to a powder and then top-dressed
on oats. Horses received metformin at the 15 mg/kg q12h dosage for the first treatment
period and 30 mg/kg q12h for the second period.
Morphometric measurements – Physical examination variables, including rectal
temperature, heart rate, and respiratory rate were recorded along with morphometric
measurements at 0, 2, 4, 6, 8, and 10 weeks. Morphometric measurements included body
weight, body condition, girth circumference, and neck circumference. Neck circumference
was measured perpendicular to the neck crest at 0.25, 0.50 (mid neck), and 0.75 of the
distance from the withers to the poll with a measuring tape, as previously described.6 Mean
neck circumference values were calculated.
CGIT procedure – A 14-gauge polypropylene catheter was inserted into the jugular vein the
night before each CGIT was performed. Horses received a single flake of hay at 8 PM the
night before, but no other feed until the test was completed the next morning. Water was
available ad libitum. Patency of the IV catheter was maintained overnight by injecting 100
mg of heparin into a heparin lock injection cap.b For the CGIT procedure, an injection cap
and infusion setc (length, 30 cm; internal diameter, 0.014 cm) were attached to the catheter.
The CGIT procedure first described by Eiler238 was used. Briefly, 150 mg glucose/kg bwt
a
b
c

Metformin hydrochloride, Apotex Corp., Toronto, Ontario, Canada
Heparin Lock Injection Site, Medical Specialties Dist., LLC, Sloughton, MA
Butterfly, Abbott Laboratories, North Chicago, IL
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was infused as a bolus within 1 minute using 50% (wt/vol) dextrose solutiond immediately
followed by 0.1 IU regular insuline/kg bwt as a bolus followed by 20 mL heparinized saline.
Blood samples were collected via the catheter 10, 5 and 1 min before, and 1, 5, 10, 15, 25, 35,
45, 60, 75, 90, 105, and 120 min after infusion of dextrose and insulin. At each time point, 3
mL blood was withdrawn from the infusion line and discarded. Blood was collected into
tubes containing potassium oxalate/sodium fluoride and tubes without anticoagulant and then
5 mL heparinized saline was infused. Plasma and serum were harvested after centrifugation
(3,500 × g) and then stored at -20o C until further analysis. Pre-injection glucose and insulin
concentrations were averaged and are referred to as fasted concentrations.
Blood glucose and insulin concentrations – Plasma glucose concentrations were measured
by use of a colorimetric assayf on an automated discrete analyzer.g

Serum insulin

concentrations were determined by use of a radioimmunoassayh previously validated for use
in horses.393 Each sample was assayed in duplicate and intra-assay coefficients of variation <
5% or < 10% were required for acceptance of glucose and insulin assay results, respectively.
Statistical analysis – Insulin concentrations did not fit a normal distribution, so data were log
transformed prior to analysis. Time and treatment effects were evaluated for all variables by
repeated measures analysis of variance (ANOVA) using statistical software.i When time or
treatment effects were significant, the protected least square difference mean separation
method was used to compare different treatment periods. Significance was defined as a value
P < 0.05.

4.3 Results
Physical examination parameters remained within normal limits for all horses
throughout the study period. Mean body condition score, mean girth circumference, and
overall mean neck circumference did not change over time (Table 4.1), but mean body

d
e
f
g
h
i

Dextrose 50% injection, Abbott Laboratories, North Chicago, IL
Humulin R, Eli Lilly and Co., Indianapolis, IN
Glucose, Roche Diagnostic Systems Inc., Somerville, NJ
Cobas Mira, Roche Diagnostic Systems Inc., Somerville, NJ
Coat-A-Count insulin , Diagnostic Products Corp., Los Angeles, CA
PROC MIXED, SAS, version 9.2, SAS Institute Inc., Cary, NC
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Table 4.1: Mean ± s.d. physical measurements for 6 insulin-resistant, obese, previously
laminitic horses that were returned to pasture for 10 weeks and received metformin for 2
weeks at dosages of 15 mg/kg bwt q 12h and 30 mg/kg bwt q 12h

Time (wk)
0

2

4

6

8

10

Time

Stall

G only

15
mg/kg

G only

30
mg/kg

G only

P

483 ± 56a

477 ± 65ab

482 ± 60a

477 ± 59ab

482 ± 62a

471 ± 60b

0.015

7.8 ± 1.0

7.8 ± 1.0

7.5 ± 1.0

7.6 ± 0.9

7.3 ± 0.8

7.6 ± 0.7

0.080

92.7 ±
12.4

91.9 ±
12.4

93.2 ±
12.4

93.0 ±
12.5

93.1 ±
11.9

93.0 ±
13.0

0.320

183.4 ±
7.5

184.0 ±
7.6

183.6 ±
7.7

184.5 ±
7.8

185.0 ±
7.0

183.8 ±
7.7

0.521

Measure

Body weight (kg)

BCS

Mean neck
circumference
(cm)

Girth (cm)

BCS = body condition score; G only = horses were on pasture with no metformin
a,b

For each variable, means with different superscripts differ significantly; P , 0.05
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weight significantly decreased over time (2.5 %) when compared to the baseline value (P =
0.015).
Fed glucose concentrations significantly increased when horses were transferred to
grass paddocks, but then decreased (P < 0.001) over time (Table 4.2). Fasted glucose
concentrations significantly decreased over time (P = 0.021) with the lowest concentration
detected after metformin administration at the 30 mg/kg metformin dosage (Figure 4.1).
Mean AUCg decreased (P < 0.001) by 19% across 10 weeks, with the lowest AUCg value
detected at 8 weeks after 30 mg/kg metformin treatment (Figure 4.2). Time for glucose
concentrations to return to baseline during the CGIT ranged from 35 to 120 minutes at Week
0 and 25 to 120 minutes at Week 10. Five of 6 horses failed to return to baseline glucose
concentrations by 45 minutes at week 0 and 3 of 6 horses at week 10.
Fed and fasted insulin concentrations significantly decreased over time (P < 0.001;
Figure 4.1). Mean fasted insulin concentration was significantly lower at the end of the 30
mg/kg treatment period (Week 8) when compared with the pre-treatment (Week 6) value.
Mean AUCi significantly decreased by 42% (P = 0.003) across the 10-week study period.
The lowest AUCi value was detected following metformin treatment at the 30 mg/kg dosage
(Figure 4.2). Insulin concentrations at 45 minutes collected during the CGIT ranged from
146.2 to 393.9 mU/mL at the beginning of the study and from 44.1 to 233.1 mU/mL at time =
10 weeks. Six of 6 horses had insulin concentrations > 100 mU/L at the beginning of the
study and 3 of 6 horses at week = 10.

4.4 Discussion
Results of this study indicate that hyperinsulinemia and insulin resistance improved
when obese, insulin-resistant horses were turned out into grass paddocks. Horses lost weight
in response to turn-out and this was attributed to increased exercise as exercise had been
restricted in these horses for ≥ 15 months. Metformin lowered resting insulin concentrations
when administered at the 30 mg/kg dosage, but results remain inconclusive. Horses in this
study lost weight over time, with mean body weight decreasing by 2.5%. Metformin induces
weight loss and this has been attributed to reduced gastrointestinal absorption of
carbohydrates, anorectic effects, and lower leptin concentrations, as well as the promotion of
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Figure 4.1: Mean ± s.d. plasma glucose (A) and serum insulin (B) concentrations during
OGTs performed in 6 obese, insulin-resistant horses receiving metformin at 15 mg/kg q 12h
for 14 days or 30mg/kg q 12h for 14 days while having access to pasture. Samples were
collected in the fed state (light bars; fine text) and the fasted state (dark bars; bold text).
G-only = pasture only, no metformin; G-15 = pasture and 15 mg/kg bwt metformin q 12h;
G-30 = pasture and 30 mg/kg bwt metformin q 12h.
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Figure 4.2: Mean ± s.d. area under the glucose curve (AUCg; top panel) and area under the
insulin curve (AUCi; bottom panel) during OGTs in 6 obese, insulin-resistant horses horses
receiving metformin at 15 mg/kg q 12h for 14 days or 30mg/kg q 12h for 14 days while
having access to pasture.
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Table 4.2: Mean ± s.d. resting, fasting, and area under the curve measures for 6 insulin-resistant, obese, previously laminitic horses that were
returned to pasture for 10 weeks and received metformin for 2 weeks at dosages of 15 mg/kg bwt q 12h and 30 mg/kg bwt q 12h
Time (wk)
Resting Glucose (mg/dL)
Fed
Fasted
Resting Insulin (mU/mL)
Fed
Fasted
AUCg ([mg/dl] · min) × 103
AUCi (mU/ml] · min) × 103

0a

1

2

4b

6

8c

10

Time
P

81.18 ± 3.4e

99.35 ± 6.7a

97.12 ± 8.1ab

91.27 ± 4.3bc

88.21 ± 6.3cd

83.68 ± 7.3de

81.88 ± 4.0e

< 0.001

94.74 ± 8.0ab

98.84 ± 7.1a

93.98 ± 4.7abc

90.83 ± 7.7bc

88.74 ± 4.1bc

88.09 ± 9.1c

88.55 ± 5.3c

0.021

56.7 ± 38.8bc

130.2 ± 60.9a

108.4 ± 52.5a

60.1 ± 35.3bc

86.9 ± 45.4ab

50.0 ± 39.7bc

16.7 ± 12.8c

< 0.001

106.4 ± 88.3a

38.8 ± 27.4bc

26.6 ± 13.8bcd

18.6 ± 10.8d

40.1 ± 34.0b

22.1 ± 13.6cd

16.7 ± 7.1d

< 0.001

15.3 ± 2.5ab

17.3 ± 2.1a

15.9 ± 2.2ab

14.8 ± 2.5bc

12.7 ± 2.1cd

12.0 ± 1.2d

12.5 ± 3.7d

< 0.001

34.7 ± 9.6a

26.5 ± 9.9b

25.5 ± 7.1b

22.8 ± 6.7bc

24.3 ± 8.7bc

18.0 ± 6.8c

20.1 ± 7.0bc

0.003

a, b, c

For time, a = Horses housed in stalls; b = Day 14 of metformin treatment (15 mg/kg); c = Day 14 of metformin treatment (30 mg/kg)
AUCg = area under the curve for glucose; AUCi = area under the curve for insulin
a,b,c,d,e

For each variable, means with different superscripts differ significantly; P < 0.05.
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lipolysis and fatty acid oxidation.405 However, it is also likely that horses lost weight as a
result of increased exercise.
Bioavailability of metformin depends upon the species.

In

humans, metformin

pharmacokinetics result in a moderate oral bioavailability of 50 to 60% with maximal
concentrations reached 1 to 3 hours post-dosing with 500 to 1000 mg.279 Metformin has a
calculated half-life of 6 hours and terminal elimination of 9 to 17 hours in humans.279,283 In
rats, metformin at a dose of 50 mg/kg bwt results in a maximal concentration of 3.9 µg/mL at
1.3 hours post oral dosing and half-life of 3.2 hours.406
Recently, pharmacokinetics of metformin have been assessed in horses.283 Metformin
was administered at a dose of 6g three times orally (in fed or unfed states) or intravenously.
Plasma concentrations were no longer detectable 4 hours post-IV administration, suggesting a
clearance rate 10 times greater than humans. Oral bioavailability was poor and varied with
feeding. Fed animals showed oral bioavailability of 3.9 ± 1.0 % compared with fasted
animals (7.1 ± 1.5 %),283 suggesting administration after a short fast may be beneficial.
These results suggest that the dosages selected, which were equivalent to 7.5 and 15 g for
500-kg horse, were still too low to elicit full effects. The half-life of orally administered
metformin has not been determined in the horse, but more frequent dosing may also be
necessary.
Insulin resistance and resting hyperinsulinemia are predictors of pasture-associated
laminitis in ponies.372,407 Metformin has been used to treat insulin resistance in horses and
ponies in order to lower laminitis risk.

In this clinical study, metformin was orally

administered at a dosage of 15 mg/kg bwt q 12h and insulin sensitivity was evaluated by
proxy measures following short (6-14 days) and long-term therapy (23-220 days).276 Shortterm administration resulted in significant improvement in insulin sensitivity, but this was not
detected with long-term treatment. Results may have been confounded because animals
included in the study were fed low-glycemic feeds, allowed zero to minimal grazing, and
exercise.

In the study reported here, horses had unlimited access to grass within their

paddocks and unstructured exercise. Horses were observed running in paddocks and their
activity level appeared to increase after turnout.
Exercise has been associated with improvements in insulin sensitivity and glucose uptake into
peripheral tissues as well as weight loss in humans.405 However, results of a study assessing
the effect of exercise training on glucose and insulin dynamics in Arabian geldings did not
support the assumption that exercise increases insulin sensitivity, although body weight and
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fat mass decreased over time.408 Hypoglycemia is a potential complication of metformin use
in horses. This problem was suspected in a horse with type 2 diabetes mellitus when
metformin was administered at a dosage of 15 mg/kg bwt q12h.409 Hypoglycemia was not
detected in the study reported here.
Weaknesses of our study design included the use of the CGIT to assess insulin
sensitivity and unmeasured exercise. Assessment of insulin sensitivity using the CGIT is
complicated by the administration of exogenous insulin immediately following glucose.
Interpretation of the CGIT for the diagnosis of insulin resistance is based upon the glucose
and insulin concentrations at 45 minutes. Insulin resistance is diagnosed when glucose
concentration fails to return to baseline by 45 minutes and/or the insulin concentration
exceeds 100 mU/mL at 45 minutes.379 The glucose measurement at 45 minutes represents the
insulin sensitivity and the insulin measurement represents the pancreatic output. Horses in
this study met the criteria for IR based on these results.
We conclude that insulin-resistant horses benefit from turnout into grass paddocks.
Lower AUCi values indicated improved insulin sensitivity in these animals, suggesting that
our hypothesis was supported. Improvement in insulin sensitivity over time might also be
attributed to metformin treatment, but effects of time and treatment cannot be separated in
this study.
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Chapter 5a
Validation of an enzyme-linked immunosorbent assay (ELISA)
for the measurement of active GLP-1 in equine plasma
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This paper is formatted from a version to be submitted for consideration for
publication to the American Journal of Veterinary Research
My primary contribution to this paper included I) execution of the study discussed
herein and II) primary author of this paper. Co-authors include Dr. Nicholas Frank who I)
served as mentor, II) co-designer, and III) editor of the study, and Amy Schuver who I) was
involved in sample collection and II) animal management.

Abstract
Glucagon-Like Peptide 1 (GLP-1) is an incretin hormone secreted the small intestine that
plays a role in satiety and stimulates insulin release from pancreatic β-cells. The objective of
this study was to validate a commercially available (Millipore Corporation) human active
GLP-1 enzyme-linked immunosorbent assay (ELISA) for use with equine plasma. Resting
blood samples were collected from one insulin-resistant horse and one healthy horse. Plasma
was collected with EDTA and treated with dipeptidyl-peptidase IV inhibitor.

Dilution,

linearity, and lowest limit of detection were assessed using sample buffer included in the kit
and plasma from the insulin-resistant horse. For spike and recovery, the high standard was
diluted in equine plasma from one healthy horse. Intra-assay variability was calculated from
quadruplicate measures of GLP-1 in blood collected at 3 time points during oral sugar tests in
3 healthy horses. Inter-assay variability was assessed from concentrations of quality control
solutions provided in the kit on 3 plates. Dilution of equine plasma resulted in a linear plot of
GLP-1 concentrations (r2 = 0.995). The lowest limit of detection for the assay was 1.7
pmol/L because this was the value obtained for the sample buffer. Overall recovery was
98.3%, for active GLP-1 in equine plasma. Inter-assay coefficient of variation (CV%) value
of 2.3% and 2.6% were obtained for the two quality control solutions. Mean ± SD intraassay CV% was 9.5 ± 5.1%. Results indicate that GLP-1 can be measured in equine plasma
using the ELISA evaluated in this study.
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5a.1 Introduction
Glucagon-like peptide 1 (GLP-1) is an incretin hormone secreted by the L cells of the
distal small intestine in a dose-dependent manner in response to dietary glucose.212,219
Incretins act upon β-cells of the pancreas to enhance insulin secretion before blood glucose
levels rise after a meal.215

Following ingestion, glucose and GLP-1 enter the portal

circulation and circulate through the liver. Glycogen synthesis is stimulated by increased
activity of glycogen synthase and decreased activity of glycogen phosphorylase.225,410 Some
studies in humans have shown alterations in the secretion and sensitivity of GLP-1 in states
of obesity and insulin resistance, due to impaired potentiation of the beta cell response to
glucose.217,411,412 In women with polycystic ovary syndrome, which is an established risk
factor for type 2 diabetes, GLP-1 secretion follows a different time pattern after an oral
glucose challenge, with lower concentrations detected in the latter part of the challenge in
PCOS sufferers when compared with controls.217 A significant increase in GLP-1 has also
been detected in men with insulin-resistant myotonic dystrophy.216
Insulin resistance (IR) increases the risk of laminitis in horses and is a component of
Equine Metabolic Syndrome (EMS).379 It is therefore important for IR to be detected in
horses before laminitis develops. Since IR affects GLP-1 responses to an oral glucose
challenge in humans, it is our overall hypothesis that plasma incretin concentrations differ
significantly between healthy and insulin-resistant horses.

The objective of the study

reported here was to validate an ELISA to measure active GLP-1 in equine plasma, so that
insulin-resistant and healthy horses can be compared in the future.

5a.2 Materials and methods
Horses – Five horses (one with IR and 4 with normal insulin sensitivity) from the University
of Tennessee College of Veterinary Medicine teaching and research herd provided plasma
samples for the validation. Insulin resistance was defined by a resting insulin concentration >
20 mU/L and previous history of sensitivity to insulin (SI) values < 1.0 from frequentlysampled intravenous glucose tolerance testing and minimal model analysis. Plasma was
collected from the insulin-resistant horse following an overnight fast and at 30, 45, and 60
minutes during an oral sugar test (OST). These three plasma samples from the OST were
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pooled together to provide a high GLP-1 concentration sample. A resting blood sample was
collected from one normal horse after an overnight fast, and samples were collected at 0, 15,
and 30 minutes during an OST from 3 other normal horses (fasting conditions).
Sample preparation – Blood was collected into EDTA-treated collection tubes and
centrifuged (3,500 × g) immediately. Ten µL dipeptidyl peptidase-4 inhibitor (DPP-IV)a was
added to 1.5 mL microcentrifuge tubes and 1 mL of EDTA plasma was added immediately to
the inhibitor and inverted to mix thoroughly. Tubes were then flash frozen on dry ice and
stored at - 20° C until analyzed.
Validation – All samples were thawed on ice and assayb components were prepared
according to kit directions. Dilution, linearity, and spike and recovery were performed on a
single 96-well plate with samples analyzed in duplicate. The standard curve for the assay
was performed in accordance with the assay protocol and consisted of the following
concentrations: blank (assay buffer alone), 2, 5, 10, 20, 50, and 100 pmol/L, followed by 2
quality controls representing low and high GLP-1 concentrations (QC1 = 5.1 – 10.5 pmol/L,
QC2 = 27.8 – 57.7 pmol/l).
Dilution and linearity: Dilution and linearity were assessed by diluting the high GLP-1
sample (pooled OST samples) from the insulin-resistant horse with assay buffer provided in
the kit or fasted resting plasma sample from the insulin resistant horse. Plasma and the
respective diluent were plated in duplicate as 1:5, 2:5, 3:5, and 4:5 diluted plasma and plasma
and diluent alone.
Lowest limit of detection: Lowest limit of detection was performed by analyzing serially
diluted sample in duplicate. Each of the 4 serial dilutions was performed by mixing 2 parts
sample with 3 parts assay buffer and was plated to included assay buffer alone, 4 serial
dilutions, and pooled GLP-1 sample from the insulin-resistant horse.
Spike and recovery: Spike and recovery was performed using the resting plasma from a
fasted normal horse and the high standard solution (100 pmol/L) from the kit. Samples were
plated in duplicate as follows: high standard alone, 1:1 plasma and high standard, 1:3 plasma
and previously diluted sample across 3 serial dilutions, and plasma alone.

a
b

DPP-4 Inhibitor, Millipore Corp., Billerica, MA
Human Active GLP-1 ELISA, Millipore Corp., Billerica, MA
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Inter- and intra-assay variability: Inter-assay variability was calculated by plating the same
QC1 and QC2 from the assay on 3 different plates. Intra-assay variability was calculated
from quadruplicate measures of active GLP-1 in 3 samples collected from 3 normal horses at
0, 15, and 30 min during an OST.

5a.3 Results
A quadratic curve with r2 = 0.9997 was obtained with standards provided in the kit
(Figure 5a.1). Dilution and linearity tests of pooled equine plasma from an insulin-resistant
horse diluted with assay buffer resulted in a linear plot of GLP-1 concentrations with an
observed slope of 5.0 and r2 = 0.99, compared with an expected slope of 4.9 and r2 = 1.00
(Figure 5a.2). Dilution and linearity tests of pooled equine plasma from an insulin-resistant
horse diluted with plasma from the same horse under fasted conditions resulted in a linear
plot of GLP-1 concentrations, with an observed slope and r2 of 3.8 and 0.99, respectively
versus expected values of 3.6 and 1.00, respectively (Figure 5a.3). Lowest limit of detection
for the assay was 1.7 pmol/L because this was the value calculated when assay buffer was
plated alone (Figure 5a.4). The manufacturer states a concentration of 2 pmol/L as the
lowest detectable by the assay, with no background subtraction performed when calculating
concentrations (personal communication). Spike and recovery produced calculated slope and
r2 values of 85.1 and 0.98, respectively, compared with the expected values of 97.6 and 0.99,
respectively (Figure 5a.5). Overall validation procedures for the ELISA revealed a mean ±
s.d. observed-to-expected ratio for dilution and linearity of 97.0 ± 4.4% when using assay
buffer as diluent and 100.0 ± 3.8% when samples were diluted with plasma from a fasted
insulin-resistant horse. Mean ± s.d. observed-to-expected ratio for spike and recovery was
97.6 ± 10.5% and the overall recovery for this assay was 98.3% for active GLP-1 in equine
plasma. Mean ± s.d. intra-assay CV% was 9.5 ± 5.1% and inter-assay CV% for the 2 quality
controls was 2.3% and 2.6%, respectively.
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Figure 5a.1: Standard curve for active GLP-1 in equine plasma.
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Figure 5a.2: Dilution and linearity plot using assay buffer provided with the kit as the diluent
and plasma from an insulin-resistant horse following an oral sugar test (pooled 30, 45, and 60
minutes post-sugar) as the sample.
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Figure 5a.3: Dilution and linearity plot using fasted plasma from an insulin-resistant horse as
the diluent and plasma from the same horse during an oral sugar test pooled from 30, 45, and
60 minutes post-sugar bolus.
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Figure 5a.4: Lowest limit of detection plot using assay buffer provided with the kit and
fasted plasma from an insulin-resistant horse.
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Figure5a.5: Spike and recovery plot using the 100 pmol/L standard provided with the assay
as the spike solution and fasted plasma from a clinically normal horse as the sample that was
spiked.
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5a.4 Discussion
Results of this study indicate that active GLP-1 can be measured in equine plasma
using an ELISA kit designed for humans. This commercially available kit can be used to
measure GLP-1 concentrations in horses and assess influences of different metabolic states
and diets.
Glucagon-like peptide 1 may serve as a potential marker for identification of horses at
risk for developing laminitis. In humans, alterations in GLP-1 concentrations have been
identified in conditions associated with insulin resistance and obesity.212,217 Relationships
among obesity, fat oxidation, and its influence on GLP-1 are reflected in the “glucose-fattyacid-cycle proposed by Randle.219-221,413 According to the Randle Theory, competition exists
between fat oxidation and glucose uptake, such that the body preferentially utilizes fatty
acids for energy and this impairs insulin action.413 Increased concentrations of fasting GLP-1
have been detected in association with obesity and increased resting metabolic rates and fat
oxidation in humans.219 Pima Indians have the highest reported prevalence of non-insulin
dependent diabetes.221 In this population, there is an increased affinity for intestinal binding
of long-chain fatty acids resulting in increased fat oxidation and a decreased insulin
activity.221 Kunz et al.220 confirmed that a higher fat mass results in an increased resting
metabolic rate and fat oxidation with a decrease in carbohydrate oxidation, most likely as a
result of impaired insulin activity. Obesity therefore impairs insulin action by enhancing fat
oxidation, and this is associated with higher fasting GLP-1 concentrations. Higher fasting
concentrations of GLP-1 are detected in obese humans, but concentrations are lower during
oral glucose tolerance tests.211,218 However, the opposite is noted in situations where IR is the
predominant process. In men with myotonic dystrophy, a condition characterized by IR and
hyperinsulinemia, resting GLP-1 concentrations are lower compared to healthy individuals,
but higher during oral glucose tolerance tests.216
Diet influences GLP-1 concentrations in rats, dogs, and humans.414-417 In rats, highfat feeding attenuated GLP-1 secretion following oral glucose loads, whereas no change was
detected when rats were fed a standard chow diet.415 In contrast, high fat and high-calorie
feeding increased GLP-1 concentrations in dogs and humans, respectively.415,416 Diets of
different fiber types have also been associated with alterations in GLP-1 concentrations.417-419
Results have varied however, with significant increases in GLP-1 concentrations observed
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when dogs ingested high-fermentable fiber over long periods.418 Humans also required 12
months on a high-wheat fiber before GLP-1 concentrations increased after oral glucose
challenge.417 However, there was no significant effect of feeding a highly fermentable fiber
diet on GLP-1 concentrations in another study performed in dogs.419
Horses that are at higher risk of IR and laminitis are generally obese and have
elevated blood lipid concentrations.6

Since higher GLP-1 concentrations have been

associated with obesity and impaired insulin action in humans, it is likely that GLP-1 will
reflect the metabolic status of the horse.

However, GLP-1 responses appear to vary

according to the predominant mechanism (obesity versus IR), which explains the variation in
reported results from other species.216,217
Human metabolic syndrome (MetS) is similar to Equine Metabolic Syndrome in that
both syndromes include hyperinsulinemia, IR, dyslipidemia, and obesity122,420.

These

conditions are risk factors for cardiovascular disease and type 2 diabetes in humans and
laminitis in horses. In humans, GLP-1 concentrations were higher in subjects with a cluster
of MetS risk factors that did not include adiposity.122 Basal active GLP-1 concentrations
range from 28.4 to 42.9 pg/mL, with overweight individuals having lower concentrations
compared to lean controls.421 Concentrations also vary according to sampling location, with
portal vein concentrations ranging from 50 to 60 pmol/L in humans and 30 to 60 pmol/L in
dogs due to clearance from the circulation.422,423 In dogs, basal concentrations range from 4.4
to approximately 15 pmol/Lin different studies.414
Normal ranges have not been established in horses as this is, to the authors’
knowledge, the first study to measure active GLP-1 in equine plasma. The strong correlation
with MetS risk factors and GLP-1 concentrations in humans suggests that this incretin
hormone may be a useful marker for EMS and laminitis risk in horses. However, it is
apparent from studies performed in other species that concentrations must be measured under
different metabolic and dietary conditions in order to fully understand the normal physiology
of GLP-1 in horses. We conclude that a commercial assay is available to measure GLP-1 in
equine plasma.
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Chapter 5b
Plasma glucagon-like peptide 1 (GLP-1) concentrations in
response to an oral sugar test in healthy and insulin-resistant
horses
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served as mentor, II) co-designer, and III) editor of the study, and Amy Schuver who I) was
involved in sample collection and II) animal management.

Abstract
Glucagon-like peptide 1 (GLP-1) is an incretin hormone secreted by the small
intestine in response to feeding. Studies in other species indicate that obesity and insulin
resistance are associated with alterations in GLP-1 concentrations after feeding. An enzymelinked immunosorbent assay for human active GLP-1 has recently been validated for use with
equine plasma in our laboratory. We tested the hypothesis that healthy and insulin-resistant
horses differ in their GLP-1 response to an oral sugar test (OST). Eleven healthy horses and
six insulin-resistant horses underwent an OST after overnight fasting. After baseline blood
samples were collected, 50 mg sugar per kg body weight was administered as Karo®
Original Light Corn Syrup (10g sugar/30 mL syrup) via dose syringe. Blood samples were
then collected at 15, 30, 45, 60, 75, 90, 105, and 120 min. Active GLP-1 was measured in
EDTA plasma treated with dipeptidyl-peptidase IV inhibitor.
Mean GLP-1 concentrations significantly increased (P < 0.001) during the OST, but
individual responses varied widely. Median (range) maximum percent increase in GLP-1
concentration after sugar administration was 67% (–15% to 188%) in healthy horses and
148% (35% to 286%) in insulin-resistant horses. Metabolic status did not affect GLP-1
concentrations (P = 0.623), percent change (P = 0.167), fold change (P = 0.161), or area
under the curve in response to sugar administration (P = 0.281). Healthy and insulin-resistant
horses did not differ with respect to GLP-1 responses to Karo® syrup in this study, but
specific nutrients should be tested in the future.
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5b.1 Introduction
Incretin hormones are peptide hormones that are secreted by the intestine in response
to glucose intake and enhance secretion of insulin following glucose intake.217 Glucagon-like
peptide 1 (GLP-1) is an incretin hormone secreted from L-cells of the small intestine that
exerts its effect on the β-cells of the pancreas resulting in elevations in insulin in a glucose
dependent manner.214,215,222 Other effects of GLP-1 secretion include slowing gut motility
and gastric emptying, which delays blood sugar increases following a meal,215 inhibition of
glucagon release and promotion of satiety,410 reduction in insulin clearance, which raises
blood concentrations,20 and effects on cardiac function.210 Receptors for GLP-1 have been
identified in the pancreatic islets, gastrointestinal tract, kidney, heart, lung, central nervous
system, and adipose tissue.214
Aberrations in GLP-1 secretion and function have been detected in diabetes and other
medical conditions associated with impaired glucose regulation, insulin resistance, and
obesity.210,217,219

In humans, type 2 diabetes, polycystic ovary syndrome (PCOS), and

myotonic dystrophy are associated with insulin resistance (IR) and abnormal GLP-1
responses following oral glucose challenges.216,217,416 Results have differed among studies
with some showing greater increases in GLP-1 concentrations following oral glucose in
males with myotonic dystrophy216, and others revealing that concentrations are lower in the
later stages of oral glucose tolerance tests in women with PCOS.217 In states of obesity, basal
fat oxidation is increased, and this is associated with higher fasting GLP-1 concentrations.219221

We hypothesized that there would be a difference in GLP-1 concentrations in
response to an oral sugar test (OST) between insulin-resistant and normal horses.

5b.2 Materials and Methods
Horses – A total of 17 horses were included in the study. Six horses with EMS which
included histories of IR and obesity were compared with 11 healthy mares. Geldings and
mares were included in the IR group. All horses were owned by the University of Tennessee.
Insulin-resistant horses were housed alone in individual stalls (2.75-m × 3.5-m) with attached
outdoor dry-lots (3.7-m × 10-m) in a barn. Healthy horses were part of the teaching and
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research herd and were housed outdoors on pasture with access to run-in sheds. Insulinresistant horses did not have access to pasture for ≥ 15 months prior to and throughout the
study. Body condition scores (BCS) of insulin-resistant horses were obese (≥ 7/9), whereas
healthy horses ranged from 4 to 6/9. Body weights ranged from 429 to 559 kg (mean, 475 ±
59 kg) for insulin-resistant horses, and from 445 to 507 kg (mean, 469 ± 25 kg).
Diet – Insulin-resistant horses were fed orchard/timothy grass hay ad libitum and healthy
horses were allowed to graze unrestricted. Water was available ad libitum via automatic
waterers or water troughs.
Experimental design – A randomized block design, blocked on metabolic status with
repeated measures was used. Each horse underwent an OST on a single occasion with blood
samples collected q15 min for 120 minutes following baseline samples and sugar
administration.
Oral sugar test procedure – A 14-gauge polypropylene jugular catheter was placed the
evening prior to OST testing. All horses were enclosed in stalls overnight and received a
single flake of hay at 2000 and then no feed until after testing the following morning. Water
was available ad libitum throughout the procedure. Patency of the IV catheter was maintained
overnight by injecting 100 mg heparin into a heparin lock infusion cap.a For the OST
procedure, an injection cap and infusion setb (length, 30 cm; internal diameter, 0.014 cm)
were attached to the catheter. An OST procedure designed by our research group was used.
Baseline blood samples were collected at 0800 via the catheter and then corn syrup was
administered via dose syringe at a dosage of 0.15 mL/kg bwt to provide 150 mg dextrose
derived digestible sugars per kg bwt. Samples were then collected via the catheter at 15, 30,
45, 60, 75, 90, 105, and 120 minutes relative to sugar administration. At each time point, 3
mL of blood was withdrawn from the infusion line and discarded. Blood was collected into
tubes containing EDTA and then 5 mL of heparinised saline was infused. Plasma for active
GLP-1 measurements was centrifuged immediately (3500 × g) for 3 minutes. After plasma
was harvested, a 1 mL aliquot was added to 10 µL dipeptidyl peptidase-IV inhibitorc in a 1.5
mL microcentrifuge tube on ice. Samples were immediately inverted to mix thoroughly and
were then flash frozen on dry ice. Samples were stored at
a
b
c

-20° C until further analysis.

Heparin Lock Injection Site, Medical Specialties Dist., LLC, Sloughton, MA
Butterfly, Abbott Laboratories, North Chicago, IL
DPP-4 inhibitor, Millipore Corp., Billerica, MA
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Plasma GLP-1 concentrations – Plasma active GLP-1 concentrations were measured by use
of a commercially available human active GLP-1 ELISAd previously validated by our
laboratory for use in the horse. Each sample was assayed in duplicate and intra-assay
coefficients of variation (CV%) < 10% were required for acceptance of assay results.
Statistical analysis - Active GLP-1 concentrations did not fit a normal distribution, so data
were log transformed prior to analysis. Metabolic status and time effects for all variables
were evaluated by repeated measures analysis of variance (ANOVA) using statistical
software.e When main effects were significant, the protected least square difference mean
separation method was used to compare different effects. Significance was defined as a value
P < 0.05.

5b.3 Results
Overall active GLP-1 concentrations significantly increased (P < 0.001; Figure 5b.1)
over time during the OST compared to baseline, with peak concentrations measured at 60 to
75 minutes. However, individual animals varied markedly. No group × time (P = 0.623) or
group (P = 0.320) effects were detected for active GLP-1 concentrations.

Baseline

concentrations of GLP-1 in the study reported here ranged from 1.5 to 6.5 pmol/L (median,
3.3 pmol/L) for healthy horses and 2.2 to 6.3 pmol/L (median, 3.4 pmol/L) for insulinresistant horses, and did not differ between groups. Peak concentrations ranged from 2.8 to
12.7 pmol/L (median, 4.6 pmol/L) in healthy horses and 3.7 to 18.3 pmol/L in insulinresistant horses (median, 9.2 pmol/L). Area under the curve values for active GLP-1 did not
differ (P = 0.281; Figure 5b.2) between groups. Median (range) maximum percent increase
in active GLP-1 concentrations after sugar administration was 67% (˗15% to 188%) in
healthy horses and 148% (35% to 286%) in insulin-resistant horses, but groups did not differ
significantly (P = 0.170). Metabolic status did not affect percent change in GLP-1 (P =
0.167) or fold change in GLP-1 (P = 0.161) during the OST.

d
e

Human active GLP-1 ELISA, Millipore Corp., Billerica, MA
PROC MIXED, SAS, version 9.2, SAS Institute Inc., Cary, NC
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Figure 5b.1: Mean ± s.d. active GLP-1 concentrations in healthy (n = 11; circles) and
insulin-resistant (n = 6; squares) horses during an oral sugar test (OST) with Karo® corn
syrup. Within a group, a significant difference from the baseline (time = 0) mean values is
denoted by an asterisk (time effect; P < 0.001).
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Figure 5b.2: (A) Scatterplots of mean GLP-1 AUC for normal (n = 11) and EMS (n = 6)
horses (left) and peak active GLP-1 concentrations of normal (n = 11) and EMS (n = 6)
horses; (B)Mean ± s.d. area under the GLP-1 curve in healthy (n = 11) and insulin-resistant (n
= 6) horses during an oral sugar test (OST) with Karo® corn syrup (treatment × time effect; P
= 0.281).
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5b.4 Discussion
Results of this study indicate that the OST can be used to assess active GLP-1
secretion in horses. However, no significant differences were detected between healthy and
insulin-resistant horses when corn syrup was used for this test, so further studies are required
to examine the GLP-1 response to different oral sugars in horses.
Results of this study contrast with findings from studies performed in humans.216,217
Conditions associated with IR and/ or type 2 diabetes, such as PCOS in women and myotonic
dystrophy in men, have been studied in regards to active GLP-1 concentrations.216,217
Women suffering from PCOS have the same GLP-1 responses during the majority of the
OGTT when compared to controls, except at 180 min when concentrations are significantly
lower.217 However, results of another study were consistent with our findings in that GLP-1
responses were the same in healthy women and those with PCOS during an OGTT.424 It is
important to note that horses were only sampled until 120 minutes in this study, so the OST
should be extended to 180 minutes in the future.
When GLP-1 was measured in men with myotonic dystrophy, significantly higher
concentrations were detected during OGTTs in insulin-resistant subjects compared to those
with normal insulin sensitivity.216 Although plotted GLP-1 concentrations here appeared
higher in insulin-resistant horses, values were not significantly different. The question of
whether IR impairs GLP-1 secretion has not been answered yet in human medicine. Shortterm glucosteroid administration, which induces glucose intolerance and IR, impairs the
incretin effect in humans.416 It has also been shown that impairment of the incretin response
can be reversed after normalization of glucose tolerance, as reported with gestational
diabetes, suggesting that this impairment results from IR.213
Metabolic syndrome in humans is a collection of risk factors for cardiovascular
disease and diabetes.122 In contrast, Equine Metabolic Syndrome (EMS) is a set of risk
factors for the development of laminitis.379 There are similarities between the two disorders,
including obesity, insulin resistance, hyperinsulinemia, and dyslipidemia.122,420 A condition
in humans referred to as non-alcoholic fatty liver disease (NAFLD), or hepatic steatosis,
results from ectopic accumulation of triglycerides within the cytoplasm of hepatocytes, and
is closely related to obesity and sometimes associated with IR.425 It has been established in
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humans that NAFLD increases dipeptidyl peptidase-IV (DPP-4) activity, which is the enzyme
responsible for rapid degradation of active GLP-1 in the circulation.212,426,427 This may
explain the common finding that GLP-1 concentrations following a meal are often diminished
in people with type 2 diabetes. In horses suffering from EMS, a state of hepatic insulin
resistance is believed to play a role in hyperinsulinemia that is commonly detected. It is
possible that this may result in elevated activity of DPP-4 and explain the lack of significant
findings in the study reported here.379 Hepatic insulin resistance is a result of ectopic lipid
accumulation and has been documented on post-mortem examination of some obese, insulinresistant horses studied by our research group (unpublished data). Hepatic lipid accumulation
may lead to elevated DPP-4 concentrations and lowered GLP-1 responses during the OST.
In has been shown in humans that a higher body mass index (BMI), which reflects a
state of obesity, results in significantly greater basal energy expenditure as a result of
increased fat oxidation.220 Higher rates of fat oxidation have been associated with increased
fasting plasma GLP-1 concentrations in humans.219 The Randle Theory suggests that lipids
and carbohydrates compete as the oxidative fuel source for skeletal muscle and by doing so,
skeletal muscle glucose uptake is impeded and results in IR.221,413 This may explain why
some studies have shown elevated fasting GLP-1 concentrations in obese individuals.211
In healthy humans, peripheral blood GLP-1 concentrations can rise to 30 pmol/L, but
generally remain below 10 pmol/L following a meal.422
concentration of approximately 20 pmol/L.422

Rats show a postprandial

Studies in dogs have detected basal

concentrations of approximately 4.9 pmol/L after feeding once or twice daily.414 These
baseline concentrations are similar to the concentrations detected in the study reported here
(range, 1.5 to 6.5 pmol/L). In a study of women with PCOS, peak GLP-1 concentrations
were approximately 7 pmol/L following an oral glucose load,217 and 60 pmol/L and 27
pmol/L following a carbohydrate or fat meal, respectively in healthy women.211 In contrast,
obese women with PCOS showed peak responses of approximately 25 pmol/L and 27 pmol/L
following a carbohydrate or fat meal, respectively.211

Peak responses did not differ

statistically between normal and insulin-resistant horses in this study.
As previously discussed, GLP-1 is secreted in response to dietary glucose in a dose
dependent manner so a commercially available sugar source was utilized in this study.
However, studies in rats and dogs have shown variability in GLP-1 responses, depending
125

upon food type. A study performed by Massimino et al.418 determined that the chronic
ingestion of high fermentable dietary fiber in dogs resulted in significantly greater GLP-1
concentrations when compared to dogs fed low fermentable fiber.

In conjunction with

elevated GLP-1 secretion, an increase in intestinal glucose transport capacity and glucose
homeostasis following an oral glucose challenge was also detected. A more recent study
found opposite results.419 Post-prandial concentrations of GLP-1 did not differ significantly
between groups of dogs fed high and low fermentable fiber diets, and interestingly dogs
consuming the high fermentable fiber showed lower voluntary feed intake.419 A study by
Lubbs et al.414 assessed the effects of different dietary macronutrients on GLP-1 secretion in
dogs.

An overall higher GLP-1 concentration was measured in dogs fed twice daily

compared to dogs fed once daily.

When dogs were challenged acutely with water,

carbohydrates, fat, or protein, those dosed with carbohydrates peaked at 60 minutes and then
decreased, before spiking once more at 360 minutes, which was the final time point in the
study. A study in rats detected a decrease in GLP-1 concentrations when rats were fed a
high-fat diet compared to a basic chow diet.415
This is, to the authors’ knowledge, the first study to evaluate active GLP-1
concentrations in horses in response to an oral sugar test. Insulin-resistant horses in the study
reported here were restricted to a hay-only diet whereas normal horses had access to pasture.
It is possible that variability in the amount and type of fiber consumed by these horses may
have influenced results. Although statistical significance was not attained in this study, and
as a result did not support our hypothesis, horses within groups varied markedly with insulinresistant horses often having higher GLP-1 concentrations when compared to healthy
controls. Further studies are therefore required to determine whether certain horses with IR
exhibit abnormal GLP-1 responses compared to controls and if this abnormality impacts the
health of the animal. Further study is required to assess GLP-1 responses in individual
animals during transition from one metabolic state to another in an attempt to eliminate
variability. More animals must be evaluated to determine whether obesity and IR affect
GLP-1 responses to feeding in horses.

126

Chapter 5c

Effects of weight gain on plasma active glucagon-like peptide 1
(GLP-1) concentrations and glucose tolerance test responses in
horses

127

This paper is formatted from a version to be submitted for consideration for
publication to the American Journal of Veterinary Research
My primary contribution to this paper included I) execution of the study discussed
herein and II) primary author of this paper. Co-authors include Dr. Nicholas Frank who I)
served as mentor, II) co-designer, and III) editor of the study, Sarah B. Elliott who I) assisted
with sample collection, II) animal preparation, and III) technical assistance, and Amy
Schuver who I) was involved in sample collection and II) animal management.

Abstract
Insulin resistance (IR) is associated with obesity, type 2 diabetes, metabolic
syndrome, polycystic ovary syndrome, and myotonic dystrophy. Aberrations in glucagonlike peptide 1 (GLP-1) have been identified in these conditions. Insulin resistance and
obesity also occur, in association with laminitis, and this syndrome is referred to as Equine
Metabolic Syndrome (EMS). We have previously observed that some horses with EMS have
higher GLP-1 concentrations (Chapter 5). However, it is unclear whether obesity and IR
raise or lower GLP-1 concentrations in horses. We therefore tested the hypothesis that
induction of weight gain in horses with histories of IR and chronic obesity would result in
alterations in GLP-1 concentrations. Six horses with histories of IR and obesity underwent
weight gain over 8 weeks by providing 2.0 × DEm per day. Oral glucose tolerance tests
(OGTT) were performed prior to initiation of weight gain and 8 weeks later. Glucose,
insulin, and GLP-1 from the OGTT were analyzed by area under the curve and repeated
measures ANOVA.
Mean body weight significantly increased (P = 0.003) over 8 weeks. Glucagon-like
peptide 1 concentrations increased over time during the OGTT (P = 0.023) but did not differ
with weight gain. Area under the GLP-1 curve did not change significantly with weight gain.
Mean glucose concentrations did not differ with weight gain, whereas insulin concentrations
increased over time (P = 0.027) as well as area under the insulin curve (AUCi; P = 0.003).
An increase in body weight over 8 weeks did not result in changes in GLP-1 concentrations.
Future studies should include more animals in order to determine whether GLP-1
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concentrations can be used to identify insulin-resistant horses and assess reductions in insulin
sensitivity due to diet.

5c.1 Introduction
Insulin resistance is a condition in which physiologic concentrations of insulin are
unable to elicit the appropriate response by insulin sensitive tissues such as skeletal muscle,
adipose tissue, or the liver.428 It is a condition that has been associated with states of obesity,
type 2 diabetes, polycystic ovary syndrome (PCOS), metabolic syndrome, and myotonic
dystrophy.122,216,217,221,429 In horses, it is a component of the Equine Metabolic Syndrome
(EMS) and is believed to be a factor predisposing horses to laminitis.379
In diseases such as myotonic dystrophy, type 2 diabetes, and PCOS where obesity and
insulin resistance occur, aberrations in glucagon-like peptide 1 (GLP-1) have been
observed.216,217 Glucagon-like peptide 1 is an incretin hormone released by the L-cells of the
distal small intestine in a dose dependent response to dietary glucose resulting in enhanced
insulin secretion by the pancreas.210 Results of studies in humans and other species have
varied with respect to fasting GLP-1 concentrations and GLP-1 responses to oral glucose
challenges.217,219,430
States of higher resting energy expenditure and fat oxidation have been associated
with higher fasting concentrations of GLP-1.219 States of obesity have been associated with
elevated states of basal fat oxidation and a resulting decrease in insulin action, both of which
could be associated with elevated GLP-1 concentrations.219-221

We hypothesized that

inducing weight gain and obesity in horses with histories of chronic insulin resistance would
increase basal concentrations and GLP-1 responses during oral glucose tolerance tests.

5c.2 Materials and methods
Horses – Six adult horses that had been donated to the University of Tennessee and
maintained for > 24 months were included in the study. Each horse had been donated due to
histories of laminitis and chronic insulin resistance. At the beginning of the study horses had
a mean body condition score of 6/9 and ranged from 4 to 8.5/9; scores ≥ 7 are considered
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overweight according to the 1 to 9 scoring system devised by Henneke et al.9 The study was
performed from May 2010 to July 2010. Custom farrier care was provided as needed. All
horses were housed individually in orchard grass paddocks (15-m × 55-m) with run-in sheds.
Three mares and 3 geldings were included in the study and ranged in age from 8 to 22 years
(median, 16 years), with initial body weights ranging from 381 to 533 kg (median, 423 kg).
Diet – All horses were allowed free access to pasture, and were supplemented with a diet to
provide 2 × DEm. Forty percent of digestible energy was provided by timothy/orchard grass
hay which provided 1100 kcal/lb, on a dry matter basis, and 60% with a sweet feed that
provided 1330 kcal/lb on a dry matter basis.

Hay provided 13.7% water-soluble

carbohydrates (WSC), 0.9% starch, and 10.8% simple sugars (ESC) on a dry matter basis and
sweet feed provided 8.8% WSC, 17.4% starch, and 6.2% ESC on a dry matter basis, as
determined by a commercial forage testing laboratory.a Horses were transitioned to the diet
over a span of 1-week by incrementally feeding 0.25 × target amount twice daily on day 1,
0.5 × target amount on days 2, 3, and 4, 0.75 × target amount on days 5, 6, and 7, and the full
amount by day 8. Water was available ad libitum via automatic waterers and grain and hay
were offered between 0700 and 0800 and again between 1500 and 1530.
Experimental design – A longitudinal prospective study with 6 horses serving as their own
controls was performed. All horses underwent intravenous glucose tolerance test (IVGTT)
and oral glucose tolerance test (OGTT) procedures prior to the initiation of weight gain (time
= - 1 week) and again after 8 weeks on the weight gain diet (time = 9 weeks). Tests were
performed on consecutive days with the IVGTT being performed on the first day and the
OGTT being performed the next day. Horses were transported to the teaching hospital in
pairs 2 days prior to the first test to allow acclimation to the surroundings. At both time
points, morphometric measurements were collected along with blood samples. The study
protocol was approved by the University of Tennessee Institutional Animal Care and Use
Committee.
Morphometric measurements – Morphometric measurements included neck circumference,
body weight, body condition score (BCS), girth circumference, and rump fat thickness. Neck
circumference was measured perpendicular to the crest of the neck at 0.25, 0.50 (mid neck),
and 0.75 of the distance from the withers to the poll with a measuring tape as previously
a

Dairy One Forage Testing Laboratory, Ithaca, NY
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described.6 Mean neck circumference values were calculated. Rump fat thickness was
measured via ultrasonography placed 5 cm lateral from the dorsal midline at the center of the
pelvic bone as previously described by Carter et al.431
Testing procedure – Two 14-gauge polypropylene catheters were inserted into the left and
right jugular veins using aseptic technique the day before the first test was performed. Horses
underwent an overnight fast before testing was performed and tests were performed under
fasting procedures with the exception of water which was available throughout the
procedures. Patency of IV catheters was maintained by infusion of 5 mL saline solution
containing heparin (4 U/mL) into the catheter q 6h. An injection cap and infusion setb
(length, 30 cm; internal diameter, 0.014 cm) were attached to each catheter.
IVGTT procedure – Dextrose as a 50% solution (wt/vol) dextrose solutionc was infused in
one jugular catheter at a concentration of 150 mg/kg bwt followed by 20 mL heparinised
saline. Blood samples were collected from the other jugular catheter 15 minutes before
dextrose infusion and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 15, 16, 19, 22, 23, 24, 25, 27, 30, 35, 45,
50, 60, 75, 90, 105, 120, 150, and 180 minutes relative to dextrose infusion. At each time
point, 3 mL of blood was discarded and then blood was collected into tubes containing a
glycolytic inhibitor (potassium oxalate/ sodium fluoride) and tubes without anti-coagulant.
Following sample collection, 5 mL heparinised saline was infused. Plasma and serum were
harvested via centrifugation (3,500 × g) and then stores at -20° C until further analysis. Preinjection insulin and glucose concentrations are referred to as baseline concentrations.
Following completion of this test, the dextrose infusion catheter was removed.
OGTT procedure - During the OGTT procedure, dextrose powderd was weighed to provide
150 mg/kg bwt dextrose. Powder was mixed with water and gently heated to bring into
solution. The dextrose solution was administered to horses via dose syringe. Blood samples
were collected 15 minutes prior to dextrose administration and 15, 30, 45, 60, 75, 90, 105,
120, 135, 150, 165, and 180 minutes relative to oral dextrose administration. At each time
point, 3 mL of blood was withdrawn and discarded and blood samples for glucose and insulin
were collected into tubes containing a glycolytic inhibitor (potassium oxalate/ sodium
fluoride) and tubes without anti-coagulant. Samples for GLP-1 were collected into EDTA
b
c
d

Butterfly, Abbott Laboratories, North Chicago, IL
Dextrose 50% Injection, Abbott Laboratories, North Chicago, IL
D - (+) – Dextrose Powder, Sigma Life Sciences, St. Louis, MO
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treated tubes and centrifuged immediately (3,500 × g for 3 minutes).

Following

centrifugation, 1 mL of plasma was added to 10 µL of dipeptidyl peptidase-IV inhibitor
(DPP4)e in 1.5 mL microcentrifuge tubes on ice. Samples were inverted to mix thoroughly
and then flash frozen on dry ice and stored at -20° C until further analysis. Samples for
glucose and insulin were centrifuged following sample collection.
Blood glucose, insulin, and GLP-1 concentrations – Plasma glucose concentrations were
measured by use of a colorimetric assayf on an automated discrete analyzer.g Serum insulin
concentrations were determined by use of a radioimmunoassayh previously validated for use
in horses.393 Each sample was assayed in duplicate and intra-assay coefficients of variation
(CV%) < 5% or < 10% were required for acceptance of glucose and insulin assay results,
respectively.

Glucagon-like peptide 1 was measured by use of an enzyme-linked

immunosorbent assay (ELISA)i previously validated for use with horse plasma in our
laboratory. Each sample was assayed in duplicate and CV% of < 10% was required for
acceptance of GLP-1 results.
Statistical analysis – Area under the glucose curve (AUCg) data did not fit a normal
distribution, so data were rank transformed prior to analysis. Time, treatment, and test effects
were evaluated for all variables by repeated measures analysis of variance (ANOVA) using
statistical software.j When time, test, or treatment effects were significant, the protected least
square mean separation method was used to compare different treatment periods.
Significance was defined as a value P < 0.05.

5c.3 Results
Testing was performed at baseline and 4 weeks later in one mare due to the development of
laminitis. Mean body weight significantly increased over the treatment period (P = 0.003;
Table 5c.1; Figure 5c.1). Mean body weight prior to diet intervention was 438 ± 61 kg
(range, 381 to 533 kg) and increased to 464 ± 61 kg (range, 394 to 550 kg). Percent body

e
f
g
h
i
j

Dipeptidyl Peptidase – IV Inhibitor, Millipore Corporation, Billerica, MA
Glucose, Roche Diagnostic Systems Inc., Somerville, NJ
Cobas Mira, Roche Diagnostic Systems Inc., Somerville, NJ
Coat-A-Count insulin, Diagnostic Products Corp., Los Angeles, CA
GLP-1 (Active) ELISA, Millipore Corporation, Billerica, MA
PROC MIXED, SAS, version 9.2, SAS Institute Inc., Cary, NC
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Table 5c.1: Mean ± s.d. physical measurements for 6 horses with chronic insulin resistance
that received a diet providing 2 × DEm per day for 8 weeks.

Treatment

Variable
Pre (0 wks)

Treatment
Post (8 wks)

P

Body Weight
(kg)

438 ± 61

464 ± 61

0.003

BCS
(1 to 9 scale)

6.1 ± 1.6

8.0 ± 0.8

0.006

0.25 × neck
(cm)

74 ± 3

80 ± 5

0.003

0.5 × neck
(cm)

88 ± 7

97 ±5

< 0.001

0.75 × neck
(cm)

105 ± 7

112 ± 6

0.002

Mean neck circumference
(cm)

89 ± 6

96 ± 5

< 0.001

Girth circumference
(cm)

180 ± 7

184 ± 8

0.012

Rump fat thickness
(cm)

1.85 ± 0.69

2.50 ± 0.86

0.002

Neck-to-height
(ratio)

0.60 ± 0.04

0.64 ± 0.4

< 0.001

BCS = Body condition score; x = Distance from the poll to the withers; P < 0.05
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Figure 5c.1: Mean ± s.d. body weight at baseline and following administration of a diet
providing 2 × DEm per day for 8 weeks to horses with chronic insulin resistance (n = 6).
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weight gain ranged from 2 to 10%, with the lowest gain occurring in a horse that was on the
diet for 8 weeks. Body condition score significantly increased over the treatment period (P =
0.006). Mean BCS was 6 ± 2 (range, 4 to 8.5) prior to diet intervention and increased to 8 ±1
(range, 7 to 9). Mean neck circumference significantly increased during the study (P <
0.001).

Girth circumference increased by the end of the diet intervention and was

significantly (P = 0.011) different when compared to baseline measurements. Rump fat
thickness also increased significantly (P = 0.002) when horses were fed a weight gain diet,
with mean values increasing from 1.85 ± 0.69 cm to 2.50 ± 0.86 cm. Mean neck-to-height
ratios significantly increased with weight gain (P < 0.001). Weak correlations were detected
between body weight and mean neck circumference (r = 0.22; P = 0.678) and rump fat
thickness (r = 0.24; P = 0.643) following weight gain.

Mean neck circumference

measurements showed a strong correlation with rump fat thickness (r = 0.85; P = 0.031),
BCS (r = 0.91; P = 0.013), and a weak correlation with girth circumference (r = 0.16; P =
0.770) following weight gain. Rump fat thickness was correlated with BCS (r = 0.62; P =
0.186) and girth circumference (r = -0.29; P = 0.573) after weight gain.
Blood glucose concentrations were higher during the IVGTT (P < 0.001) compared to
the OGTT, and were higher prior to weight gain (P = 0.001). When AUCg data for the
IVGTT were rank transformed (Figure 5c.2), significant treatment (P = 0.012), test (P <
0.001), and treatment × test effects (P = 0.049) were detected when comparing the IVGTT
with the OGTT. This was a result of AUCg values being greater prior to weight gain, greater
during the IVGTT, and the highest during the pre-weight gain IVGTT.
Baseline OGTT serum insulin concentrations did not differ after weight gain (P =
0.142; Figure 5c.3), but differed dependent on tests (P < 0.001; Table 5c.2), and a treatment
× test effect was detected for the IVGTT (P = 0.038). Insulin concentrations were higher
after weight gain and highest in the post-weight gain IVGTT. For the OGTT, baseline insulin
concentrations did not differ significantly after weight gain, but AUCi differed between preand post-weight gain values (P = 0.003) and between the two tests (P = 0.024). Area under
the insulin curve during the IVGTT significantly increased following weight gain (P = 0.001;
Figure 5c.4). Insulin concentrations during the OGTT were significantly higher after weightgain. Plasma GLP-1 concentrations did not show a treatment effect (P = 0.141), but did show
a time effect within the OGTT (P = 0.023; Figure 5c.5 with the highest concentrations
measured at 45 minutes compared to baseline.
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Figure 5c.2: Mean ± s.d. glucose concentrations during an IVGTT at baseline and following
administration of a diet providing 2 × DEm per day for 8 weeks to horses with chronic insulin
resistance (n =6; pre-weight gain (•), post-weight gain (■). Inset: Mean ± s.d. area under the
glucose curve.
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Figure 5c.3: Mean ± s.d. insulin concentrations during an OGTT at baseline and following
administration of a diet providing 2 × DEm per day for 8 weeks to horses with chronic insulin
resistance (n =6; pre-weight gain (•), post-weight gain (■). Inset: Mean ± s.d. area under the
insulin curve.

137

*

20
15
10
5

ei
gh
t

ga
in

ga
in

0

-w
Po
st

Pr
ew
ei

gh
t

Insulin AUC ([mU/L  min]) × 103

25

P = 0.024

200

Insulin (mU/L)

150

100

50

0
0

50

100

150

Time (minutes)

Figure 5c.4: Mean ± s.d. insulin concentrations during an IVGTT at baseline and following
administration of a diet providing 2 × DEm per day for 8 weeks to horses with chronic insulin
resistance (n =6; pre-weight gain (•), post-weight gain (■). Inset: Mean ± s.d. area under the
insulin curve.
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Figure 5c.5: Mean ± s.d. GLP-1 concentrations during an OGTT at baseline and following
administration of a diet providing 2 × DEm per day for 8 weeks to horses with chronic insulin
resistance (n =6; pre-weight gain (•), post-weight gain (■). Inset: Mean ± s.d. area under the
GLP-1 curve.
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Table 5c.2: Mean ± s.d. blood measures for 6 horses with chronic insulin resistance that
received a diet providing 2 × DEm per day for 8 weeks.
Variable

Pre (0 wks)

Treatment
Post (8 wks)

Treatment
P

Mean baseline
OGTT glucose
(mg/dL)

86.77 ± 6.80

81.30 ± 8.09

0.261

AUCg
([mg/dL] · min) × 103

16.93 ± 7.35

18.71 ± 1.63

0.012

Mean baseline
OGTT insulin
(mU/L)

10.88 ± 3.78

24.18 ± 16.16

0.142

AUCi
([mU/L] · min) × 103

7.26 ± 4.30

11.37 ± 4.63

0.003

GLP-1
(pmol/L)

0 min – 5.8 ± 2.2
45 min – 7.6 ± 3.7

0 min – 5.5 ± 2.2
45 min – 6.8 ± 4.0

0.836

AUC GLP-1
1.33 ± 0.48
1.24 ± 0.49
([pmol/L] · min) × 103
AUCg = area under the glucose curve; AUCi = area under the insulin curve;

0.285

GLP-1 = Glucagon-Like Peptide 1; OGTT = oral glucose tolerance test; P < 0.05
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A weak correlation was detected between insulin and GLP-1 (r = 0.29; P = 0.583) and mean
neck circumference (r = 0.34; P = 0.511) prior to weight gain, but there was a stronger
correlation between insulin and girth circumference (r = 0.61; P = 0.200). Area under the
GLP-1 curve showed a negative correlation with body weight before weight gain (r = -0.019;
P = 0.972; Figure 5c.6) and a positive correlation following weight gain (r = 0.379; P =
0.459). However, the relationship between insulin and GLP-1 became negative following
weight gain (r = -0.23; P = 0.660; Figure 5c.7).
Minimal model data analysis for IVGTT data detected a non-significant decrease in
insulin sensitivity (P = 0.721; Figure 5c.8) in response to weight gain, as well as a nonsignificant increase in the disposition index (P = 0.665). However, a significant increase in
the AIRg was detected (P = 0.042) as a result of weight gain.

5c.4 Discussion
Provision of a diet containing 2 × DEm for 8 weeks resulted in significant weight gain
in 6 horses with chronic insulin resistance. Increase in weight gain was associated with
increased OGTT and IVGTT AUCi values but not GLP-1 concentrations. However, weight
gain was positively correlated with area under the GLP-1 curve and negatively correlated
with AUCi during both the IVGTT and OGTT. Data from the mare that was removed from
the weight gain diet after 4 weeks was included in the analysis with all other animals. This
mare had gained an acceptable amount of weight in that time period (6% gain) for her data to
be included with the other animals. This mare was removed from the study because laminitis
developed and this problem subsided once she was removed from the diet. An earlier study
performed to compare active GLP-1 concentrations between normal and insulin resistant
horses did not detect a significant effect of metabolic status; however, the numbers were low
(8 normal horses and 10 insulin-resistant horses) and horses underwent an OST versus the
OGTT performed here.
Studies in other species have revealed varying findings with respect to GLP-1 concentrations
and obesity.210,219 Some studies have shown an association between higher rates of basal fat
oxidation, which is related to the state of obesity, and fasting GLP-1 concentrations219-221 and
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Figure 5c.6: Correlation plot of body weight against GLP-1 AUC for 6 horses pre- (•;
r = -0.019; P = 0.972) and post-weight gain (■; r = 0.379; P = 0.459).
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others have reported reduced secretion in states of obesity, with improved secretion measured
following weight loss.210 This reported decrease in secretion associated with obesity has been
suggested to be a result of L-cell responsiveness, presumably due to elevations in circulating
free fatty acid concentrations.210 However, in a study of type 2 diabetic and non-diabetic
humans, free fatty acids did not appear to have an effect, but body mass index was negatively
associated with GLP-1 secretion.218
In the study reported here, body weight increased after feeding of a diet designed to
provide 2 × DEm for 8 weeks. This amount of digestible energy induced weight gain over a
period of 16 weeks in horses, which resulted in an overall gain of 20%,431 supporting its use.
In horses, an association has been found between the presence and severity of a cresty neck
and alterations in insulin sensitivity6 and that the mean neck circumference-to-wither height
ratio can be used as an indicator of the severity of neck adiposity.13 It was determined that a
neck-to-height ratio of ≥ 0.63 ± 0.1 is an indicator of a cresty neck score of ≥ 3, which
indicates increased risk for pasture-associated laminitis.13 Horses in this study had mean
neck-to-height ratio representative of a cresty neck score < 3 at the beginning of the study and
a value representing a cresty neck score of ≥ 3 after weight gain.
Glucose and insulin concentrations were higher during the IVGTT when compared
with the OGTT. This was expected because glucose is administered directly into the
circulation resulting in a more rapid response by the pancreas; however, GLP-1
concentrations were not significantly different between pre- and post-weight gain in the study
reported here during the OGTT. A negative relationship was also detected between AUCi for
both tests and area under the GLP-1 curve and this was not expected, but is supported by
findings in humans with normal glucose tolerance or type 2 diabetes.218 Toft-Nielsen et al.218
concluded that this occurs as a result of a negative feedback effect of insulin on GLP-1
secretion.
The study diet was not analyzed for fat content or fermentability of fiber. This may
have influenced results of GLP-1 concentrations because it has been shown that an acute dose
of fat resulted in a GLP-1 peak by 60 minutes and concentrations remained elevated
throughout a 360 minute period.414 It was also shown that GLP-1 increases following a
carbohydrate bolus, resulting in a peak at 60 minutes, which is similar to the findings in this
study, and decreased until peaking again at 360 minutes.414 Unfortunately, the study here
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was only extended to 180 minutes, so it is possible that we may have detected a greater
difference between pre- and post-weight gain if samples been collected for longer. In rats,
administration of a high fat diet resulted in a significant decrease in GLP-1 concentrations
when measured during an OGTT every ten days for 60 days.415
Dietary fibers with different fermentability have also been shown to influence GLP-1
secretion. In a study of dogs consuming a high- or low-fermentable fiber diet for 14 days, it
was determined that the consumption of high fermentable fiber induced a pronounced GLP-1
response to the OGTT.418 An increase in maximal glucose uptake by the small intestine was
also observed.418

It was determined that the enhanced glucose uptake was most likely

responsible for the increase in GLP-1 secretion.418 A more recent study failed to show an
effect of fiber type on post-prandial GLP-1 concentrations, but samples were collected after
regular meals rather than a specific challenge.419
Insulin resistance and obesity are components of EMS as well as metabolic syndrome
(MetS) in humans, and higher concentrations of GLP-1 have been observed in humans with
naturally occurring and experimentally induced insulin resistance.122,216,416,420

We

hypothesized the gain in body weight would lower insulin sensitivity, and GLP-1
concentrations would increase as a result.

We did not detect a change in GLP-1

concentrations following weight gain in horses with chronic IR. However, we did detect an
increase in AUCi values, suggesting a decrease in insulin sensitivity.

The negative

relationship we detected between AUCi and area under the GLP-1 curve are consistent with
results of another study.218 It is also possible that our results reflect the diet being fed to
induce weight gain or variability among assays used to measure GLP-1. The assay used in
the study reported here measures active GLP-1 which is measured after treatment of plasma
samples with DPP-IV inhibitor. However, there are assays available that measure total GLP1 and this may explain differences among studies.
This study assessed the effects of weight gain on active GLP-1 secretion in horses
with chronic insulin resistance. A significant effect was not detected here, which did not
support our hypothesis, but future work should focus upon the effects of diet type on GLP-1
concentrations. It would also be appropriate to evaluate horses after a longer duration of
obesity. More animals should be included in future studies and insulin resistant horses
should be compared with healthy animals as obesity is induced.
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Chapter 6
Identification and assessment of high-molecular weight
adiponectin in horses

6.1 Introduction
Adiponectin is a 247 amino acid adipocytokine that was discovered by multiple
laboratories in the 1990s.168-172

This protein forms multimers within adipocytes and four

species are identified in human plasma.432 These include a trimer composed of three 30 kDa
monomers that is approximately 90 kDa in size and referred to as low-molecular weight
adiponectin (LMW), an albumin-binding trimer that is approximately 158 kDa, a hexamer
that is 180 kDa referred to as mid-molecular weight (MMW) adiponectin, and a highmolecular weight (HMW) form that is generally comprised of 12 to 18 monomers (360 to
540 kDa).432,433 Adiponectin has been identified and measured in several other species,
including horses.86,433,434
Of normal circulating plasma proteins, adiponectin accounts for approximately 0.01%
in mammalian species and normal concentrations of total adiponectin appear to vary among
species.433,434 Ranges include 5 to 30 µg/mL for humans, 9 to 17.4 µg/mL for mice, 3 to 12
µg/mL in the arctic blue fox, 4 to 10 µg/mL in chickens, and 4.34 ± 0.12 µg/mL have been
measured for weanlings and 2.69 ± 0.17 µg/mL for mature mares.433-435 In dogs, a lower
range of 0.85 to 1.5 µg/mL has been detected, with a mean concentrations of 1.22 µg/mL.433
It has been determined that the HMW adiponectin is the biologically active form and is
capable of suppressing serum glucose concentrations in a dose-dependent manner, as well as
improving insulin sensitivity.436 The ratio of HMW to LMW is used as a determinant of
insulin sensitivity.436
Despite the fact that adiponectin is primarily secreted by adipose tissues,
concentrations of this adipokine are inversely proportional to the level of adiposity in both
humans and horses, with a location association in humans indicating that larger visceral fat
depots result in lower circulating concentrations.118,434 Obesity represents a chronic state of
inflammation and hypoadiponectinemia is observed in patients with visceral obesity and
147

IR.98,108,174 This observation is especially important in circumstances of excess visceral
adipose tissue, as inflammation reduces adiponectin secretion.192,437 Adiponectin possesses
anti-inflammatory properties, so lower production leads to increased secretion of other
inflammatory cytokines such as tumor necrosis factor-α (TNF- α).192,437
Aberrations in adiponectin have been associated with states of obesity, type 2
diabetes, and metabolic syndrome in humans.438 A genetic heritability of 55.1% has also
been detected in a population of humans in which the prevalence of metabolic syndrome was
29.3% in women and 37.1% in men.439 Since obesity, insulin resistance, and circulating
adiponectin concentrations are associated in humans, we hypothesized that horses with
Equine Metabolic Syndrome (EMS) would have lower circulating HMW adiponectin
concentrations when compared to healthy horses.

6.2 Materials and Methods
Horses – Nine healthy horses with normal body condition scores and resting insulin
concentrations and 16 horses diagnosed with EMS were included in the study. Equine
Metabolic Syndrome was defined by general and/or regional adiposity, hyperinsulinemia, and
abnormal intravenous glucose tolerance test results (SI values < 1.0 L·min-1·mU-1). Breeds of
EMS horses included Tennessee Walking Horse (TWH) or TWH cross (n = 2), Morgan (n =
2), Arabian or Arabian cross (n = 5), Paso Fino (n = 3), Missouri Fox Trotter (n = 1), Azteca
(n = 1), and Saddlehorse Breeds (n = 2). Healthy horses were Quarter Horse or TWH crosses
(n = 9).
Samples – Serum samples were collected from animals under fed conditions. All horses
were being maintained on a hay only (EMS), or hay and grass diet (healthy). Samples were
collected via jugular catheter into blood tubes containing no preservative or anti-coagulant.
Samples were allowed to clot at room temperature for a minimum of 20 minutes and serum
was collected via high-speed centrifugation (3,500 to 4,000 × g). Serum was stored at -80° C
until further analysis.
Morphometric measurements – Morphometric measurements included body weight, body
condition score, girth circumference, and neck circumference which was obtained by dividing
the total neck length (x) from the poll to the cranial aspect of the withers into quarters and
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obtaining circumference measurements at 0.25x, 0.5x, and 0.75x. Body condition scores
were assessed for healthy horses.
Dialysis procedure – Dialysis buffer was made by adding 0.01 mol sodium phosphate dibasic
(Na2HPO4), 0.16 mol sodium chloride (NaCl), and 0.01 mmol ethylenediaminetetraacetic
acid (EDTA) into a total volume of 2L distilled water. Samples were added to dialysis
cassettesa in a volume of 50 µL and floated in dialysis solution at 4° C overnight
(approximately 12 h) with a stir bar to maintain uniform temperature. Samples were removed
from dialysis cassettes by attaching a gel loading tip to a 1 mL syringe and withdrawing the
dialysate. Recovered volume was recorded and total sample volume was brought to 500 µL
to produce a 1:10 dilution of the original sample. Dialyzed samples were then further diluted
to a total dilution of 1:500 prior to mixing with sample buffer and loading onto gels.
Western blot procedure – Three procedures were used in which samples were mixed with
three different sample buffers according to overall running conditions.

These included

sodium dodecyl sulfate (SDS; Procedure 1), Laemmli (Procedure 2), and Tris-HCl
(Procedure 3) for reducing, reducing and denaturing, and native gel conditions, respectively.
Transfer buffer was the same for all procedures (Tris/glycine buffer plus 800 mL methanol
into a total volume of 4L). All samples were thawed on ice before use in the system.
Positive and negative standards to assess specificity of antibodies included recombinant
human adiponectinb, equine IgGc, equine albumind, and human apolipoprotein Be.

Gel

electrophoresis and blotting were performed as described in Appendix I with a primary antiadiponectin antibody produced in rabbitsp and a peroxidase labeled secondary antibody
against rabbit IgG produced in goatsq.

6.3 Results
Healthy horses had body condition scores ranging from 4 to 6/9 and all EMS horses had BCS
of ≥ 7/9. Mean resting insulin concentrations collected under fed conditions were 2.5 ± 1.3
mU/L for healthy horses and 82.5 ± 66.0 mU/L for insulin resistant horses.
a
b
c
d
e

Slide-A-Lyzer Dialysis Cassettes, 20,000 dalton, Rockford, IL
Recombinant Human Adiponectin, San Diego, CA
Equine IgG, Montgomery, TX
Equine Albumin, Rancho Dominguez, CA
Human Apolipoprotein B, Billerica, MA
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Procedure 1 – Under reducing conditions, HMW adiponectin band density showed wide
variability among horses classified in both groups. However, horses with EMS subjectively
appeared to have lower density HMW adiponectin bands when compared to healthy horses.
Multiple bands were visible with this method and were located at 50 to 75 kDa, 100 kDa, 150
kDa, and > 250 kDa (Figure 6.1 a and b). Recombinant adiponectin was used as a positive
control and showed similarity in banding pattern compared to samples. Negative standards
did not show any visible bands in response to the antibodies (Figure 6.2).
Procedure 2 – When samples were reduced and denatured, band pattern changed to show
recombinant adiponectin as a single band of ~37 kDa and horse samples produced three main
bands at ~37 kDa, 37 to 50 kDa, and 50 to 75 kDa. Differences in band density were not
evident when healthy and EMS horses were compared (Figure 6.3).
Procedure 3 – Bands differed in appearance with the native system when compared to the
first two procedures in which SDS was included. Band density differed between groups with
EMS horses having lower density HMW adiponectin bands. Three main bands were visible
for recombinant adiponectin with this procedure and were between 140 and 232 kDa, 440 to
669 kDa, and > 669 kDa. Horse samples showed two bands located at 440 to 669 kDa and
> 669 kDa (Figure 6.4). These bands were presumed to be MMW and HMW adiponectin,
respectively.

6.4 Discussion
Of the three different procedures assessed, only the third procedure represented a true
native protein protocol as no reducing agents or denaturing steps were included. Sodium
dodecyl sulfate is a detergent that functions by binding proteins in a sample, resulting in
linearization of the folded protein by disrupting the secondary structure and altering
charge.440,441 In the case of adiponectin, it results in disruption of the disulfide bonds that are
involved in the tertiary structure of the protein and HMW form.440,441 The sulfate groups
within SDS are negatively charged and by binding to lipophilic portions of a protein, it results
in an overall negative charge.441 By altering the structure of proteins to a more linearized
form and producing an ultimate negative charge, proteins that are loaded on a polyacrylamide
gel will migrate in
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Figure 6.1a: Procedure 1 – High-molecular weight adiponectin band density of 4 healthy
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Figure 6.1b: Procedure 1 – High-molecular weight adiponectin band density of 4 healthy
horses (same in Figure 6.1a) and 8 EMS horses (9 to 16 out of 16).
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Figure 6.2: Positive (human recombinant adiponectin) and negative (human apolipoprotein
b, equine IgG, and equine albumin) standards used to assess specificity of antibodies.
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Figure 6.3: Procedure 2 – High-molecular weight adiponectin band density of 4 healthy
horses and 6 EMS horses under reducing and denaturing conditions.
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Figure 6.4: Procedure 3 – High-molecular weight adiponectin band density of 4 healthy
horses and 4 EMS horses under native conditions.
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relation to their molecular size, rather than charge, therefore resulting in band patterns
reflecting the different sizes of individual proteins or the different parts of a multimeric
protein.
Use of a sample buffer that included 2-mercaptoethanol in Procedure 2 and boiling for
10 minutes reduced and denatured proteins. Heat denatures proteins by disrupting the weak
interactions that hold proteins together, including hydrogen bonds and hydrophobic
interactions, and this affects three dimensional structure.82 The secondary structure of the
protein is no longer in place after denaturation, so only the primary structure is left, which is
comprised of the amino acid sequence.82 When proteins in serum samples were exposed to
SDS, 2-mercaptoethanol, and heat, the band pattern of the protein changed to bands with
smaller molecular weights than native samples. This was also a different band pattern when
compared to the samples that were exposed to SDS alone (Procedure 1). The recombinant
adiponectin showed a single band at 37 kDa and the equine samples showed the same band
and 2 slightly higher bands at approximately 50 and 50 to 75 kDa, which most likely
represent dimer forms. It is possible that the temperature of the water was not high enough to
fully dissociate the oligomers of adiponectin. Chicken adiponectin completely dissociates at
100° C, whereas boiling at 70° C does not have the same effect, and this may explain the
findings in the study here.435 It was concluded that adiponectin will undergo incomplete
dissociation resulting in multiple bands under certain circumstances. The fact that the HMW
isoform appears to dissociate in the presence of reducing agents suggests that disulfide bonds
are involved. Dimer forms may be held together by non-covalent bonds since heat is capable
of dissociating them.
In the native procedure, proteins migrated within the gel based on molecular weight
and electrical charge. The native conformation was important for the purposes of this work
because the HMW form is the most biologically active.435 Circulating levels of HMW, rather
than total adiponectin, are inversely related to the incidence of type 2 diabetes and insulin
resistance, and selective down-regulation of the HMW isoform is associated with
hyperinsulinemia in humans.435 Two bands were seen under native conditions. These may
represent two HMW forms because multimers can form from 12 monomers to >18.435
Chicken HMW adiponectin is >669 kDa, but can also occur as oligomer forms with 242 kDa
and 330 kDa bands.435 Alternatively, the second band reported here represented MMW
adiponectin.
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There were similarities in band pattern identified in the work reported here when
compared to other mammalian species, however some discrepancies were noted and these
could be a species differences. Currently no work had been performed to evaluate the native
distribution of HMW adiponectin in the horse. It has been established in humans that
different environmental factors, such as glucose concentration affect post-translational
modification of adiponectin.435 Differences among animal species are thought to be a result
of variation in the amino-terminal variable region which contains the cysteine residues
involved in the formation of the different multimer forms via the formation of disulfide
bonds.440 It has been established that mice have one HMW species whereas multiple HMW
species have been detected in humans.440 In Procedures 1 or 3, no bands representing the
monomer form of adiponectin were evident. This is similar to findings in human and mouse
samples, because under non-reducing and heat-denaturing conditions, adiponectin monomers
were not detected.442 It was concluded that trimer and monomer forms are less abundant in
serum samples under non-reducing and heat-denaturing conditions and may not be abundant
enough concentrations to be detected with some procedures.442
Band densities for HMW adiponectin bands appeared to differ between healthy horses
and those with EMS, but there was considerable individual variability. This may reflect
differences in the ability of multimerization of adiponectin into the HMW isoform or
differences in adipose distribution of individual animals. In chickens, it has been determined
that abdominal fat pad mass is inversely proportional to adiponectin concentrations in
plasma.435 In horses, a clinical sign of EMS is the deposition of adipose tissue along the
nuchal ligament of the crest as well as above the tail-head and along the ventral aspect of the
abdomen. The amount of adiposity within the crest of the neck has also been associated with
the level of insulin resistance and risk of developing laminitis.13,373 Recent findings have
determined that the nuchal adipose tissue is a more biologically active depot for the
production of pro-inflammatory cytokines.443 Increased gene expression of interleukin-6 (IL6) and interleukin-1β (IL-1 β) have been detected in nuchal adipose tissue when compared to
omental adipose, which differs from the situation in humans.443 Adiponectin has an antiinflammatory role so inflammation may become more pronounced when concentrations
decrease, and this may be associated with insulin resistance.444
By showing that many horses with EMS have lower HMW adiponectin band
densities, we may be able to identify animals with insulin resistance. In humans, differences
156

in multimerization potential of adiponectin have been associated with the diabetic phenotype
and hypoadiponectinemia.440 Eight mutations of human adiponectin have been reported, but
four main mutations have been associated with the diabetic and hypoadiponectinemic
phenotype.440 When these mutants are present, adiponectin is secreted only as a trimer, or as
MMW multimers and trimers that are unable to form stable HMW multimers.440 Mutants are
not only defective in the synthesis of adiponectin multimers, but also its secretion.445
Multimers are formed exclusively within the adipocyte and are stable, preventing
interconversion to other forms once in the circulation.445 More recently, a disulfide-bond A
oxidoreductase-like protein was found to have a regulatory role in the formation of different
adiponectin multimers and is diminished in fat tissues with obesity.445 To date, the genetic
component of adiponectin formation has not been investigated in horses, so it is possible that
similar mutations exist in this species. These mutations might predispose animals to the
development of insulin resistance and, as a consequence, decreased concentrations of HMW
adiponectin.
This study provides preliminary evidence to support the hypothesis that HMW
adiponectin band density is lower in horses with EMS, when compared to healthy
counterparts. Our findings add to the work of determining different metabolic aspects that
play a role in the development of EMS and laminitis. Differences in HMW adiponectin
concentrations might explain why some horses are overweight but not insulin resistant.
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Chapter 7
Conclusions and Future Directions

Equine Metabolic Syndrome (EMS) resembles human metabolic syndrome, except
that horses develop laminitis instead of atherosclerosis or cardiovascular disease.446 The
human metabolic syndrome is still being investigated and scientific advances are needed to
truly understand its connection with type 2 diabetes and cardiovascular disease. However,
some of the advances made in human medicine can be applied to horses as both syndromes
include obesity, insulin resistance, and dyslipidemia.446 Results of studies presented in this
dissertation have advanced our knowledge of EMS in some areas, while also revealing new
areas for study.
When horses were treated with a combined chromium and magnesium supplement to
assess the effects of body weight, adiposity, insulin sensitivity, and glucose dynamics, no
improvements were noted following its administration for 16 weeks. It is possible that
bioavailability of the compounds was poor, as pharmacokinetics and pharmacodynamics of
chromium and magnesium have not been assessed in horses. The 2 oz. dose administered to
horses was considered to be the loading dose by the manufacturer and is recommended as a
therapeutic dose, whereas 1 oz. of the supplement is considered to be a maintenance dose.
Horses in our studies were severe chronic cases of EMS and it is possible that a longer
duration of treatment was needed or components included in the supplement were ineffective
in severe cases. Horses were not exercised or placed on a weight loss diet, so this too may
have had an effect on the results observed. Additional studies are required to determine the
bioavailability of this supplement and assess management interventions because most owners
would be inducing weight loss by feed restriction and exercise as the same time.
The administration of levothyroxine sodium to horses suffering from insulin
resistance and obesity resulted in similar findings to earlier studies performed by our research
group.11,249 Administration of 48 mg levothyroxine per day for 24 weeks resulted in mild
decreases in body weight, but increasing the dosage to 72 mg/d an additional 12 weeks
induced a significant decrease in body weight when compared to baseline values. Over the
duration of the study there was also a significant decrease in mean neck circumference, which
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might reflect an improvement in insulin sensitivity because neck adiposity and circumference
are inversely related to insulin sensitivity in horses. These measures can serve as indicators
of the risk of developing insulin resistance, and neck circumference-to-height ratio is a
predictor for pasture-associated laminitis.6,13 The nuchal fat has also been shown to actively
secrete inflammatory cytokines which have been associated with aberrations in insulin
sensitivity.443 However, in the study reported here, we did not see a significant improvement
in insulin sensitivity following administration of levothyroxine for 36 weeks. It is possible
that a longer duration of treatment or using the higher dosage throughout the study period
would have resulted in greater improvements. The initial dosage of 48 mg/d was chosen on
the basis of our previous results, but these studies were performed in healthy horses. Our
results indicate that a higher dosage of levothyroxine is appropriate for horses with severe
chronic EMS.
Metformin hydrochloride has been used as a therapy for diabetes since the 1950s.401403

Its primary function is to inhibit hepatic gluconeogenesis but the drug also plays a role in

enhancing fatty acid oxidation in the muscle and liver and enhances the intracellular activity
of the insulin receptor pathway.287,402 Studies of metformin in horses with insulin resistance
have shown that the drug has positive effects, but they appear variable and short-lived.276 We
administered metformin at two dosages (15 mg/kg q 12h and 30 mg/kg q 12h) to our obese,
insulin-resistant horses and observed improvements in insulin and glucose concentrations
across the study period. Interestingly, we did not see expected rebounds in values when
metformin was discontinued. Overall glucose and insulin values decreased as an effect of
time and it is difficult to determine if this resulted from change in season or unrestricted
access to the outdoors and exercise after having been confined for over a year. Further work
is therefore required to determine whether effects were due to treatment or the other
confounders mentioned. Since our study was performed, it has been shown that metformin
has poor oral bioavailability in horses.283 This drug warrants further examination because
generic metformin is relatively inexpensive and administration with a small amount of oats
was accepted by the horses in the study performed here.
Glucagon-like peptide 1 is an incretin hormone secreted by the small intestine in
response to oral glucose in a dose dependent manner.222

Aberrations in secretion and

sensitivity of GLP-1 following oral glucose challenge tests have been identified in medical
conditions involving insulin resistance.217,411,412 We hypothesized that insulin-resistant horses
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would differ in their GLP-1 response to an oral glucose tolerance test when compared to
horses with normal insulin sensitivity. We were unable to detect a significant difference
between groups although insulin-resistant horses generally showed higher concentrations, as
visualized with a scatterplot, but there was obvious variability between and within groups.
The number of horses included in this study was small, so more horses should be included in
the future to increase power. We also evaluated the effects of weight gain another study to
determine if it had an effect on GLP-1 concentrations; we expected that obesity would
increase the severity of insulin resistance. For the 6 horses used in this study, we were unable
to detect a significant difference after weight gain, and this may be explained by the modest
amount of weight gained, which was lower than that observed in a another weight-gain study
with Arabian geldings.431 Further studies are required to examine more animals and the
effects of greater weight gain. A model for experimentally induced insulin resistance could
also be used to determine differences between insulin-sensitive and insulin-resistant animals.
Adiponectin is an important circulating marker for insulin resistance. This measure
can identify individuals at risk for developing type 2 diabetes because low percentages of
HMW adiponectin are detected in type 2 diabetics, when compared to total adiponectin.447
The concentration of HMW adiponectin relative to total adiponectin is referred to as the SA
index and is used as a marker for diabetes because it is tightly correlated with glucose
intolerance and the phenotypes of metabolic syndrome.447 We attempted to show that horses
with insulin resistance have low concentrations of circulating HMW adiponectin compared to
normal controls, as represented by band density during western blotting procedures. More
work is needed in this area to obtain consistency in band appearance, but our preliminary
results indicate that horses with insulin resistance have lower concentrations of HMW
adiponectin. Interestingly, there is obvious intra-group variability as some normal animals
show band density similar to insulin-resistant horses and vice versa. In the future, we must
try to determine the cause of these differences within groups.
The work performed here with a genetically diverse population of horses suffering
from EMS has introduced more questions than answers. The physical characteristics of EMS
were perhaps the only component that was consistent within the 16 horses included in our
studies. We observed that responses to pharmacologic interventions varied among horses and
group responses differed from earlier studies, although this was attributed to the chronic
disease state of horses included our studies.
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The primary goal of this work was to examine strategies for diagnosing and managing
EMS in horses. After completing this work, it can still be concluded that diagnosis is most
consistent when methods currently used in veterinary practice are applied, including the
frequently-sampled intravenous glucose tolerance test (FSIGTT) and combined glucoseinsulin tolerance test (CGIT). However, our research group was able to establish a simple
diagnostic test that we refer to as the oral sugar test (OST). Horses with insulin resistance
showed a more pronounced response to an oral sugar challenge when compared to normal
animals. This test shows great promise because it is less invasive than the CGIT or FSIGT,
and is easier to perform by the veterinarian or researcher; the corn syrup used in the test is
readily available. From a clinical standpoint, an owner can administer the syrup to their
horse while it remains in its normal environment, which should reduce stress and minimize
confounding of results. The veterinarian can arrive at a pre-established time to collect a
blood sample.
The goal of identifying easily measured blood markers proved to be more challenging
than anticipated. Adiponectin is a difficult protein to work with because it forms multimers
in circulation (HMW adiponectin) and this is the form of interest. Results obtained by
western blotting techniques were very difficult to obtain consistently. It is possible that the
protein would be better measured prior to freezing or it may degrade over time. Currently,
there is no easy method to measure equine adiponectin, although a human HMW adiponectin
ELISA has recently been validated for use with equine serum.448 It must also be recognized
that ELISAs are expensive and the cost of performing a western blot is considerably cheaper.
Glucagon-like peptide 1 can now be measured in equine plasma using an ELISA
validated by our research group, but significant differences have not been detected between
normal and insulin-resistant animals. This may be a result of the low number of animals
studied to date, so more work is required in the future to truly conclude if differences are
detectable between these groups of animals.
Current management practices for horses with EMS include weight loss by dietary
restriction in conjunction with exercise, along with restricted grazing or complete prohibition
of grazing. Induction of weight loss has been shown to result in improvements in insulin
sensitivity.11 In more severe cases, pharmacologic intervention is undertaken and this has
included levothyroxine sodium, metformin, and herbal supplements in the past. To date,
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levothyroxine and metformin are the only compounds with supportive scientific evidence of
efficacy. However, as we saw with our population of EMS horses, results were variable.
This further supports the notion that EMS is not a “black and white” disorder, so one method
does not work for all.

The best results we obtained were with the administration of

levothyroxine, but it was still the case that some horses responded better than others. This
suggests that there are different levels of severity of this disorder and it must be managed on
an individual basis.
Interestingly, we discovered that an acute re-introduction to pasture did not adversely
affect the health of insulin-resistant horses. Insulin concentrations decreased over time, and
animals lost weight, presumably due to increased exercise. No lameness related to grazing
was identified, and some horses used in these studies had histories of laminitis related to
grazing. In contrast, we observed that 2 of 6 horses developed laminitis (with a third showing
equivocal signs) while undergoing weight gain via overfeeding. It was not clear whether this
was a result of the amount of grain fed, presence of grain in the diet, or the combination of
grain and pasture grass. This point again reinforces how responses are very variable among
horses, so these points must be taken into account when attempting therapy and management.
As the results of the studies discussed here indicate, EMS is not an easy disorder to
understand. The work performed here has introduced more questions than answers, so more
studies are required to elucidate the causes and treatments for this syndrome in horses.
Ongoing genetic studies may reveal mechanisms and targets for therapies so that we may one
day identify animals at risk for developing laminitis prior to its occurrence.
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Buffer components
1) Sodium dodecyl sulfate (SDS) 5x sample buffera - 0.3 M Tris-HCl, 5%
SDS, 50% Glycerol and proprietary pink dye
2) SDS running bufferb 0.025 M Tris, 0.192 M Glycine, and 0.1% SDS per
4L
3) 2x Laemmli sample bufferc 4% SDS, 20% Glycerol, 10% 2mercaptoethanol, 0.004% Bromophenol Blue, and 0.125 M Tris-HCl pH
6.8
4) Tris/Glycine running bufferd - 0.025 M Tris and 0.192 M Glycine per 4L
5) Native sample buffere - 62.5 M Tris-HCl pH 6.8, 40% Glycerol, and
0.01% Bromophenol Blue
Procedure 1
1. Gently remove the comb from a pre-cast Tris/HCl 4 to 15% gradient gelf and
carefully cut along the solid black line along the bottom with a scalpel and
carefully remove the tape strip, rinse both sides of the gel cassette with de-ionized
water. Place gels within gel electrophoresis unitg according to instruction manual.
2. Fill the gel assembly (upper chamber) with SDS running buffer to the top of the
wells. Place the gel assembly into the tank (lower chamber) and fill with running
buffer to approximately 2/3 height.
3. Dilute samples 1:200 with distilled water and mix with non-reducing sample
buffer.
4. Load samples into wells in a final volume of 15 µL. A kaleidoscope standard
ladderh which consisted of 10 pre-stained recombinant proteins of 10, 15, 20, 25,
37, 50, 75, 100, 150, and 250 kDa was loaded into lane 1.
5. Run samples at 80 V for 20 minutes and then increase voltage to 120 V until the
dye front reaches the bottom of the gel.

a
b
c
d
e
f
g
h

Lane Marker Non-Reducing Sample Buffer, Rockford, IL
Tris/Glycine/SDS Buffer, Solon, OH
Laemmli 2x concentrate, St. Louis, MO
Tris/Glycine Buffer, Solon, OH
Native Sample Buffer, Hercules, CA
4-15% Tris-HCl Gradient Gels, Hercules, CA
Mini-PROTEAN Tetra Cell, Hercules, CA
Precision Plus Protein Kaleidoscope Standards, Hercules, CA
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6. Chill transfer buffer at 4° C.

Soak paper membranes, fiber pads, and

nitrocellulose membrane in chilled transfer buffer.
7. Remove gel from its frame by cutting along the solid black lines on either side of
the gel and place gel plastic side down in chilled transfer buffer and store at 4° C
for 15 minutes to allow for shrinkage.
8. Assemble gel holder cassettes for transfer as follows:
a. Fiber pad
b. Paper membrane
c. Gel- placed glass side up
d. Nitrocellulose membrane
e. Paper membrane
f. Fiber pad
9. Place assembled gel holder cassette into the electrode module with the black side
of the cassette facing the black side of the electrode module.
10. Place an ice pack in the buffer tank and place the electrode module into the buffer
tank with the black side of the electrode module facing the ice pack. Place a small
stir bar below the cassette. Add chilled transfer buffer to the base of the lip of the
buffer tank.
11. Place the unit on a stir plate to allow adequate circulation of the transfer buffer.
12. Run the transfer at 80 V for 1 ½ h.
13. Following transfer, remove the membrane and cover with ponceau staini for
approximately 5-minutes to visualize quality of the transfer.
14. Rinse membrane 3 times in a 0.5% Phosphate Buffered Saline (PBS)-Tween (500
µL Tween-20j per 100 mL of PBS) solution for 5-minutes per rinse until all
visible ponceau stain is removed.
15. Place membrane in 5% milk solution (5g powdered non-fat milk per 100mL of
PBS-Tween) and block for 1h at room temperature on a rocker.
16. Rinse membrane 3x in PBS-Tween for 5-minutes per rinse.
17. Incubate membrane with 1° antibody (Anti-adiponectin antibody produced in
rabbitk) for 1h at room temperature at a concentration of 1:250 with 5% milk
solution.
i
j

Ponceau-S, St. Louis, MO
Tween-20, Fairlawn, NJ
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18. Rinse membrane 1x in PBS-Tween for 5 minutes.
19. Incubate membrane with 2° antibody (Peroxidase-labeled affinity purified
antibody to rabbit IgGl) for 1h at room temperature at a concentration of 1:8,000
with 5% milk solution.
20. Rinse membrane 3x in PBS-Tween for 5 minutes per rinse.
21. Rinse membrane 3x in PBS for 5 minutes per rinse.
22. Blot membrane of excess PBS using lint-free paper and cover with prepared
chemiluminescent substratem and incubate for 5 minutes at room temperature.
23. Blot membrane of excess substrate with lint-free paper and place in a clear sheet
protector or plastic wrap and expose to x-ray filmn.

Develop film in x-ray

processor.

Procedure 2 – steps differing from Procedure 1
Protocol procedure is the same as Procedure 1 with the exception of the following
steps:
3. Mix diluted samples with 2x Laemmli buffer (in 1:1 ratio). Boil samples for 10
minutes. Perform a quick spin with a microcentrifuge to release steam from the
samples.

Procedure 3 – steps differing from Procedure 1
2. Fill the buffer tank with Tris/Glycine running buffer.
3. Dilute samples 1:500 following the dialysis procedure and then mix
with 2x native sample buffer (in 1:1 ratio).
4. Load samples to provide a total volume of 20 µL per well. Load native highmolecular weight standard consisting of lyophilized proteins of
thyroglobulin (669 kDa), ferritin (440 kDa), catalase (232 kDa), lactate
dehydrogenase (140 kDa), and bovine serum albumin (67 kDa) in lane 1.
5. Run gel at 80 V until dye front runs down 2/3rd distance (approximately 3.3 cm)
from the base of the wells.
7. Do not chill gel in transfer buffer prior to assembling gel holder cassette.
k

Anti-adiponectin antibody produced in rabbit, St. Louis, MO
Peroxidase-labeled Affinity Purified Antibody to Rabbit IgG (H+L), Gatlinburg, MD
m
SuperSignal West Pico Chemiluminescent Substrate, Rockford, IL
n
Blue X-ray Film, Candler, NC
l
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17. Incubate membrane with 1° antibody for 1h at room temperature at a
1:2,000 dilution.
19. Incubate membrane with 2° for 1h at room temperature at a 1:12,000 dilution.
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